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Abstract 
Food security is the idea by which a population has enough food to sustain itself 
without famine.  A large number of factors can influence the stability of food 
production, including diseases caused by microorganisms.  Pectobacterium spp. 
is one of the leading causes of soft rot disease, resulting in crop losses both pre- 
and post-harvest.  
Bacteriocins are potent narrow spectrum protein antibiotics which target closely 
related bacteria to the producing strain.  Ferredoxin-containing bacteriocins 
produced by and targeted towards Pectobacterium species have both a different 
domain organisation and uptake mechanism to all known Gram-negative 
bacteriocins.  This work has shown that pectocins are able to pass through the 
outer membrane of Pectobacterium spp. by parasitising the ferredoxin uptake 
receptor, FusA.  This uptake requires the pectocins to be flexible in order to pass 
through the lumen of the barrel and enter the periplasm.  This work has shown 
an interaction between FusB and pectocin M1, suggesting a novel mechanism of 
uptake.   
Streptococcus agalactiae is the causative agent of disease in a wide range of 
hosts, ranging from human neonates to farmed Tilapia.  S. agalactiae infection 
has a detrimental effect on the dairy industry each year as it is the leading 
cause of mastitis in cattle.  As well as this, the prevalence of S. agalactiae in 
farmed fish has resulted in large numbers of infected fish and subsequently the 
infection of consumers.   
Bacteriocins produced by Gram-positive bacteria are often small modified 
peptides which target the peptidoglycan layer or cytoplasmic membrane of the 
target cell.  However, a small number of protein bacteriocins produced by Gram-
positive bacteria have been discovered, with the best characterised of these 
being lysostaphin.  It has been shown that bacteriocins similar to lysostaphin are 
also produced by other Gram-positive bacteria, such as zoocin A produced by 
Streptococcus zooepidemicus. Prior to this work a novel protein bacteriocin 
produced by and targeted towards S. agalactiae, named agalacticin A, was 
discovered.  It was predicted that this bacteriocin was similar in structure and 
5 
function to zoocin A.  This work has gone some way to structurally characterising 
agalacticin A, showing a two-domain structure joined by a flexible linker region 
allowing for the two domains to move independently.  As well as this it has 
shown the importance of the histidine residues at the predicted active site 
confirming the similarities between agalacticin A and zoocin A.  Together this 
work has gone some way to showing the potential of agalacticin A as a novel 
therapeutic.  
Altogether this work has characterised three novel bacteriocins active against 
pathogenic bacteria to gain a better understanding of their structure, 
mechanism of action and uptake.   
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 Food security  
Food security is the idea that an entire population has enough viable food to 
sustain itself without famine.  Hunger and malnutrition are prevalent with more 
than 800 million people suffering worldwide [1] and this number is ever 
increasing as the population increases.  There are a large number of factors that 
affect the stability of crop production including crop diversity, susceptibility to 
diseases, phytopathogens such as bacteria and fungi, and lack of nutrient rich 
soil are a few of the environmental factors that can affect the production of 
good quality crop plants in many countries around the world [1,2].   
Plant pathogens destroy at least 10% of crop plants every year [2–4] with a 
further 6-12% being lost post-harvest [2,3]. This crop loss can be devastating as a 
large proportion of a population can be dependent on a single crop species [3]. It 
is important therefore to develop novel methods to prevent diseases within crop 
plants in order to increase the amount of viable food produced.   
Bacteria can cause a wide-range of diseases affecting both plant and animal 
species [5,6].  There are a large number of both Gram-positive and negative 
bacteria that can be detrimental to the health of domesticated animals such as 
farmed cattle and fish [5,7].  One organism which can infect a wide range of 
host species is Streptococcus agalactiae, also known as Group B Streptococcus 
(GBS).  GBS is an opportunistic human pathogen which is the major causative 
agent of neonatal sepsis [8,9].  Moreover, GBS is one of the leading causes of 
mastitis in cattle, which in turn has a significant impact on milk production [5].  
Not only does this organism infect cattle, but GBS infection can also have a 
detrimental impact on the populations of farmed fish, particularly those grown 
in south Asian countries [7].  The first line of defence against GBS infection is 
the use of β-lactam antibiotics, such as penicillin, however the overuse of these 
to treat human disease and in aquaculture is leading to an increase in the 
development of resistant bacterial populations therefore the development of 
novel control strategies is essential [10,11].  
22 
 Bacteria targeted in this work  
 Pectobacterium spp. 
Plant pathogens employ one of two methods to invade host tissue: stealth or 
brute-force [12].  Pathogens that rely on living plant tissue as a nutrient source, 
such as Pseudomonas spp., employ stealth mechanisms to maintain an infection 
and avoid the host immune system [12].  However, necrotrophs, such as 
Pectobacterium spp., employ a brute-force method of infection as they do not 
require living plant tissue to gain nutrients [12].  Pectobacterium spp. are 
aggressive phytopathogens characterised by their large arsenal of plant cell-wall 
degrading enzymes and ability to macerate plant tissue causing necrosis [12].  
Maceration of plant tissue is particularly damaging to crops pre- and post-
harvest, as even if the infection can be treated the crop plants are still likely to 
be unusable due to the necrosis that may have occurred during infection [3,13].   
 The two species within the Pectobacterium genus are P. atrosepticum and 
Pectobacterium carotovorum which have a narrow and broad host range 
respectively [14].  P. atrosepticum is a prolific pathogen which infects only 
Solanum tuberosum (potato) both in the field (blackleg) and during storage (soft 
rot) [15].  The characteristic symptoms of blackleg infection are black rot lesions 
which are wet and slimy in appearance, however under dry conditions these can 
appear as a yellow wilt in the stems and leaves [15].  Soft rot is confined to the 
tuber after harvest, the tuber tissue is macerated and becomes black when 
exposed to the air [15].   
The spread of infection most commonly occurs through interaction with infected 
tissue, as survival of Pectobacterium species in the soil is limited to a maximum 
of 6 months under ideal conditions [15].  The most likely cause of disease 
transmission is through the release of bacteria into the soil after the planting of 
infected seed potatoes and the subsequent soil water contamination [15].  Once 
in the soil Pectobacterium spp. can colonise the roots of the host and utilise the 
vascular system to enter the plant tissue, leading to colonisation and potentially 
infection [15].    
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In order for a successful infection to be established Pectobacterium spp. must 
colonise the plant tissue, grow and evade the hosts innate immune defences 
[13].  During colonisation Pectobacterium spp. acquires essential nutrients from 
the plant tissue, however once this supply of nutrients has been exhausted it is 
thought that this triggers the deployment of cell-wall degrading enzymes in 
order to overcome this nutrient deficiency [13].  Within a large majority of 
pathogenic bacteria the type III secretion system is relied upon to secrete 
effector proteins to evade the hose immune system [12], however it has been 
shown that some Pectobacterium wasabiae strains lack this system entirely [16] 
suggesting an alternative method of evasion.  This lack of a type III system is not 
a universal trait of Pectobacterium species, with work showing that the presence 
of this system is essential for the early colonisation of potato leaf by P. 
carotovorum [17].  
The prevention of soft rot within S. tuberosum has been achieved primarily 
through the breeding of partially resistant tubers.  However, it has also been 
shown that pre-treatment of plants with calcium can reduce infection rates [15]. 
One of the most commonly used methods of disease prevention is the removal of 
diseased crops through careful inspection prior to certification [15].  Although 
this method is widely used the presence of latent infections within seed tubers is 
difficult to detect [15].   
Preliminary work to examine the use of biological tools to combat 
Pectobacterium spp. infection began with the use of lytic bacteriophage 
particles [4].  Bacteriophages have been tested against a variety of soft rot 
pathogens and were shown to be successful at reducing bacterial load in tubers, 
however more work to develop this as a long-term prevention method against 
Pectobacterium infection is needed [18].  Several other methods of biocontrol 
have been investigated including the use of Streptomyces [19], carob extracts 
[20] and the disruption of quorum sensing [21], however, to date no definitive 
biocontrol strategy has been successfully implemented in the field.     
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 Streptococcus agalactiae  
GBS is a Gram-positive opportunistic commensal bacteria which causes disease in 
a wide range of host species [22].  The ability to colonise and persist in different 
hosts is dependent on a variety of virulence factors and adherence capacities as 
well as the ability to successfully form biofilms [22].  It has been shown that 
some sequence types of GBS have shown host specificity by remodelling their 
metabolism to suit their preferred host environment as well as tailoring their 
genome to best suit their preferred host [23].  Despite the adaptation of some 
GBS sequence types to a specific host, a large number of GBS strains are able to 
successfully colonize a range of both warm and cold blooded hosts with little 
change in their physiology [24].   
GBS is a causative agent of both mastitis in cattle and streptococcosis in fish 
resulting in losses in both agricultural industries each year [5,25,26]. The 
prevalence of mastitis within the dairy industry is one of the leading causes of 
profit loss, with GBS being the primary causative agent of this disease [27].  
Within recent years the number of GBS mastitis outbreaks has been reduced due 
to improved farming and control methods, however the passing of the organism 
between species still poses some risk to the industry [27].   
GBS colonises the urogenital tract of up to 30% of healthy adults but can be 
transmitted vertically to neonates [28].  GBS can colonise neonates either in 
utero or during birth, with infections occurring in 1-2% of colonized new-borns 
[22]. Prophylactic treatment of GBS positive expectant mothers with β-lactam 
antibiotics before or during labour has been shown to be an effective method of 
reducing the number of neonatal GBS infections [28].  Early onset infections 
generally occur within the first 6 days of life with symptoms typically presenting 
within the first 24 hours [29].  Infections within neonates can lead to the 
development of bacteraemia and meningitis which can lead to mortality [29].   
In 2015, an outbreak of invasive GBS infection in non-pregnant adults was 
retrospectively associated with the consumption of uncooked fish colonised by 
the bacteria [30].  Recent years have seen an increase in GBS outbreaks within 
farmed fish species, resulting in the annual loss of 40 million dollars within the 
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industry [26].  The persistent asymptomatic colonisation by GBS within farmed 
Tilapia is a worldwide concern due to the transmission of the bacteria between 
colonised fish and humans, either through contact or consumption [26].   
Within aquaculture an increased use and dependence on antibiotics for the 
successful rearing of farmed fish has resulted in an increase in the prevalence of 
antibiotic resistance within GBS strains [10].  There are two major concerns with 
the use of antibiotics in aquaculture: The prevalence of antibiotic residue in the 
edible tissues and the emergence of antimicrobial resistance in zoonotic 
pathogens [31].  Due to the nature of aquaculture large amounts of prophylactic 
antibiotics are used in both the water and food which has led to an increase in 
the presence of antibiotic resistance genes within bacteria isolated from farmed 
fish [32].  This prevalence of antibiotic resistance transmission between fish, 
mammals and humans is becoming a growing concern for both human health and 
food security [10,33].   
The first approach to treating GBS infection is through the use of β-lactam 
antibiotics, such as penicillin, however in recent years an increasing number of 
isolates have been shown to be resistant to this treatment method due to the 
alteration of peptidoglycan amino acids [11].  This is further complicated by the 
presence of resistance markers to alternative antibiotics, such as erythromycin, 
in as many as 50% of colonising isolates [34–36].  Due to the widespread 
prevalence of GBS worldwide, the development of novel antibiotics treatments 
has been examined for some time.  Unfortunately, widespread prevalence and 
diversity has meant that no current vaccine is effective against all strains of GBS 
at present [22,37].   
 Bacteriocins  
 Bacterial competition  
The competition for nutrients and the occupation of a niche are the focal point 
of the microbial competition machinery [38].  Bacteria have developed an 
arsenal of antimicrobial mechanisms in order to displace and outcompete 
neighbouring cells [39].  Microbes can compete indirectly through the 
consumption of resources, depleting the supply of nutrients and outcompeting 
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other members of the niche [39].  Direct competition occurs through the 
production of inhibitory substances which damage competing cells [39]. 
Bacteriocin production is widespread amongst both Gram-negative and Gram-
positive bacteria in order to directly compete for nutrients and space [39–41].   
Bacteriocins from Gram-positive bacteria are generally found to be small peptide 
antibiotics which target other Gram-positive bacteria usually from within the 
same genus [42].  In contrast, Gram-negative bacteriocins are more commonly 
found to be protein antibiotics targeting peptidoglycan synthesis, degrading 
nucleic acids or creating pores in the cytoplasmic membrane causing 
depolarisation [43].  The mechanism and uptake of bacteriocins has been of 
interest for many years as they are a good candidate for novel antibiotics due to 
their narrow spectrum and potency [44].   
 Peptide bacteriocins 
Both Gram-positive and Gram-negative bacteria produce an array of 
antimicrobial compounds, including small peptides.  Small peptide bacteriocins 
are most commonly produced by Gram-positive bacteria and can have a narrow 
or a broad spectrum [45].  One of the most well studied and widely used of these 
peptide bacteriocins is nisin.  Nisin is a post-translationally modified peptide 
consisting of 34 amino acids (AA) which depolarises the cytoplasmic membrane 
to cause cell lysis [46].  Unlike most bacteriocins, nisin has a broad-spectrum 
and is able to target multiple Gram-positive bacteria [46].  Due to its potency 
against food-related pathogens nisin has been successfully implemented as a 
food preservative worldwide [47].   
 Colicins  
Bacteriocins have been found to be produced by most, if not all, Gram-negative 
bacteria and are generally classified by their cytotoxic activity [48].  The most 
well studied group of Gram-negative bacteriocins are those produced by and 
targeted towards Escherichia coli, named colicins.   
Unlike the bacteriocins of Gram-positive bacteria, Gram-negative bacteriocins 
have to cross the outer membrane of the target cell in order to cause cell lysis 
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[49,50].  For this to occur the bacteriocins must interact with at least one outer 
membrane receptor for translocation [51].  Colicins have a conserved three 
domain arrangement regardless of their mechanism of action or outer membrane 
receptor [43].  This structure consists of an N-terminal translocation domain 
which contains a disordered N-terminal intrinsically unstructured translocation 
domain (IUTD), a receptor binding domain and C-terminal cytotoxic domain,  the 
nuclease type colicins also possess a C-terminal immunity protein which remains 
bound to the protein until translocation (Figure 1-1) [43].   
 
Figure 1-1 Schematic of colicin domain structure with the crystal structure of colicin Ia, a 
group B colicin, (PDB ID 1CII) used as an example model.  The N-terminal intrinsically 
unstructured translocation domain (IUTD) in purple (not shown in crystal structure), followed by a 
translocation domain (blue), receptor binding domain (red) and cytotoxic domain (green).  Group A 
colicins also possess a C-terminal immunity protein (not shown).   
It has been shown that the majority of colicins require two outer membrane 
proteins for successful translocation [40,43].  The colicin primarily binds to an 
outer membrane receptor with high affinity, this outer membrane receptor is 
responsible for the anchoring of the colicin to the outer membrane and is the 
first interaction between the protein and the target cell [40].  
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Once bound to the cell, the translocation domain of the colicin interacts with a 
co-receptor.  The N-terminal region of the colicin consists of a disordered region, 
known as the intrinsically unstructured translocation domain (IUTD), which can 
pass through the lumen of an outer membrane receptor or porin to interact with 
TonB or TolB in the periplasm, completing the translocon and initiating 
translocation [52].  
Finally, the C-terminal domain of the colicin is the catalytic or cytotoxic domain.  
This domain is responsible for the lysis of the target cell, whether through pore-
formation, DNase or RNase activity or by disrupting the synthesis of 
peptidoglycans [40,43].  Nuclease type colicins act by either degrading 
chromosomal DNA (e.g. colicin E9) or through the cleavage of RNA, either 
ribosomal 16S or tRNA (e.g. colicin E3 and E5 respectively) [53].   
In contrast to the nuclease colicins, pore forming colicins are amongst the most 
structurally diverse of the colicins and their uptake is mediated by a variety of 
different outer membrane receptors [40]. The pore-forming domains are 
structurally similar and consist of a tightly packed bundle of α-helices which is 
able to rearrange itself upon contact with the cytoplasmic membrane in order to 
form a voltage-gated ion channel, destabilising the membrane and subsequently 
causing cell lysis [43].   
Although colicins are the most well studied of the bacteriocins, the conserved 
domain structure can be seen in bacteriocins from other Gram-negative 
bacteria.  Pyocins are bacteriocins produced by and targeted towards 
Pseudomonas species and have been seen to have a similar domain organisation 
[54].  This conserved organisation suggests a universal domain organisation of 
Gram-negative bacteriocins in order to parasitise existing nutrient uptake 
receptors [43,54,55].   
 Crossing the outer membrane 
 Mechanisms of bacteriocin uptake 
The outer membrane of Gram-negative bacteria allows the selective passage of 
nutrients into the cell [56].  The selective uptake of proteins and nutrients has 
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led to the parasitisation of outer membrane uptake machinery by bacteriocins in 
order to enter the target cell [43].  Both Tol- and TonB-dependent bacteriocins 
possess an N-terminal IUTD which is known to be important for the uptake of 
colicins and pyocins into the periplasm of the target cell (Figure 1-2) [43,55].   
The E-type colicins of E. coli utilise the Tol system to enter the cell through the 
recruitment of the periplasmic TolB protein. E-type colicins first interaction with 
the cell surface is the high affinity binding to BtuB, an outer membrane TonB-
dependent receptor [50,57,58]. The receptor binding domain of colicin E3 has 
been shown to interact with the extracellular loops of BtuB [58].  This primary 
interaction is thought to be to coordinate the colicin close to the membrane 
surface in order for it to interact with its secondary receptor, OmpF [58].   
The translocation domain of E-type colicins is important for the recruitment and 
occlusion of the OmpF porin [59].  The IUTD of the colicin is passed through the 
OmpF channel to recruit the periplasmic Tol complex, forming the translocon 
[52].  The interaction between TolB and the colicin connects the colicin to the 
proton motive force (PMF) of the inner membrane, triggering the release of the 
bound immunity protein and initiating cell entry [59].   
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Figure 1-2 Schematic of translocation uptake systems of colicins into E. coli.  Group A and B 
colicins utilise the Tol and Ton systems respectively, this diagram illustrated the uptake routes of 
each group into the target cell.  Taken from [40] with reproduction rights obtained from the nature 
publishing group.  
Colicin N is an unusual group A colicin which has been seen to only use the OmpF 
porin for uptake [60].  Like the other colicins, colicin N has the same three 
domain structure, however the receptor binding and translocation domains are 
much smaller than those of other group A colicins [60].  Unlike other colicins, 
the receptor binding domain of colicin N interacts with lipopolysaccharide (LPS) 
on the surface of the target cell rather than an outer membrane receptor 
[60,61].  Colicin N has a high affinity to OmpF, once bound the unfolded IUTD 
threads through the pore of OmpF to interact directly with TolA for 
translocation, though the exact mechanism for translocation still remains elusive  
[52,60,62].   
Unlike the group A colicins, group B colicins interact with the inner membrane 
TonB-protein complex to gain entry into the cell [43].  TonB-dependent outer 
membrane receptors, such as BtuB, interact with the TonB protein complex 
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within the periplasm to harness the PMF for substrate uptake [63].  Therefore 
like the group A colicins, group B colicins also rely on the recruitment of the PMF 
by the IUTD to gain entry into the cell [63].   
Pyocin S2 is a DNase type bacteriocin produced by and targeted towards 
Pseudomonas species and is known to parasitise the Pseudomonas FpvAI outer 
membrane receptor [63].  FpvAI is a TonB-dependent receptor that actively 
imports the iron-binding siderophore ferripyoverdine [63,64].  The interaction of 
pyocin S2 and FvpAI was seen to mimic the native substrate, ferripyoverdine, in 
both structure and receptor binding site [63].  The similarity of the pycocin S2 N-
terminal domain to the natural substrate allows it to mimic the natural substrate 
upon interaction with FpvAI and thus induce the conformational change in the 
receptor needed for import (Figure 1-3) [63].  This conformational change allows 
for the interaction of the PMF-coupled TonB with the now exposed TonB-box of 
the FpvAI, promoting the partial unfolding and exit of the plug domain from the 
barrel [63].  Subsequently, a second copy of TonB interacts with the IUTD of 
pyocin S2 to pull the bacteriocin through the FpvAI channel after the plug 
domain is displaced [63].   
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Figure 1-3 Model of Pyocin S2NTD translocation through FpvAI as a model for TonB-
dependent pyocin uptake.  Pyocin S2NTD mimics the native substrate ferripyoverdine and binds to 
TonB-dependent outer membrane receptor FpvAI.  Substrate binding induces a conformational 
change and release of the TonB-box and partial unfolding of the plug domain by TonB.  This allows 
the IUTD of pyocin S2 to recruit a second copy of TonB for translocation through the FpvAI lumen.  
Reproduced from [63] under a creative commons licence.  
Unlike pyocin S2, colicin Ia recruits two copies of the same TonB-dependent 
receptor for uptake.  The colicin Ia receptor (Cir) is both the primary binding 
site and the translocon which allows colicin Ia to enter the cell [65].  Colicin Ia 
binds with high affinity to Cir on the cell surface, it then locates a second copy 
of the Cir protein which is used for translocation into the periplasm [65].  
Translocation of colicin Ia is dependent on both the presence of a functional Cir 
outer membrane protein and a functional TonB suggesting that TonB is also 
necessary for successful uptake (Figure 1-4) [65].  Despite the variation between 
outer membrane uptake receptors all bacteriocins appear to require the 
recruitment of the inner membrane PMF for translocation into the periplasm 
[52,63].   
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Figure 1-4 Model of colicin Ia receptor recruitment and uptake showing the interaction of 
colicin Ia with two Cir outer membrane proteins and interaction with TonB  a) Binding of the 
second copy of Cir triggers the rearrangement of the TonB-box allowing for the plug domain to be 
partially unfolded, allowing for the IUTD of colicin Ia to pass through the lumen to interact with a 
second copy of TonB in the periplasm .  Reproduced from [65] with the publishers permission.  
 TonB-dependent receptor structure 
Gram-negative bacteria use outer membrane transporters dependent on the 
periplasmic TonB protein interaction to take up nutrients from the environment 
[66].  This family of receptors is highly conserved with an N-terminal “plug” 
domain of around 130-150 amino acids which is folded to occlude the C-terminal 
barrel of the receptor, which in turn is composed of 22 antiparallel β-strands 
[66,67].  Despite a highly conserved structure the substrates of these outer 
membrane proteins vary from carbohydrates to vitamins [68].  Amongst this 
family are receptors utilised by bacteriocins, including BtuB, FepA and FhuA from 
E. coli (Figure 1-5) [67,69].  
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Figure 1-5 Crystal structures of three TonB-dependent receptors from E. coli showing their 
conserved structure. The N-terminal domain (blue) is shown to form a plug within the β-barrel 
(green) of BtuB (PDB ID 3RGM), FepA (PDB ID 1FEP) and FhuA (PDB ID 1BY3).   
The extracellular loops of FhuA, FepA and BtuB are shown to be important for 
substrate interaction [70].  These extracellular loops show some degree of 
flexibility that may be important for interaction and coordination of the 
substrate [70].  Through the deletion of the extracellular loops of FhuA it was 
shown that these loops are essential for substrate interaction and uptake, but 
that the substrate binding site is not ubiquitous for all substrates [71].  Moreover 
this has been supported by studies of both BtuB and FepA which showed that the 
extracellular loops are essential for substrate uptake [72,73].   
FhuA and BtuB are two of the most well studied of the E. coli TonB-dependent 
receptors and are involved in the uptake of siderophores and vitamin B12, 
respectively.  As well as this, both receptors are important for the uptake of 
colicins into the target cell [70,74]. The N-terminal plug domain of TonB-
dependent outer membrane receptors occludes the barrel to prevent the 
transport of unwanted molecules into the cell, however it must be at least 
partially removed in order to allow substrate translocation [75,76].  The 
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mechanism and conformation in which the plug domain exits the barrel is not 
well understood.  It has been suggested that the plug domain can completely 
unfold, partially unfold or remain folded when exiting the barrel [77–79].  
Evidence is present for each of these theories, but to date the strongest 
evidence suggests that the plug domain partially unfolds and exits the barrel to 
allow for substrate uptake [63,76].   
The examination of the TonB-BtuB complex using atomic force microscopy 
showed that the interaction of TonB with BtuB can facilitate the remodelling of 
the BtuB plug domain to allow for the uptake of its substrate, vitamin B12 [76].  
The examination of FhuA has given support to this model of partial unfolding 
suggesting that this may be a conserved mechanism between TonB-dependent 
outer membrane receptors [78].   
However, work examining other TonB-dependent proteins suggests that the plug 
domain may remain folded once it has exited the barrel.  Work examining the 
structure of the plug domain of FepA suggests that it has the properties of an 
autonomous globular protein [80].  The FepA plug domain appears to have a 
hydrophobic core and charged and polar side chains suggesting that it might be 
stable in the absence of the C-terminal barrel, however it was shown to only be 
partially folded in solution [80].  Contrary to this, work examining TbpA from 
Neisseria spp. showed that the plug domain, although unable to interact with 
the substrate, remained folded and globular in the absence of the barrel, 
supporting the idea that the plug domain remains folded when exiting the barrel 
[77].    This discrepancy suggests that there may not be a universal mechanism 
of plug displacement within TonB-dependent receptors.   
The plug domain of TonB-dependent outer membrane receptor may also be 
important for the interaction and translocation of the substrates into the 
periplasm.  It has been shown that the plug domain of FepA can bind its 
substrate, ferric enterobactin, in the absence of the C-terminal barrel [80].  The 
substrate interaction with the extracellular binding sites is thought to drive the 
conformational change needed for import [80].  This is supported by the 
conformational change shown in the crystal structure of FhuA in the presence of 
its substrate, ferretin, showing a conformational change in the N-terminal 
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domain consistent with the unfolding of the TonB-box during substrate binding 
[77,81].   
 TonB complex 
The PMF of the cytoplasmic inner membrane is harnessed for outer membrane 
substrate translocation by periplasmic proteins such as the TonB protein complex 
[82].  The TonB complex is comprised of three inner membrane proteins which 
are required for the active transportation of substances across the outer 
membrane of Gram-negative bacteria [82].  The energy transfer from the 
cytoplasmic membrane to the TonB-dependent outer membrane receptor is 
mediated by the 5-7 residue TonB-box located at the N-terminus of the receptor 
(appendix 1) [82].  It has been predicted that each TonB complex serves a large 
number of TonB-dependent receptors to allow substrate uptake rather than a 1:1 
molar ratio of receptor to TonB complex [83] 
TonB is a proline-rich protein which provides a functional link between the inner 
and outer membranes of Gram-negative bacteria [84].  TonB is anchored to the 
cytoplasmic membrane by an N-terminal transmembrane helix and has been 
shown to directly interact with the TonB-box of the outer membrane proteins 
[84].  TonB is a highly flexible protein making structural characterisation 
difficult, however it has been shown that TonB can extend across the periplasm 
in order to interact with the outer membrane receptors [83].   
TonB is in complex with two cytoplasmic membrane proteins, ExbB and ExbD 
which enhance the efficiency of TonB–dependent uptake [85].  The crystal 
structure of ExbB shows the presence of a transmembrane domain consisting of 
three α-helices and a cytoplasmic 5 α-helix bundle [82].  ExbB forms a pentamer 
in the membrane creating a pore across the cytoplasmic membrane [82].  ExbD 
is thought to be more similar in structure to TonB with an N-terminal membrane 
anchor and large periplasmic domain and is a dimer in both the presence and 
absence of TonB [82].  The pore formed by the ExbB pentamer is thought to be 
the site at which protons are translocated across the cytoplasmic membrane as 
well as anchoring ExbD within the membrane [82,85,86].   
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It has been shown that TonB interacts in an edge to edge manner with the TonB-
box of the outer membrane receptor [67].  The β-sheet of TonB interacts with 
the extended TonB-box, the extension of which is known to be substrate 
mediated [67].  The N-terminal of the outer membrane receptor FhuA has been 
shown to be disordered and extend 15-20 Å  into the periplasmic space in order 
to interact with TonB [67].  The interaction between the outer membrane 
protein and TonB is mediated by the presence and interaction of the TonB-box 
with the TonB protein in order to drive uptake of the substrate [67,87].   
 Targeting the peptidoglycan layer 
1.5.1.1 Current antimicrobials 
The peptidoglycan layer is an integral part of the bacterial cell structure and 
therefore a good antimicrobial target [56].  One of the most frequently used 
classes of antibiotics is the β-lactams which interfere with assembly of the 
peptidoglycan layer [88].  β-lactams interact with penicillin binding proteins 
preventing the successful construction of the peptide cross-bridges, destabilising 
the cell [89,90].  Vancomycin, a potent antibiotic against Gram-positive 
bacteria, inhibits cell wall synthesis by interacting with peptidoglycan precursors 
[91].  Peptidoglycan plays an essential role in maintaining the shape of both 
Gram-positive and Gram-negative cells [92].  Therefore the disruption of 
peptidoglycan synthesis or break-down of the peptidoglycan layer can lead to 
cell lysis [93].  
1.5.1.2 Gram-positive protein bacteriocins and M23 metalloproteases 
Within Gram-positive bacteria the number of protein bacteriocins that have 
been discovered and characterised is limited, with the majority found to be 
similar in both structure and function to M23 metalloproteases.  The M23 
metalloprotease are a family of zinc dependent peptidases which exhibit glycyl-
glycine endopeptidase activity [94].  This family contains both bacteriocins and 
autolysins, such as LytM produced by Staphylococcus aureus which is known to 
cleave Staphylococcal peptidoglycan during cell division [94].  Recent work has 
shown a conserved active site within M23 metalloproteases consisting of three 
histidine residues, a tyrosine residue and an aspartic acid residue which co-
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ordinate tetrahedrally around the zinc ion present in the active site (Figure 1-6) 
[94].  This work also suggested the importance of a tyrosine residue at the active 
site which has been shown to be important for activity [94].  The co-
crystallisation of LytM in the presence of a substrate analogue has identified the 
substrate binding site as well as suggesting a proposed mechanism by which the 
water molecule is recruited into the active site by the histidine residues [94].   
 
Figure 1-6 Conserved active site of LytM, Lysostaphin (LSS, PDB ID 4QPB) and LasA from 
Pseudomonas aeruginosa (PDB ID 3IT5).  Structures of the active site of three M23 
metalloproteases showing the conserved histidine, aspartic acid and tyrosine residues coordinating 
the zinc ion (orange) with the substrate analogue bound to LytM shown in white.  Taken from [94] 
under the creative commons licence.  
The mostly widely studied of the Gram-positive protein bacteriocins is 
lysostaphin, an M23 metallopeptidase produced by Staphylococcus similins which 
has activity against S. aureus [95].  Lysostaphin is similar in structure and 
function to autolysins such as LytM, having a conserved active site and 
mechanism of action.  In contrast, lysostaphin is released from the producing 
strain to target other Staphylococcal species within the same niche [94,95]. It 
has been known for some time that lysostaphin is a bacteriolytic agent with 
activity against S. aureus making it an important potential therapeutic [96]. 
Lysostaphin has proved to be an effective therapeutic in vivo when tested 
topically in rodent models and is currently undergoing clinical trials [95].   
Structural characterisation of lysostaphin has shown it to be a two domain 
protein with an inter-domain flexible linker region joining the N-terminal 
catalytic domain with the C-terminal cell-wall targeting domain [95]. The 
lysostaphin catalytic domain is similar in structure to LytM with the 
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characteristic HXXXD and HXH motifs co-ordinating the zinc ion in the active site 
[95].  As with other M23 metalloproteases the active site is located in the 
substrate binding groove with the floor of the groove built by the β-sheet and 
the wall made of unstructured loops [95].  
The cell wall targeting domain of lysostaphin is thought to directly interact with 
the inter-peptide bridges within the peptidoglycan layer, although the exact 
interaction site is yet to be confirmed [95].  It has been shown that the cell wall 
targeting domain has a higher affinity for the stem peptide within the 
peptidoglycan than towards the glycine cross-bridges [97] suggesting that the 
initial contact between the cell wall targeting domain and the peptidoglycan 
does not occur at the cleavage site [97].  The C-terminal domain of lysostaphin 
is necessary for the targeting of the molecule to the cell wall of S. aureus [98]. 
Previous work has shown that the deletion of this targeting domain does not 
interfere with enzymatic activity but does abolish the lysis of S. aureus cells 
suggesting that it is essential for the correct functioning of lysostaphin [98].   
The flexible inter-domain region of lysostaphin allows the two domains to move 
independently [95]. With the use of small angle X-ray scattering (SAXS) it was 
shown that the flexible linker allows the elongation and contraction of the 
protein with the two domains moving separately [97].   
1.5.1.3 Zoocin A  
Zoocin A (ZooA) is a bacteriocin produced by Streptococcus equi ssp. 
zooepidemincus and targeted towards other Streptococcal species.  ZooA is 
similar in both structure and function to lysostaphin with an N-terminal catalytic 
domain and a C-terminal targeting domain [99,100].  The zooA gene and the 
gene encoding its immunity protein zifA are adjacent on the chromosome [101] 
with the zooA gene encoding a 285 amino acid (AA) ZooA pre-peptide.  The pre-
preptide includes a 27 AA leader sequence to allow for the translocation of ZooA 
across the cell membrane, it is presumed that this is cleaved at the cell surface 
resulting in the 262 AA active molecule [102].   
The structure of both the N- and C-terminal domains of ZooA have been solved 
individually using NMR spectroscopy [99,100] showing an N-terminal domain 
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similar in structure to the catalytic domain of lysostaphin, and a unique C-
terminal domain predicted to be involved in cell wall targeting [103]. Previous 
work has shown ZooA to be a peptidoglycan hydrolase targeted towards 
Streptococcal species [104].  Work by Heath et al (2004) suggested that ZooA is a 
D-alanyl-D-alanine endopeptidase which acts by hydrolysing the alanine cross-
bridges present in the Streptococcal peptidoglycan layer [104,105].   
The presence of Streptococcus mutans in multispecies biofilms can cause dental  
disease in humans [106].  It has been shown that treatment with ZooA can 
successfully reduce the number of S. mutans bacteria present in these biofilms 
suggesting it can be used as a novel treatment against Streptococcus species in 
vivo [106].  Furthermore, at sub-lethal concentrations ZooA can be used to 
permeabilise the membrane of S. mutans in order to deliver anti-sense 
oligonucleotides to the cytoplasm [107].  As lysostaphin is a successful 
antimicrobial it is predicted that similar bacteriocins, such as ZooA, are also 
promising antimicrobials.   
1.5.1.4 Gram-negative bacteriocins targeting the peptidoglycan layer 
Colicin M is a unique colicin that targets the renewal of the peptidoglycan layer 
to cause cell lysis [108].  Unlike the other colicins, colicin M acts by hydrolysing 
the peptidoglycan precursor lipid II [109], thus preventing the production of 
mature peptidoglycan.  Since the discovery of colicin M, several other M-type 
bacteriocins have been characterised, for example pyocin M from Pseudomonas 
and BurM from Burkholderia, however no structures have been solved to date 
[110,111].   
The crystal structure of colicin M showed that it has a three domain structure 
similar to the other colicins [112,113].  It consists of an N-terminal IUTD, a 
central domain which interacts with its outer membrane receptor and the C-
terminal catalytic domain [108].  The N-terminal unstructured domain showed a 
higher degree of flexibility than the other two domains, with a high number of 
proline residues [108].  This highly flexible IUTD is found in other colicins as it 
contains the TonB- on Tol-box motif which interacts with the TonB or Tol proteins 
in the periplasm [43,108].  The central domain is globular and consists entirely 
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of alpha-helices and is predicted to be involved in uptake or in the interaction of 
colicin M with the inner membrane [108].  Finally, the C-terminal domain of 
colicin M is made up of both α-helix and β-strand motifs and is enzymatically 
active (Figure 1-7) [108].  Although the exact mechanism by which M-type 
bacteriocins degrade lipid II remains unclear, mutagenesis studies have identified 
an essential motif (DXYDX5HR) required for hydrolysis [41].  This motif can be 
found within the short β-strand and loop at the C-terminal end of colicin M and 
is conserved within other M-type bacteriocins, such as those produced by 
Pectobacterium spp. and Pseudomonas spp. [41].   
 
Figure 1-7 X-ray crystal structure of colicin M (PDB ID 2XMX) shown with the N-terminal as 
blue and the C-terminal as red. 
Colicin M is a group B colicin and is dependent on the TonB system for uptake 
[108].  The N-terminal IUTD encodes a TonB-box like motif which has been shown 
to be necessary for successful uptake [108].  It is thought that this interaction 
allows for the removal of the plug domain of the outer membrane receptor FhuA 
to allow for colicin M to translocate into the periplasm [108].  Although the 
translocation domains of M-type bacteriocins are specific for their target 
organism, the cytotoxicity of the catalytic domain can indiscriminately target 
peptidoglycans from other Gram-negative bacteria as well as lipid II from Gram-
positive bacteria [114,115].   
As well as M-type bacteriocins, bacteriocins which cleave mature peptidoglycan 
causing cell lysis.  One of these bacteriocins is pesticin from Yersinia pestis 
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which targets related bacteria in the same niche, including Y. pestis and E. coli 
strains [116].    Similarly to the colicins, the pesticin gene is plasmid encoded 
and the pst operon contains both the gene for the bacteriocin and the 
corresponding immunity protein (Pim) [116].   
Like the colicins, pesticin is characterised by its three domain structure, an IUTD 
of ~40 amino acids at the N-terminus, followed by an elongated translocation 
domain consisting of both α-helices and β-strands [116].  The cytotoxic domain 
of pesticin, located at the C-terminus, is unlike any known colicins and is more 
closely related to a phage lysozyme [116].   
The structure of pesticin (Figure 1-8) is novel in many ways and does not 
resemble other proteins, with the N-terminal domain thought to be specifically 
folded to allow for the interaction with the outer membrane receptor FyuA 
[116].  The predicted mechanism of uptake is similar to that of the colicins, the 
interaction of the bacteriocin with the outer membrane receptor, the passage of 
the IUTD into the periplasm of the cell to interact with TonB and the subsequent 
uptake of the bacteriocin [116].  It has been shown that the IUTD is essential for 
the translocation of pesticin into the cell which supports this model [116].   
 
Figure 1-8 X-ray crystal structure of pesticin (PDB ID 4AQN) with the N-terminus shown in 
blue and the C-terminus in red.  
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The cytotoxic domain of pesticin is unique and similar to that of a phage 
lysozyme with additional secondary structure elements [116].  Structural 
unfolding has been shown to be necessary for the uptake of pesticin, this 
flexibility is uncommon amongst bacteriocins and suggests a potential novel 
mechanism of translocation [116].   
 Ferredoxin-containing bacteriocins 
Bacteriocins, such as colicins and pyocins, have a conserved domain structure for 
binding, translocation and cytotoxicity with an N-terminal IUTD needed for 
uptake [43,52,57].  However, the recent discovery of ferredoxin-containing 
pectocins suggests a novel entry mechanism for bacteriocins in the absence of an 
IUTD [117].   
Ferredoxins are small, soluble proteins that function as electron carriers in 
bacteria, plants and animals [118,119].  These proteins are characterised by the 
presence of an iron sulphur cluster, however the number of elements within this 
cluster differs depending on the organism with bacterial ferredoxins typically 
containing either one or two [4Fe-4S] clusters [120].  Plant-type ferredoxins are 
characterised by the presence of a [2Fe-2S] cluster and are part of the 
chloroplast electron transport chain (Figure 1-9) [121].  They are the first 
soluble electron acceptor within the stromal side of the chloroplast and are 
essential for the distribution of electrons to different metabolic pathways [119].   
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Figure 1-9 Structure of spinach (Spinacia oleracea) ferredoxin showing the positioning of 
the iron-sulphur cluster.  Structure of spinach ferredoxin showing the position of the iron-sulphur 
cluster (spheres) within the loop, the N-terminus is shown in blue and the C-terminus in red 
(PDB:1A70).   
Plant-type ferredoxins are distinguished by their small size with a mass of ~10 
kDa and the conserved nature of their amino acid sequence and structure 
between organisms, including cyanobacteria and higher plants [119,122].  
Structurally ferredoxins are composed of three to five β-strands forming a β-
sheet and up to three α-helices with the [2Fe-2S] cluster located near the C-
terminal end of the protein [119].  The [2Fe-2S] cluster is tetrahedrally 
coordinated by four cysteine residues and is surrounded by hydrophobic residues 
[119].  This is in contrast to the rest of the protein which contains a large 
number of charged residues important for binding partner interaction [119].   
Ferredoxin-containing pectocins (hereafter pectocins) are a novel class of 
bacteriocins produced by and targeted towards Pectobacterium species.  To date 
three pectocins have been discovered: pectocin M1, M2 and P.  Pectocins share 
an N-terminal domain which is homologous to spinach ferredoxin II [117].  The 
crystal structure of pectocin M2 showed structural similarities to both spinach 
ferredoxin II at the N-terminal and a C-terminal cytotoxic domain homologous to 
colicin M (Figure 1-10) [123].   
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Although the N-terminal domain of pectocins appears to be specific to 
Pectobacterium species, the cytotoxic domain of the protein has a broader 
killing spectrum if expressed within the cell [114].  Recent work has shown that 
the periplasmic expression of pectocin M1 within E. coli can cause cell death by 
the successful cleavage of lipid II subsequent cell lysis [114,124].   
 
Figure 1-10 Crystal structure of pectocin M2 in the elongated conformation. Pectocin M2 
(PDB ID 4N58) with the ferredoxin N-terminal domain shown in red, flexible linker region in green 
and the cytotoxic domain homologous to colicin M shown in blue   
Unlike colicins which are plasmid encoded, pectocins are chromosomally 
encoded on the genome of Pectobacterium carotovorum [117]. However, similar 
bacteriocins can be found in the genomes of several other plant pathogenic 
species, such as Dickeya chrysanthemi (Figure 1-11).  Pectocins are unique 
amongst the known Gram-negative bacteriocins as they lack an N-terminal IUTD 
suggesting a novel uptake mechanism for these bacteriocins [117].   
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Figure 1-11 Sequence alignment for pectocin M1 homologues in closely related 
phytopathogens Amino acid sequence alignments showing homology between pectocin M1 from 
P. carotovorum and hypothetical bacteriocins from three related species with conserved residues 
shown in red and non-conserved residues in blue. Residues which are shared between three 
species are shown in pink and those shared in two species are highlighted in white.  Alignment 
performed using CLC workbench.  
It is known that Gram-negative bacteriocins parasitise existing nutrient receptors 
for uptake [51], however the uptake of a bacteriocin without the deployment of 
an IUTD is highly unusual [43,117].  The high resolution structure of pectocin M2 
has shown that it is flexible and can be found in multiple conformations in 
solution [123].  The lack of an IUTD means that pectocins are unable to make 
direct contact with the Tol or TonB complexes within the periplasm to facilitate 
uptake [123], however the acquisition of an analogous substrate of the receptor 
allows the pectocin to utilise the target cells uptake machinery for translocation 
without the IUTD [123,124].  The N-terminal domain of the pectocins, as 
mentioned above, is homologous with spinach ferredoxin II, a host protein [117] 
and it has been shown that this allows the pectocins to parasitise the ferredoxin 
outer membrane receptor, FusA, in order to enter the periplasm [124].  FusA is 
found in all Pectobacterium species, with homologues seen in the genomes of 
closely related species [124].  This suggests a potential conserved mechanism of 
ferredoxin and ferredoxin-containing bacteriocin uptake in plant pathogenic 
bacteria.   
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 Ferredoxin uptake system in Pectobacterium spp. 
The ferredoxin uptake system (fus) in Pectobacterium spp. consists of four 
proteins, FusA, FusB, FusC and FusD and is thought to be necessary for the 
uptake and processing of ferredoxins acquired from host cells during infection 
[124,125] (Figure 1-12).  To date the crystal structures of two of these proteins 
have been solved [124,126].  This operon can be seen within several soft rot 
bacteria, with the fusA and fusC homologues in Dickeya dadantii being some of 
the most highly upregulated during infection [124,127].   
 
Figure 1-12 Schematic representation of the organisation of the Fus system in 
Pectobacterium cells.  Operon organisation and predicted positions of the Fus proteins the 
membranes and periplasmic space of Pectobacterium spp. showing the solved crystal structure of 
FusA (PDB ID 4ZGV) and FusC (PDB ID 6BRS) with Phyre2 models representing FusB and FusD.  
Adapted from [124–126] under a creative commons licence.  
FusA is an outer membrane TonB-dependent receptor found in Pectobacterium 
species.  This outer membrane receptor has the characteristic structure of TonB-
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dependent outer membrane receptors with an N-terminal plug domain and a C-
terminal barrel consisting of 22 transmembrane antiparallel β-strands [124].  The 
extracellular loops of FusA are larger than those of other TonB-dependent 
receptors found in related species such as E. coli [124].  These extracellular 
domains largely consist of β-sheet and non-regular secondary structure elements 
and are thought to be highly flexible [124].  The larger of these two 
extracellular loops as well as the N-terminal plug domain extend into the 
extracellular environment, it is therefore predicted that these may be involved 
in substrate coordination and binding [124].   
Once ferredoxin has translocated into the periplasm of Pectobacterium cells it is 
processed by FusC to release the [2Fe-2S] cluster [125].  The FusC crystal 
structure shows that it is a four domain zinc dependent protease found in a 
“clamshell” structure [126].  The active site is found in the centre of the protein 
and is responsible for the processing of plant-type ferredoxins [125,126].  The 
presence of the substrate in the centre of the clamshell structure induces a 
conformational change in which the FusC closes around the ferredoxin via the C-
terminal segment of the substrate [126]. FusC cleaves ferredoxin at two specific 
peptide bonds releasing the central iron coordinating loop which can then be 
taken up into the cytoplasm, presumably by FusD [125].   
So far it is known that FusA and FusC are necessary for the uptake and 
processing of ferredoxins in Pectobacterium species, however the roles and 
interactions of the other two proteins within the operon are unknown [124,125].  
FusB is predicted to be homologous to TonB and it is not known whether it 
interacts with the TonB-box of FusA or with the substrate to aid with 
translocation.  FusD it is predicted to be an ABC inner membrane transporter, 
similar to BtuCD, due to the presence of ATP-binding motifs present in the amino 
acid sequence [128].  It is therefore predicted that it will facilitate the transport 
of the cleaved ferredoxin into the cytoplasm [125].   
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 The study of proteins in solution  
 The principles of small angle scattering  
Small angle scattering (SAS) is a well-established technique which can be used to 
examine both ordered and disordered proteins in solution [129].  SAS allows for 
proteins in a multitude of conformations and orientations to be examined and 
therefore the in solution state of a particle to be deduced [129].  Unlike X-ray 
crystallography, SAS allows for the characterisation of a conformationally 
heterogenous samples as well as flexible and intrinsically disordered proteins 
[129].   
There are two major types of small angle scattering used within the study of 
proteins: small angle neutron scattering (SANS) and small angle X-ray scattering 
(SAXS), the principles of which are largely similar.  Both types of SAS rely on the 
deviation of incoming radiation from its incident path once it comes into contact 
with a macromolecule (Figure 1-13) [130].  This deviation (q) is measured using a 
detector, at a set distance, which measures both the angle and the intensity at 
the angle (i(q)).   
 
Figure 1-13 Schematic representation of small-angle scattering.  The incident wave (either X-
rays or neutrons) interacts with the sample and the angle at which it scatters (2θ) is denoted as q.  
(Adapted from [131]).   
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In order to examine the ‘true’ scattering of a protein corrections are made for a 
variety of physical fluctuations, such as normalising for the incident flux [130].  
Once the data has been corrected the scattering of the solvent is subtracted 
from the scattering of the sample to give only the scattering data for the protein 
in solution [129,130].   
SAXS can be used to examine both soluble and insoluble proteins, however due 
to the tendency of detergent micelles to scatter in a similar way to proteins 
these proteins are more often examined using SANS.  SANS can be used to 
visualise detergent solubilised proteins in solution by matching out the detergent 
using deuterated water.  Using a ratio of water and deuterated water (D2O) a 
contrast match point for the detergent can be found in which the scattering 
length density of the solvent is the same as the detergent [132,133].  This allows 
for the protein to be analysed without visualising the micelle.  Both methods 
however are useful in examining protein conformation in solution.   
Previously, measurements were taken of a stationary sample within a cuvette 
meaning that the protein sample needed had to be in a singular oligomeric state 
for the data to be analysed.  However, the development of size-exclusion 
chromatography small angle scattering (SEC-SAS) has allowed for complex or 
transiently self-associating systems to be separated in situ [134,135].   
  Shape and flexibility analysis of a molecule 
SAS can be used to examine the properties of a given macromolecule in solution 
to determine if a predicted or in crystallo model is a good representation of the 
proteins behaviour and conformations within solution.  Moreover, the ability to 
examine proteins within solution allows for their flexibility and conformational 
changes to be examined more closely.   
The Guinier region is the linear region observed at low scattering angles allowing 
for the extrapolation of the data to the scattering intensity at 0 (i(0)) [129,131] .  
Investigation of the Guinier region of the SAXS scattering curve yields 
information about both the i(0), which is proportional to the molecular weight, 
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and the radius of gyration (Rg) which yields information about the inter-electron 
distances within the particle [130,136].   
The shape and order of a protein can also be examined using a dimensionless 
Kratky plot which is normalised for both mass and concentration.  If the data 
forms a Gaussian distribution, with the peak of the distribution occurring around 
qRg = √3 (~1.73), it suggests that the particle is ordered and globular.  If the 
qRg2(I(q)/I(0)) continues to increase as the qRg increases, this suggests that the 
particle is intrinsically disordered and flexible [129].  In this way a particle can 
be characterised as globular, elongated or highly disordered.  Comparison of the 
Kratky-Debye and Porod-Debye plots simultaneously allows for the particle to be 
classified as compact or flexible [129,137] .  By examining which data set 
plateaus at the highest q value in the low q range the particle can be deemed to 
be either compact or flexible [138].  Together this can determine if a particle is 
flexible in solution, and if so does this flexibility come from a flexible region 
within a folded protein or due to the nature of a highly disordered protein 
[139,140].   
 Low-resolution structural modelling and Computational 
methods of flexibility analysis 
A low-resolution structural envelope of a protein can be created based on the 
pair set distribution of the radial distances between electrons (SAXS) or neutrons 
(SANS) within the particle (p(r)) through an indirect Fourier transformation of 
the scattering data [129,141].  The maximum distance within the particle is 
calculated and ab initio modelling can be used to create a low resolution 
envelope of the protein in solution [141].  In order to construct this model a 
sphere with a radius equal to half the maximum particle dimensions (Dmax) is 
filled with smaller spheres either belonging to the particle or the solvent [141].  
Using DAMMIF, an algorithm is used to determine which small spheres belong to 
the particle and fit the scattering data [141].  This process is done up to 23 
times and the final models are averaged to give the final low resolution envelope 
of the particle [141].  High resolution models or structures obtained from X-ray 
crystallography can be compared with these low-resolution envelopes to 
determine if they are similar in size and shape to known or predicted structures.  
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As mentioned above SAS is a useful tool for examining the flexibility of proteins 
in solution, however, like X-ray crystallography, this flexibility is not always 
shown in structural models.  The advantage of SAS is that it can provide 
information about intrinsically flexible proteins or proteins which contain 
interdomain flexible linker regions.  However, due to the flexibility of these 
molecules in solution it is assumed that the experimental data is an average of 
unknown conformers in solution [142].   
Ensemble optimisation modelling (EOM) can be used to determine which 
conformations from a large pool of randomly generated models best fits the 
experimental SAS data [142].  EOM creates a large pool of available 
conformations and a sub-set of these conformers are selected by the fit to the 
experimental SAS data [139].  Previous work examining pectocin M2 used EOM to 
determine that pectocin M2 can be found in multiple conformations in solution, 
with the structure of two of these conformations being solved using X-ray 
crystallography [123].   
 Aims  
The threat to food security has led to the need to develop novel biocontrol 
strategies to feed an ever-growing population.  This project aims to further 
understand the structure and function of novel bacteriocins from 
Pectobacterium species and GBS to potentially develop them as novel 
therapeutics.  This project aims to characterise a novel bacteriocin from GBS to 
understand the enzymatic activity as well as the structure of the protein.  As 
well as this it aims to elucidate the uptake mechanism of ferredoxin-containing 
bacteriocins, the role of the proteins within the fus operon in bacteriocin uptake 
and the structural and biochemical properties of the bacteriocins themselves.  
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 Chemicals used 
Unless otherwise stated all chemicals and reagents used in this study were 
procured from Sigma Aldrich, Thermofisher or Promega.  
 Culture of bacteria used in this study 
 Pectobacterium atrosepticum strains 
All P. atrosepticum strains were cultured in lysogeny (LB) liquid broth (5% yeast, 
10% tryptone, 10% sodium chloride) or on LB solid agar (LB broth with 1.5% agar).  
All cultures were grown at 28-30oC with liquid cultures shaken at 180 rpm.   
Strain Relevant characteristics Source 
P. atrosepticum   
LMG2386 Isolated from Solanum tuberosum (stem rot) BCCM 
SCRI1043 Isolated from Solanum tuberosum (tuber soft rot) SCRI 
LMG2386 ΔfusA Knock-out of FusA gene Grinter et al. 
(2016)  
 
 Streptococcus agalactiae strains 
GBS strains were cultured on Columbia agar supplemented with 5% sheep’s blood 
(SGL) or TSA supplemented with 5% sheep’s blood (E&O laboratories) at 37oC.  
GBS strains were grown in BHI broth (Oxoid) at 37oC, shaking at 180 rpm.   
Table 2-1 Streptococcus strains used in this study 
Strain Relevant characteristics Source 
STIR CD01 (ST7) Isolated from Mullet, serotype Ia Kuwait 
MRI Z1-354 (ST67) Isolated from Cattle, serotype Ia Denmark 
MRI Z2-197 (ST7) Isolated from Cattle  United Kingdom 
MRI Z2-366 (ST263) Isolated from Tilapia, serotype III Vietnam 
STIR CD25 (ST263) Isolated from Tilapia, serotype III Thailand 
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 Escherichia coli strains  
All E. coli strains were commercially available laboratory strains and grown in 
the appropriate antibiotics at 37oC.   
Table 2-2 E. coli strains used in this study 
Strain Relevant characteristics Source 
DH5-α F- Φ80lacZΔM15 Δ(lacZYA-argF) U169 recA1 endA1 
hsdR17(rk-, mk+) phoA supE44 thi-1 gyrA96 relA1 λ 
Invitrogen 
BL21 (DE3)* F-ompT hsdSB (rB-, mB-) galdcmrne131 (DE3) Invitrogen 
BL21 (DE3) pLysS F–, ompT, hsdSB (rB–, mB–), dcm, gal, λ(DE3), pLysS, 
Cmr. 
Promega 
 
 Antibiotics used in culturing  
All antibiotics used in this study were procured from Melford or Sigma Aldrich.   
Table 2-3 Antibiotics used in this study 
Antibiotic Final Concentration Solvent 
Ampicillin 100 μg μl-1 Water 
Kanamycin 50 μg μl-1 Water 
Chloramphenicol 32 μg μl-1 Ethanol 
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 Plasmids used in this study  
Table 2-4 Plasmids used in this study 
Plasmid Relevant characteristics Source 
   
pfusA2386 fusA gene from P. atrosepticum LMG2386 
synthesised for complementation  
DNA 2.0 
pfusA2386N151A As above with an N151A mutation This study 
pfusA2386Y155A As above with an Y155A mutation This study 
pfusA2386P157G As above with an P157G mutation This study 
pfusA2386F376A As above with an F376A mutation This study 
pfusA2386F378A As above with an F378A mutation This study 
pfusA2386F380A As above with an F380A mutation This study 
pfusA2386N401A As above with an N401A mutation This study 
pfusA2386G489A As above with an G489A mutation This study 
pfusA2386N491A As above with an N491A mutation This study 
pPCM1_pJ404 Plasmid containing codon optimised Pectocin 
M1 gene 
DNA 2.0 
pFRIB1043 Expression plasmid containing the fusA gene 
from P. atrosepticum SCRI1043 in a pET28a 
vector.  
Rhys Grinter 
pfusB1043 FusB gene from P. atrosepticum SCRI1043 
codon optimised for expression in E. coli 
DNA 2.0 
pfusA-Plug pET21a vector plasmid containing AAs 29-210 
of fusA from P. atrosepticum SCRI1043 
This study 
pPCM1T3A As above with a T3A mutation in pJ404 This study 
pPCM1K5A As above with a Y4A mutation in pJ404 This study 
pPCM1K5A As above with a K5A mutation in pJ404 This study 
pPCM1K7A As above with a K7A mutation in pJ404 This study 
pPCM1N12A As above with a N12A mutation in pJ404 This study 
pPCM1F15A As above with a F15A mutation in pJ404 This study 
pPCM1E16A As above with a E16A mutation in pJ404 This study 
pPCM1D19A As above with a D19A mutation in pJ404 This study 
pPCM1C38A As above with a C37A mutation in pJ404 This study 
pPCM1S52A As above with a S25A mutation in pJ404 This study 
pPCM1R58A As above with a R57A mutation in pJ404 This study 
pPCM1S60A As above with a S60A mutation in pJ404 This study 
pPCM1E65A As above with a E65A mutation in pJ404 This study 
pPCM1Y70A As above with a Y70A mutation in pJ404 This study 
pPCM1K86A As above with a K86A mutation in pJ404 This study 
pPCM1Y4AK5E As above with a Y4A and K5E mutations in 
pJ404 
This study 
pPectocinP Codon optimised Pectocin P sequence in 
pET100a with a TEV cleavable 6x histidine tag  
GeneArt  
pAgaA pJ404 plasmid containing codon optimised 
agalacticin A gene 
DNA 2.0 
pAgaAH23A As above with H23A mutation in pJ404 This study 
pAgaAH108A As above with H109A mutation in pJ404 This study 
pAgaAC67A As above with C63A mutation in pJ404 This study 
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 DNA manipulation  
 Polymerase chain reaction  
50 μl reactions were set up for each polymerase chain reaction (PCR).  Each 
reaction contained 20 ng of DNA, 1 x pfu turbo buffer, 40 mM dNTPs, 0.1 μM 
forward and reverse primer and 1-2.5 units of pfu turbo polymerase.  The 
standard programme for a PCR reaction is as below (Table 2-5).  A lower number 
of cycles were used for site-directed mutagenesis (SDM) whereas a higher 
number of cycles were used for amplification of genes for cloning.  
Table 2-5 Standard PCR program used in this study 
 
 
 
If no product was seen within the first reaction 10% DMSO and 2.5 mM MgCl2 were 
added to subsequent reactions to enhance binding of oligos.  Temperatures from 
45-65oC were also tested if necessary. 
 
 
  
Temperature Duration (m) 
95 oC 5 minutes 
95 oC 45 seconds 
57 oC 45 seconds 
68 oC 1 min per kb +1 min 
68 oC 5 minutes  
18/35 cycles  
58 
Table 2-6 List of primers used for sequencing reactions 
Primer Sequence (5’-3’) Use 
FusA2386_Seq1_F ATG AAT AAG AAC GTC TAT TTA 
ATG ATG Sequencing first 500bp of fusA in LMG2386 FusA2386_Seq1_R CTT AGC CGA AAT ATT ACT ATC  
FusA2386_Seq2_F GAT AGT AAT ATT TCG GCT 
AAG  Sequencing bps 500-1000 of 
fusA in LMG2386 FusA2386_Seq2_R CTG ATA TCC CGC CAG ACT GGT 
C  
FusA2386_Seq3_F GAC CAG TCT GGC GGG ATA 
TCA G  Sequencing bps 1000-1500 of 
fusA in LMG2386 FusA2386_Seq3_R CGT TCA GAT TTT CCA AGA AGT 
C  
FusA2386_Seq4_F GAC TTC TTG GAA AAT CTG AAC 
G  Sequencing bps 1500-2000 of 
fusA in LMG2386 FusA2386_Seq4_R GAA GTA AGT ATC CAC ACT CAG 
G  
FusA2386_Seq5_F CCT GAG TGT GGA TAC TTA CTT 
C  Sequencing bps 2000+ of fusA in LMG2386 FusA2386_Seq5_R TTA CCA GGT GTA AGC GAC GC  
PCM1_Seq_F AGGAGGTAAAACATATGGCC Sequencing PCM1 ORF in 
PCM1_pJ404 plasmid PCM1_Seq_R CTC GAG CTA GTG GTG ATG 
Zoo_Seq_F AGG AGG TAA AAC ATA TGG 
ACA C Sequencing Zoo ORF in Zoo_pJ404 plasmid Zoo_Seq_R GGT GGT GGT GGT GCT CTT TG 
 
Table 2-7 List of primers used for site-directed mutagenesis of plasmids 
Primer Sequence (5’-3’) 
Pectocin M1 (PCM1_pJ404) – all mutations are in the primer name 
PCM1_T3A_F GGTAAAACATATGGCCGCGTACAAAATTAAAG 
PCM1_T3A_R CTTTAATTTTGTACGCGGCCATATGTTTTACC 
PCM1_Y4A_F AGG AGG TAA AAC ATA TGG CCA CGG CCA AAA TTA AAG ATC TGA 
CCG 
PCM1_Y4A_R CGG TCA GAT CTT TAA TTT TGG CCG TGG CCA TAT GTT TTA CCT CCT 
PCM1_K5A_F AAA ACA TAT GGC CAC GTA CGC AAT TAA AGA TCT GAC CGG TAA TG 
PCM1_K5A_R CAT TAC CGG TCA GAT CTT TAA TTG CGT ACG TGG CCA TAT GTT TT 
PCM1_K7A_F GCCACGTACAAAATTGCAGATCTGACCGGTAATG 
PCM1_K7A_R CATTACCGGTCAGATCTGCAATTTTGTACGTGGC 
PCM1_N12A_F AAA GAT CTG ACC GGT GCT GTT GAG TTT GAG TGT TCG G 
PCM1_N12A_R AAC ACT CAA ACT CAA CAG CAC CGG TCA GAT CTT T 
PCM1_S52A_F TCG CGC TGT TAA TTG CCG GTT CTG TTG ATC AGC 
PCM1_S52A_R GCT GAT CAA CAG AAC CGG CAA TTA ACA GCG CGA 
PCM1_Y70A_F GGA TGA AGA ACA GCA AAA GGC CTT TGT CCT CAC CTG TGC 
PCM1_Y70A_R GCA CAG GTG AGG ACA AAG GCC TTT TGC TGT TCT TCA TCC 
PCM1_K86A_F GAA CAG CAA CTG TGT GAT CGC GAC CGG CGT GGA AGA AAT 
PCM1_K86A_R ATT TCT TCC ACG CCG GTC GCG ATC ACA CAG TTG CTG TTC 
PCM1_Y4AK5E_F AAA ACA TAT GGC CAC GGC CGA AAT TAA AGA TCT GAC CGG TAA 
PCM1_Y4AK5E_R TTA CCG GTC AGA TCT TTA ATT TCG GCC GTG GCC ATA TGT TTT 
PCM1_D19A_F CGA TAC GTA CAT CTT GGC TGC AGC AGA AGA GGC TG 
PCM1_D19A_R CAG CCT CTT CTG CTG CAG CCA AGA TGT ACG TAT CG 
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PCM1_R57A_F GTT CTG TTG ATC AGG CTG ACG CGA GCT TCC TG 
PCM1_R57A_R CAG GAA GCT CGC GTC AGC CTG ATC AAC AGA AC 
PCM1_S60A_F CAG CGT GAC GCG GCC TTC CTG GAT GAA GAA C 
PCM1_S60A_R GTT CTT CAT CCA GGA AGG CCG CGT CAC GCT G 
PCM1_E64A_F GAG CTT CCT GGA TGC AGA ACA GCA AAA GTA CTT TG 
PCM1_E64A_R CAA AGT ACT TTT GCT GTT CTG CAT CCA GGA AGC TC 
PCM1_F15A_F GAC CGG TAA TGT TGA GGC TGA GTG TTC GGA CGA TAC 
PCM1_F15A_R GTA TCG TCC GAA CAC TCA GCC TCA ACA TTA CCG GTC 
PCM1_E16A_F CGG TAA TGT TGA GTT TGC GTG TTC GGA CGA TAC 
PCM1_E16A_R GTA TCG TCC GAA CAC GCA AAC TCA ACA TTA CCG 
  
fusA 2386 mutants (pfusA2386) 
FusA_N151A_F GTG AAT TGG GCT CGG CTC CTG ATG GAT ACA GCC 
FusA_N151A_R GGC TGT ATC CAT CAG GAG CCG AGC CCA ATT CAC 
FusA_Y155A_F GA ATC CTG ATG GAG CCA GCC CGA CCG ATT TAC CTG 
FusA_Y155A_R CAG GTA AAT CGG TCG GGC TGG CTC CAT CAG GAT TC 
FusA_P157G_F GAT GGA TAC AGC GGG ACC GAT TTA CCT GCT GGT GG 
FusA_P157G_R CC ACC AGC AGG TAA ATC GGT CCC GCT GTA TCC ATC 
FusA_F376A_F GAG CAT GAA TCT AAT GAG GCT ATT AGC TGG TTC CAC ACT GTT CC 
FusA_F376A_R CC CAG GAA CAG TGT GGG CCC AGC TAA TAA ACT CAT TAG ATT CAT 
FusA_S378A_F CAT GAA TCT AAT GAG TTT ATT GCC TGG TTC CAC ACT GTT CCT GGG 
T 
FusA_S378A_R A CCC AGG AAC AGT GTG GAA CCA GGC AAT AAA CTC ATT AGA TTC 
ATG 
FusA_F380A_F ATG AAT CTA ATG AGT TTA TTA GCT GGG CCC ACA CTG TTC CTG GG  
FusA_F380A_R CC CAG GAA CAG TGT GGG CCC AGC TAA TAA ACT CAT TAG ATT CAT 
FusA_N401A_F GGC AGA CTA CAA ACA GAG CTT CAC AGG TTGGTG GCT ATG 
FusA_N401A_R CAT AGC CAC CAA CCT GTG AAG CTC TGT TTGTAG TCT GCC 
FusA_G489A_F CCC GGT GAG CAG TTT GCT GCC ACT AAC ATAGTT TAC CCA G 
FusA_G489A_R CTG GGT AAA CTA TGT TAG TGG CAG CAA ACTGCT CAC CGG G 
FusA_N491A_F GTG AGC AGT TTG CTG GCA CTG CCA TAG TTTACC CAG CCC G 
FusA_N491A_R CGG GCT GGG TAA ACT ATG GCA GTG CCA GCAAAC TGC TCA C 
  
 Agalacticin A mutants (pAgaA) 
AgaA_H23A_F GTT TTA ATG GTT ATC CGG GTG CTT GCG GCG TTG ATT ACG C 
AgaA_H23A_R GCG TAA TCA ACG CCG CAA GCA CCC GGA TAA CCA TTA AAA C 
AgaA_C63A_F GAC CGA TCT GGC TGG TAA CGC TGT TAT GAT CCA ACA TGC CG 
AgaA_C63A_R CGG CAT GTT GGA TCA TAA CAG CGT TAC CAG CCA GAT CGG TC 
AgaA_H109A_F CCG GTA TGG CGA CGG GTC CGG CCT TGC ACT TTG AGT TCC TG 
AgaA_H109A_R CAG GAA CTC AAA GTG CAA GGC CGG ACC CGT CGC CAT ACC GG 
 
Table 2-8 List of primers used for amplification and cloning of genes. 
Primer Sequence (5’-3’) Use RE site 
FusA_Plug_NdeI GCATACATATGGATGAAAATCAGCAG
AAAAAC 
Cloning the plug 
domain of FusA1043 
into pET21a 
NdeI 
FusA_Plug_XhoI GCATACTCGAGTTTATCCAGCTTGGG
ATCC 
XhoI 
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 Creation of mutants by site directed mutagenesis 
Primers were designed to be ~40 bp in length with the initial and final bases to 
end on a C or G with the mutation in the centre of the primer, the reverse 
primer was the reverse complement of the forward primer with a melting 
temperature >70oC.  
PCRs were set up as in 2.3.1 and 1 μl of DpnI was added to the final PCR product 
and incubated for 1 hour at 37oC.  5-10 μl of this reaction was transformed into 
50 μl of DH5-α cells (see section 2.3.7) and 100 μl of the final product was 
spread onto LB agar plates with the appropriate antibiotics. If no colonies were 
seen then the remaining reaction was spread after 16 hours at room temperature 
(RT).  
Plasmids were extracted from all colonies that grew (see 2.3.10) and mutations 
were confirmed by sequencing (Source Bioscience). 
 Purification of PCR fragments  
PCR products were purified using a Qiagen PCR purification kit as per the 
manufacturer’s instructions with the exception that the original DNA product 
was applied to the column twice and the elution buffer (EB) was incubated on 
the membrane for 5 minutes prior to elution. DNA concentrations were checked 
using a nanodrop 1000 spectrophotometer (Thermo Scientific).  
 Restriction enzyme digests 
1 μg of DNA was digested for a minimum of 1 hour at 37oC with 1 unit of enzyme 
in 1 x fast digest buffer (Promega) or Cutsmart buffer (NEB) depending on the 
enzyme manufacturer in a 50 μl total reaction volume.  Plasmids were 
subsequently CipA (NEB) digested for 1 hour at 37oC before ligation.  
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 Purification of DNA from agarose gels  
Gel slices were purified using a Qiagen gel purification kit as per the 
manufacturer’s instructions with the exception that the original DNA product 
was applied to the column twice and the EB was incubated on the membrane for 
5 minutes prior to elution. DNA concentrations were checked using a nanodrop 
1000 spectrophotometer (Thermo Scientific). 
 Ligation reactions  
Insert was added at a 1:3 molar ratio (plasmid:insert) to 50 ng of digested 
plasmid DNA.  Products were ligated together using 400 units (1 μl) of T4 DNA 
ligase (NEB) in 1 x ligase buffer overnight at ~16oC.  10 μl of the ligation reaction 
was transformed into competent cells (see section 2.3.7) and colonies were 
tested using both a restriction enzyme (RE) digest and PCR.  
 Creation and transformations of chemically competent E. 
coli cells by heat shock  
 DH5-α E. coli cells were inoculated 1:100 into 50 ml of LB broth and grown to 
OD600 ~0.4 at 37 oC, 180 rpm.  Cells were harvested at 4500 rpm, 4oC for 10 
minutes. Cells were resuspended in 25 ml of ice cold 0.1 M CaCl2 and harvested 
again at 4500 rpm, 4oC for 10 minutes.  This was repeated twice more halving 
the resuspension volume each time.  Cells were finally resuspended in 500 μl of 
ice cold 10% glycerol and 50 μl was used per transformation.   
For known plasmids 2 μl of plasmid (~300 ng) was placed into 50 μl of cells.  For 
ligation reactions or mutagenesis PCR reactions 5-10 μl was placed into 50 μl of 
cells.  
Cells were incubated on ice for 30 minutes, followed by at 42oC for 45 seconds 
followed by a further 5 minutes on ice.  300 μl of S.O.C. media was added and 
cells were incubated for 1-2 hours, 37oC, and 180 rpm. After incubation 100 μl 
was plated onto LB agar with the corresponding antibiotic and incubated 
overnight at 37oC.  
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 Creation and transformation of electro-competent cells  
P. atrosepticum strains were inoculated 1:100 into 50 ml of LB media and grown 
to OD600 ~0.4.  Cells were harvested at 4500 rpm, 4 oC for 10 minutes. Cells were 
resuspended in 25 ml of ice cold sterile dH2O and harvested again at 4500 rpm, 4 
oC for 10 minutes.  This was repeated twice, halving the resuspension volume 
each time.  Cells were resuspended in 500 μl of ice cold 10% glycerol and 200 μl 
was used per transformation.  
200 μl of cells and 5 μl of plasmid were added to a microporation cuvette and 
incubated for 2 minutes on ice. Cells were electroporated at 2.5 kV applied at a 
capacitance of 25 μF (Invitrogen) and incubated for 1-2 hours in 1 ml of S.O.C. 
media at 28oC and 180 rpm.  150 μl was spread on an LB plate with the 
corresponding antibiotics and incubated for 24-48 hours at 28oC with the 
remaining transformation left overnight at RT.  If no small colonies had appeared 
overnight the rest of the transformation was harvested (4500 rpm) and spread 
onto an LB plate supplemented with the required antibiotic.  
 Electrophoresis  
Agarose gel electrophoresis was used to separate DNA fragments for both PCR 
and plasmid verification. 1% agarose Tris-boric acid-EDTA gels were prepared 
with 0.1 μg ml-1 Sybrsafe (Invitrogen) to visualise the bands. Gels were imaged 
using the ChemiDoc system (Bio-Rad). 
 Plasmid DNA extraction  
5 ml of overnight bacterial cultures were harvested at 14000 rpm for 3 minutes. 
PCR products were purified using a Qiagen mini-prep kit as per the 
manufacturer’s instructions with the exception that the original DNA was applied 
to the column twice and the EB was incubated on the membrane for 5 minutes 
prior elution. DNA concentrations were measured using a nanodrop.   
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 Bacteriocin toxicity assays  
 Spot-test overlay method 
2.4.1.1 Pectobacterium spp.  
LB agar with 200 μM bipyridine was overlaid with 5-20 ml of 0.8% agar inoculated 
with 100 μl of bacterial culture in mid log phase (OD600 0.4-0.6) depending on the 
petri dish size. 2-5 μl of pectocin was spotted on in 3-fold dilutions.  ΔfusA 
strains containing complementation plasmids were grown in broth supplemented 
with D-lactose (2% w/v) and the appropriate antibiotic.  After incubation 
overnight, an overlay of 0.8% agar with a 10% PrestoBlue was added to each 
plate and incubated at RT for 10 minutes.  Plates were imaged using the 546 nm 
filter on the Chemidoc.  Prestoblue is a non-toxic resazurin based reagent which 
changes colour when metabolised by live cells [143], this was used to increase 
the contrast between zones of inhibition (blue) and live cells (pink) in order to 
better visualise the zones.  
2.4.1.2 Streptococcus agalactiae 
BHI agar plates were overlaid with 5 ml of 0.8% agar inoculated with 100 μl of 
mid-log phase bacterial culture (OD600 = 0.6).  2 μl of bacteriocin was spotted on 
in 3-fold decreasing concentrations from 0.3 mg ml-1 unless otherwise stated. 
Plates were incubated at 37oC overnight.  
 Streptococcus liquid growth assays  
Cultures inoculated with a single colony were grown overnight at 37oC.  50 ml of 
BHI broth was inoculated at a 1:50 dilution and 200 μl was added to each well of 
a 96 well plate.  Plates were incubated at 37oC, 180 rpm and readings taken 
every hour on a plate reader at OD630. After 3 hours 10 μl of filter sterilised 
bacteriocin, mutants or ampicillin was added to the corresponding well and was 
incubated for a total of 8 hours with measurements taken at hourly intervals.   
64 
 Recombinant protein expression 
 Soluble proteins 
Recombinant proteins were expressed in E. coli BL21 (DE3) pLysS (Promega) 
cells, except for pectocin P which was expressed in BL21-star (DE3) cells. 2.5 or 
5 L of LB was inoculated 1 in 50 with an overnight culture and grown to OD600 ~ 
0.6 before induction.  Bacterial cultures were induced with 0.1-0.3 mM IPTG and 
grown at 24-37oC for 3-16 hours (see Table 2-9 for details for individual proteins) 
depending on the optimal expression conditions for each protein.  
Table 2-9 Induction conditions of proteins used in this study 
Protein  Soluble/ 
insoluble 
IPTG 
concentration 
Induction 
temperature 
Induction 
time 
Pectocin M1 and 
mutants 
Soluble 0.3 mM 25oC 16 hours 
Pectocin P Soluble 0.3 mM 30oC 6 hours 
FusA Full length Insoluble 0.1 mM 25oC 16 hours 
FusA Plug Soluble 0.3 mM 37oC 3 hours 
FusB Soluble 0.3 mM 37oC 3 hours 
Agalacticin A and 
mutants 
Soluble 0.3 mM 37oC 3 hours 
FusA Barrel  Insoluble 0.3 mM 37oC 3 hours 
 
Bacteria were harvested by centrifugation at 5000 rpm, 4oC for 15 minutes.  
Pellets were resuspended in 35 ml nickel binding buffer (20 mM Tris-HCl, 500 mM 
NaCl, 10 mM Imidazole, 5% glycerol, pH 7.5) supplemented with one complete 
protease inhibitor tablet (EDTA-free), 35 mg of lysozyme and 1 mg of DNAse I.  
After resuspension the bacteria were lysed by sonication on ice for 15 minutes at 
12 mA for 15 seconds every minute. Soluble proteins were harvested by 
centrifugation at 18000 rpm for 20 minutes at 4oC.   
Crude lysate was applied to a 5 ml His-trap HP column (GE healthcare) and 
eluted over a gradient 0-350 mM imidazole over 40 ml. Fractions were checked 
for the desired protein using gel electrophoresis and fractions containing the 
protein were dialysed into size exclusion chromotography buffer (50 mM Tris-
HCl, 200 mM NaCl, 5% glycerol, pH 7.5) overnight at 4oC.  
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Dialysed samples were centrifuged for 10 minutes at 148000 rpm in a microfuge 
to remove any insoluble matter or aggregates. The supernatant was applied to a 
Superdex S75 (<40 kDa) or S200 (>40 kDa) size exclusion chromatography 
columns and fractions containing the desired protein were combined and 
concentrated as required.  
 Insoluble proteins  
Insoluble proteins were purified from inclusion bodies from BL21 (DE3) pLysS 
cells.  Cells were harvested and lysed (see for 2.5.1) and centrifuged at 18000 
rpm, 20 minutes 4oC to remove soluble proteins.  The insoluble pellet was 
homogenised in 40 ml of 50 mM Tris-HCl, 1.5% LDAO, pH 7.5 using a tight-fitting 
homogeniser and incubated for 30 minutes at RT shaking. The insoluble material 
was then harvested as above. The pellet was again homogenised and harvested 
as before.  The pellet was then washed in 50 mM Tris-HCl pH 7.5 and centrifuged 
again.  
The pellet was homogenised in 40 ml denaturing buffer (10 mM Tris-HCl, 1 mM 
EDTA, 8 M Urea, 1 mM DTT, pH 7.5) and incubated at 56oC for 30 minutes. The 
now soluble lysate was harvested at 8000 rpm for 10 minutes at 4oC and then 
added dropwise to a rapidly stirring refolding buffer at RT (20 mM Tris-HCl, 1 M 
NaCl, 5% LDAO) at a 1:1 ratio.  After refolding for 1.5 hours the proteins were 
dialysed overnight into 20 mM Tris-HCl, 500 mM NaCl, 10 mM imidazole and 0.1% 
LDAO.   
Solubilised proteins were purified using a 5 ml His-Trap HP column (GE 
Healthcare) using the above dialysis buffer and was eluted using dialysis buffer 
with 350 mM imidazole.  The eluted fractions were examined by SDS-PAGE to 
check for the desired protein and dialysed overnight in 50 mM Tris-HCl, 200 mM 
NaCl, and 0.1% LDAO.  After dialysis the protein was applied to a Superdex S200 
column and the purity assessed by SDS-PAGE.  
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 SDS-PAGE 
Tris-glycine SDS-PAGE gels were loaded with 5-10 μl of protein in 4x loading 
buffer and run until the ladder separation could be seen. Gels were incubated in 
coomaissie blue stain (0.2% Brilliant blue, 50% methanol, 10% acetic acid) for 30 
minutes and destained in 10% methanol and 10% acetic acid for 2-4 hours.  
Gels were either made in-house or pre-cast from Invitrogen. 12% gels were used 
for proteins of interest >40 kDa and 16% for proteins of interest <40 kDa.  
 In vitro protein assays  
 Nitrocefin assay  
Nitrocefin is a β-lactam which visibly changes in colour when it is hydrolysed by 
a β-lactamase (see Figure 5-6) which can be representative of peptidoglycan 
hydrolysis.  This visible colour change can be measured at an absorbance of 490 
nm and therefore is a quantitative method to assess β-lactamase activity.  
Stocks of nitrocefin were dissolved in 10 mM potassium phosphate buffer pH 5.8 
to a final concentration of 46 mM. 50μl of stock nitrocefin (230 μM) was added to 
10 ml of 50 mM Tris-HCl, pH 7.5 and stored at 4oC until needed.   
50 μl of Nitrocefin was incubated with 15 μg, 7.5 μg, 3.7 μg and 1.87 μg of 
agalacticin A in a final volume of 100 μl.  Samples were placed in a 96 well plate 
and absorbance at 490 nm was measured every 20 seconds for 30 minutes using a 
microplate reader (Elx 808IU, Bio-Tek instruments Inc).  Samples were kept at 
37oC with light shaking before each measurement 
 Micrococcus degradation assay  
Micrococcus lysodeikticus (Sigma) lyophilised cells were resuspended in Tris–HCl 
pH 7.5 at a 0.01% w/v.  160 μl Micrococcus solution was incubated with 10 μl 
lysozyme (5 mg ml-1 and 2.5 mg ml-1) and pectocin P (20 mg ml-1 and 10 mg ml-1) 
and pectocin M1 (10 mg ml-1).  Degradation of M. lysodeikticus peptidoglycan 
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was measured at 450 nm for 3 hours in a microplate reader (see 2.6.1) with 
measurements taken every 30 seconds with light shaking before each 
measurement.  
 Biophysical techniques 
 Small-angle X-ray scattering  
All small angle x-ray scattering (SAXS) data was collected at the B21 beamline at 
Diamond Light Source (Harwell, UK) using both size exclusion chromatography 
(SEC-SAXS) and a sample injection robot (bioSAXS).  Data was collected at a 
detector distance of 4 m with a flux of 12.4 keV.  All data analysis was 
performed using ScÅtter3 (Rambo, DLS) and verified using ATSAS [144]. 
For bioSAXS measurements, buffers were measured before and after sample 
measurements and an average buffer measurement was subtracted from the 
scattering data.  For SEC-SAXS samples 50 frames of buffer before elution were 
used as the buffer measurement and subtracted from the sample.   
For SEC-SAXS 45μl of protein (>5mg ml-1) was injected into a SHOdex KW-402.5 
(<50kDa proteins) or KW-403 (>50kDa proteins) column and scattering 
measurements taken every 3 seconds. 30 μl bioSAXS samples were measured at 
1-10 mg ml-1 unless otherwise stated in 2-fold dilutions.  The concentration 
showing the least radiation damage, as measured by excess kurtosis of each 
frame, was used for further analysis.  
The self-association or aggregation was measured by analysing the Guinier region 
of each scattering curve. Curves in which no Guinier region could be analysed 
were excluded. Particle shape and foldedness were analysed by raising 
examining qx i(q) vs qx where x= 1-4 and using dimensionless Kratky analysis qRg2 
(I(q)/I(0) vs qRg where Rg is the radius of gyration.  The p(r) distribution allowed 
for the calculation of the maximum particle dimensions (Dmax).  This distribution 
was used to create a dummy atom model envelope using DAMMIF [141].   
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 Small angle neutron scattering  
Small angle neutron scattering (SANS) experiments were carried out on D22 (ILL, 
Grenoble) at a detector distance of 5.6 m.  180 μl of FusA1043 was measured in a 
0.5 mm quartz cuvette for 10 minutes at a 5.6 m length.  Samples were 
measured in 5.5% D2O and reduced by Anne Martel (Beam line responsible).  Data 
was analysed as for the SAXS analysis using ATSAS [145].   
 Ensemble optimisation modelling  
The ensemble optimisation modelling (EOM) web interface was used [139] to 
model 10 000 independent models and plot hypothetical SAXS curves for each 
predicted model.  Domain 1 was kept in its original PDB co-ordinates in order to 
account for potential flexibility of the protein; however, domains 2 and 3 
remained free.  The determined Rg and Dmax were plotted using Graph-pad 
prism.  EOM was used to model the flexibility in pectocin M1, P and agalacticin A 
with the domains chosen shown below.  
Table 2-10 Amino acid residues chosen for each domain to be modelled using EOM to 
examine the flexibility of each protein.  
Protein Domain 1 Domain 2 Domain 3 
Pectocin M1 1-91 92-116 117-268 
Pectocin P 1-94 95-124 125-318 
Agalacticin A 1-132 133-164 165-274 
 
 CRYSOL modelling of SAXS data  
Predicted models for pectocin M1 were created based on the crystal structures 
of its homologue pectocin M2 which has been crystalized in two conformations 
(PDB ID 4N58 and 4N59). Models were created using both I-TASSER and Phyre2 
[146].  CRYSOL was used to create hypothetical scattering curves based on each 
of these models to determine whether the SAXS data may be made up of a mixed 
population of structures [147].  For pectocin P and agalacticin A the predicted 
flexibility models generated by EOM were used to calculate theoretical 
scattering curves for elongated and compact conformations.   
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 Circular Dichroism  
Protein spectra were measured in 50 mM Tris-HCl, 50-200 mM NaCl and 5% 
glycerol buffer at ~0.5 mg ml-1 for the far UV range and ~1 mg ml-1 for the near 
UV range with the data standardised to the absolute protein concentration. All 
spectra were obtained in a 0.2 mm path length quartz cuvette using a Jasco J-
810 spectropolarimeter.  Measurements were carried out by June Southall, 
University of Glasgow. Secondary structure estimates were made using both the 
CONTIN-LL and CDSSTR methods [148].   
 SEC-MALS 
SEC-MALS experiments were conducted by June Southall, University of Glasgow.  
FusB1043 was purified (as in 2.5.1) and concentrated to 30 mg ml-1in 200 NaCl, 50 
mM Tris-HCl, 5% glycerol pH 7.5 in HPLC grade dH2O.  FusB1043 was loaded onto a 
Waters Xbridge BEH200 SEC 3.5μ7.8x300 column at a final concentration of 30, 
10, 5 and 1 mg ml-1.   
 Analytical ultracentrifugation 
Sedimentation velocity (SV) data were acquired in a Beckman Coulter optima XL-
I analytical ultracentrifuge using either an an-50 Ti eight-hole rotor or an an-60 
Ti four holed rotor (Beckman Coulter).  360 μl of dialysate and protein solutions 
were loaded into 12 mm path-length charcoal-filled epon double sector 
centrepiece with sapphire windows.  
SV data were gathered at 49000 rpm for ~18 hours with scans collected every 7 
minutes (8 hole) or 3 minutes (4 hole) using absorbance optics at 280 nm and 
interference optics if necessary. Sample concentrations of 0.5 mg ml-1 to 3 mg 
ml-1 were measured depending on the 280 Δnm absorbance to ensure all 
absorbance was 0.5-1.5 mAU.  
SEDNTERP was used to calculate the partial specific volume (Vഥ) from the amino 
acid sequence, buffer density (ρ) and buffer viscosity (η) at both 20oC and 4oC. 
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For interacting systems average Vഥ of the components within the system was 
used.  The values were used to analyse the data and can be found in Table 2-11. 
Table 2-11 Details of proteins, buffers and corresponding parameters used in AUC data 
analysis for SV experiments 
 
Sedimentation velocity data were analysed using SEDFIT to obtain experimental 
sedimentation coefficients using the continuous c(s) distribution model.  
Hypothetical sedimentation coefficients based on predicted models of each 
protein were calculated to compare with the experimental data using US-SOMO 
[149].   
 Crystallography  
Initial crystallisation trials were set up using a Cartesian Honeybee 8+1 
dispensing robot into 96 well plates via the sitting drop method with a reservoir 
volume of 80 μl and drop size of 0.5 μl protein and 0.5 μl of the reservoir 
solution by vapour diffusion.  Proteins were screened in Morpheus, JCSG+, Midas 
and PACT trays from molecular dimensions.  Trays were incubated at 16oC for >6 
months and checked for crystal growth.  
 Plant Infections 
 Infection of Solanum tuberosum tubers 
P. atrosepticum LMG2386 were grown in liquid culture overnight in LB broth, 200 
μM bipyridine, 2% w/v D-lactose and ampicillin for complimented strains. 
Protein Temp.  Buffer  
(all pH 7.5) 
Partial 
specific 
volume 
(ml/g) 
Buffer 
density 
(g/ml) 
Buffer 
viscosity 
(poise) 
Agalacticin 
A 
4 oC 
20 oC 
50 mM Tris, 200 mM 
NaCl, 5% Glycerol 
0.72186 
0.73078 
1.0243 
1.0225 
0.018828 
0.012039 
Pectocin 
M1 
4 oC 
20 oC 
50 mM Tris, 200 mM 
NaCl, 5% Glycerol 
0.71818 
0.72711 
1.0243 
1.0225 
0.018828 
0.012039 
FusB 4 oC 
20 oC 
50 mM Tris, 200 mM 
NaCl, 5% Glycerol 
0.72027 
0.72919 
1.0243 
1.0225 
0.018828 
0.012039 
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Bacteria were harvested at 4500 rpm for 10 minutes and resuspended in 1/5th 
the original growth volume in sterile 10 mM MgCl2 or 10 mM MgSO4.   
The optical density of cultures was then corrected to A600 = 0.45 or 0.9, 
corresponding to ~5 x105 and ~10 x106 respectively.  100 μl of this standardised 
culture was placed onto the potato (S. tuberosum, Isle of Jura variety).  Slices of 
around 1 cm in thickness were incubated for 72 hours in humid conditions at 
28oC.   
For pectocin M1 tests were conducted with 500 μl of pectocin M1 at a total of 
2.5, 0.5 and 0.1 mg was added 30 minutes prior to infection and further 
incubated until 72 total hours of infection had passed.   
 Infection of Nicotiana benthamiana nahG 
Nicotiana benthamiana nahG plants (courtesy of Jonathan Jones, GAL Warwick) 
were grown for 4-6 weeks by William Rooney until the leaves were >3 cm in 
diameter. Leaves were harvested and were pressure infiltrated with 500 μl of P. 
atrosepticum cultures in 10 mM MgCl2.   
Pectocin M1 was administered by pressure infiltration at concentrations between 
3 μM and 170 μM (0.1-5 mg ml-1) in a total volume of 500 μl in 10 mM MgCl2 30 
minutes prior to infection.  Leaves were imaged using the ChemiDoc (Bio-Rad) to 
monitor cell lysis (white light).  
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characterisation of ferredoxin-containing 
bacteriocins targeting Pectobacterium spp.  
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 Introduction  
Pectobacterium atrosepticum is a prolific pathogen of Solanum tuberosum 
(potato) and is responsible for the loss of both potato plants and tubers 
worldwide [3].  P. atrosepticum, like all Pectobacterium species, is characterised 
by the production of cell-wall degrading enzymes which cause damage to both 
the potato plants (blackleg) and tubers in storage (soft rot) [3,150].  In recent 
years three novel ferredoxin-containing bacteriocins targeted towards P. 
atrosepticum have been found: Pectocin M1, M2 and P [117,123].  As attempts 
are being made to reduce the amount of traditional pesticides being used, due 
to adverse effects on both health and the environment, the discovery of novel 
phytopathogen control strategies is crucial for food security [151]. 
Colicins and colicin-like bacteriocins possess an intrinsically unstructured 
translocation domain (IUTD) of 30-40 amino acids which is essential for uptake 
[40].  This IUTD passes through the lumen of an outer membrane receptor to 
interact with  Tol or TonB for translocation [40,52,123]. Unlike other Gram-
negative bacteriocins, pectocins do not possess an IUTD which suggests a novel 
uptake mechanism [117,123].   
Ferredoxin-containing pectocins have an N-terminal domain homologous to a 
plant-type ferredoxin, specifically spinach ferredoxin II [117]. This N-terminal 
domain contains an iron-sulphur [2Fe-2S] cluster and it is thought that the gene 
encoding this domain may have been acquired by horizontal gene transfer from a 
host-species [117].  This N-terminal domain is thought to be necessary for uptake 
by the ferredoxin uptake receptor (FusA) found in Pectobacterium species 
[117,124].   
Previous work has shown that pectocin M2 can be found in multiple 
conformations in solution, with the rigid C-terminal cytotoxic domain rotating 
around the N-terminal ferredoxin domain due to the presence of a flexible linker 
region (Figure 3-1) [123].  However, the most commonly found conformations are 
an elongate and bent form for which the X-ray crystallography structures were 
solved (Figure 3-1) [123].  
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Figure 3-1 Pectocin M2 can be found in multiple conformations in solution.  X-ray crystal 
structure of pectocin M2 in both the elongated and compact conformations (overlain at the N-
terminus) showing the flexibility of the cytotoxic domain (blue) around the flexible linker region 
(green) with the ferredoxin domain shown in red (PDB IDs 4N58 and 4N59).  Reproduced from 
[123] under a creative commons licence.   
The FusA outer membrane receptor is required for the uptake of M-type 
pectocins [124].  The deletion of fusA prevents the uptake of pectocin M1 and 
subsequent cell lysis (Figure 3-2) with the complementation of fusA restoring the 
activity [123].  Docking models suggest that two separate conformations are 
required for receptor binding and uptake [124].   It is predicted that receptor 
binding can only occur in the folded conformation, but the elongated 
conformation is required for translocation due to the dimensions of the FusA 
barrel [124].  
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Figure 3-2 Uptake of pectocin M1 by P. atrosepticum LMG2386 is dependent on the presence 
of the FusA outer membrane receptor.  WT, ΔfusA and ΔfusA/pfusA strains were grown to mid-
log phase and overlain onto LB agar containing 200 μM bipyridine, 2% w/v D-lactose (as well as 
100 μg ml-1 ampicillin for the complimented strain).  7 mg ml-1 of purified pectocin M1 was spotted 
and plates were incubated overnight at 28oC.  Plates were overlain with PrestoBlue to visualise the 
spots and images taken with the Chemidoc at 546 nm.   
The three known pectocins share a conserved plant-type ferredoxin N-terminal 
domain, however the cytotoxic domains of the M-type pectocins and pectocin P 
are very different (Figure 3-3).  Pectocin M1 and M2 share a conserved colicin M-
type cytotoxic domain which is known to cleave lipid II [117,123].  However 
pectocin P has a cytotoxic domain which is similar to pesticin from Yersina pestis 
and T4 phage lysozyme, suggesting that it may act by hydrolysing peptidoglycan 
to cause cell lysis [116].   
 
Figure 3-3: Amino acid sequence alignments of pectocins M2, M1 and P.  Amino acid 
sequence alignment performed in CLC workbench aligning all three pectocins based on their 
primary structure with conserved residues highlighted in red, residues conserved between two 
proteins highlighted in pink and non-conserved residues highlighted in blue.  The conserved 
ferredoxin binding domain is highlighted in green.   
76 
As pectocin M1 is a homologue of pectocin M2, it is predicted that it will also be 
flexible in solution to allow for it to bind and translocate into the periplasm of 
the target cell.  However, as pectocin P has a different predicted structure its 
behaviour, binding and translocation mechanism are completely unknown.  It is 
presumed that, due to the homology between the ferredoxin domains, pectocin 
P also uses the FusA receptor for uptake. This chapter aims to structurally 
characterise both pectocin M1 and pectocin P to further understand both their 
mechanism of action and the conformational changes necessary for 
translocation.  
 Results 
 Predicted model of pectocin M1 
Like pectocin M2, pectocin M1 has a ferredoxin N-terminal domain with 58% 
sequence identity to spinach ferredoxin II, joined with a flexible linker region to 
a lipid II degrading cytotoxic domain with a 42% sequence identity to colicin M 
(Figure 3-4a).  Pectocin M2 is found in multiple conformations in solution [123], 
therefore it is predicted that pectocin M1 will be similar in both structure and 
behaviour.  Based on the X-ray crystal structures of pectocin M2, two models of 
pectocin M1 were created using Phyre2, with pectocin M1 in both a bent and 
elongated conformation (Figure 3-4b).   
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Figure 3-4 Cartoon representation of the structure of pectocin M1 and the domain 
homologies a) Cartoon representation of the domain structure of pectocin M1 showing sequence 
homology to both spinach ferredoxin and colicin M.  b) Bent and elongated Phyre2 models of 
pectocin M1 based on homology with pectocin M1.  The ferredoxin domain is shown in red, linker 
region in green and cytotoxic domain in blue with the predicted location of the iron-sulphur cluster 
represented by orange spheres.  
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 SAXS analysis of pectocin M1  
Pectocin M1 was examined using SEC-SAXS to determine if, like pectocin M2, it is 
both flexible and found in multiple conformations in solution.  Scattering data 
from pectocin M1 were collected and frames with the highest signal within the 
SEC-SAXS peak were chosen for analysis (Figure 3-5a).  
Analysis of the Guinier region (Figure 3-5b) showed that the sample was free of 
aggregation as the residuals were randomly distributed.  An Rg of 23.6 Å was 
calculated for pectocin M1 which is smaller than the Rg for pectocin M2 which 
was found to be 27.4 Å, suggesting pectocin M1 may be found in a more compact 
conformation in solution. Extrapolation of the Guinier region to I(0) gives a 
molecular weight for pectocin M1 of 28.5 kDa, (calculated using SAXSMoW2 
[136]) which is similar to the molecular weight of 30.3 kDa calculated from the 
amino acid sequence (using protparam [152]).  This suggests that pectocin M1, 
like pectocin M2, is monomeric in solution.   
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Figure 3-5 SEC-SAXS data for pectocin M1 a) q vs Log I(q). b) Guinier analysis of the low q 
range suggests a molecular weight of 28.5 kDa (calculated using SASMoW2 [136]) .  Data was 
obtained using a Showdex kw- 402.5 column in 50 mM Tris-HCl, 200 mM NaCl, 5% Glycerol, and 
pH 7.5 with an initial concentration of pectocin M1 measured as 12.5 mg ml-1.  
 Flexibility of pectocin M1 in solution  
Kratky analysis for pectocin M1 showed that the peak of the distribution occurs 
around √3 (Figure 3-6a).  This suggests that pectocin M1 is ordered and folded in 
solution.  It also suggests that the particle is more likely to be globular in 
solution than elongated, which is consistent with the predicted bent 
conformation of pectocin M1.   
As shown in Figure 3-6, the plateau in the scattering data for pectocin M1 occurs 
first in the Kratky-Debye (Figure 3-6b) plot and no plateau can be seen at any q 
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range in the Porod-Debye plot (Figure 3-6c).  This suggests that the particle is 
flexible in solution, supporting the idea that pectocin M1 may be found in 
multiple conformations.   
 
Figure 3-6 Flexibility analysis of pectocin M1 shows that it is both globular and flexible a) 
Dimensionless Kratky plot shows the peak of the data occurring around √3 (1.73 (as shown by the 
cross-hairs) suggests that pectocin M1 is globular in solution b) Kratky-Debye and c) Porod-Debye 
plots showing the plateau occurring first in the Kratky-Debye plot suggesting that pectocin M1 is 
flexible in solution.  
 Dummy atom modelling of pectocin M1 
The maximum particle dimension (Dmax) for pectocin M1 in solution was found to 
be 85 Å (Figure 3-7a), which is smaller than the Dmax found for pectocin M2 at 96 
Å [123]. The Dmax at 85 Å is similar to that of the elongated model at ~92 Å in 
length (Figure 3-4), suggesting an intermediate conformation between the bent 
and elongated models may exist in solution.  Using the p(r) distribution a 
predicted model of pectocin M1 in solution was created (Figure 3-7b).  
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Figure 3-7 P(r) distribution for pectocin M1 SAXS data and DAMMIF model.  a) p(r) distribution 
showing the inter-electron distances gives a Dmax of 85 Å.  b) DAMMIF model created from p(r) 
distribution with the two-dimensional measurements shown.   
When compared with the individual models of pectocin M1, the DAMMIF model 
does not fit either individual model well.  For a monodispersed single 
conformation population the p(r) distribution will represent the individual 
particle within solution, however if a particle is found in multiple conformations 
within solution the p(r) distribution represents the averaged particle [129].  
Therefore, as the DAMMIF model does not represent either individual model, it 
was predicted that pectocin M1, similarly to pectocin M2, would also be found in 
more than one conformation in solution.   
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 Pectocin M1 is in multiple conformations in solution 
In order to determine if the experimental data could be better described by 
pectocin M1 in multiple conformations over either individual model, theoretical 
SAXS curves for both the globular and elongated conformations were created 
using CRYSOL [147].  The predicted scattering curve for each of the models was 
compared with the experimental data (Figure 3-8) and it can be seen that the 
bent conformation of pectocin M1 (Figure 3-8a) has a better fit to the 
experimental data with X2 = 1.756 compared with the elongated model at X2= 
2.258 (Figure 3-8), although neither of these models describes the data very 
well.   
Ensemble optimisation modelling (EOM) was used to determine whether the 
scattering data obtained could be explained better by a protein in multiple 
conformations.  The model of pectocin M1 was separated into three domains (N-
terminal ferredoxin, flexible region and C-terminal cytotoxic domain), the N-
terminal domain was fixed in space and both the flexible linker and the C-
terminal domains were unrestrained to allow for flexibility to be modelled.  EOM 
creates a pool of randomly created conformations of the given protein and 
selects the conformations from that pool that best fit the experimental data 
[139].   
The EOM data showed that an ensemble of conformations was better able to fit 
the experimental data (X2 = 1.455) when compared with either conformation 
individually (Figure 3-8c), further supporting the idea that pectocin M1 is 
flexible in solution.   
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Figure 3-8 CRYSOL SAXS curve predictions for pectocin M1 in multiple conformations show 
that a mixed population is the best fit for the experimental data. CRYSOL predicted SAXS 
curves (red) were fit to the experimental SAXS data (black) for pectocin M1 shown in a a) globular 
conformation (X2 = 1.756), b) elongated conformation (X2=2.258) and c) mixed population (X2= 
1.455) as calculated by ensemble optimisation modelling.    
As the EOM predicted SAXS curve showed the best fit the experimental data the 
selected models were examined in more detail.  The Dmax and Rg for each of the 
models were calculated and plotted to determine the most commonly occurring 
model dimensions.  The pool of models had a range of maximum dimensions 
from 66.2 Å to 118.8 Å, however the models selected to fit the SAXS data (Figure 
3-9a) show two distinct populations with peaks at 70 Å and 90 Å.  Similarly, the 
models show two distinct populations when the Rg was measured, with peaks 
occurring at 22 Å and 26 Å (Figure 3-9b) which is consistent with the 
experimental data which gives an Rg of 23.6 Å.  When compared with the 
predicted models of pectocin M1 these dimensions are consistent with the 
globular and elongated conformations respectively (Figure 3-10).   
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Figure 3-9 Ensemble optimisation modelling of pectocin M1 based on SAXS data shows that 
pectocin M1 is found in at least two conformations in solution.  EOM predictions of a) 
maximum dimensions (Dmax) and b) Radius of gyration (Rg) suggest that pectocin M1, like M2, is 
found in multiple conformations in solution.  The maximum dimensions are consistent with the 
maximum dimensions of the predicted models.  The pool of models is shown in grey with the 
population frequency shown in red.   
In comparison to the Dmax of the scattering data the elongated form of pectocin 
M1 has a larger Dmax than the experimental data.  Similarly, the bent 
conformation has a smaller Dmax.  This further supports the idea that the 
scattering data is an average of both the bent and elongate conformations of 
pectocin M1, as well as a potential intermediate conformation.  In order to 
examine this further the ability to examine a single conformation of pectocin M1 
would be beneficial.  
Moreover, when compared with the DAMMIF model and it can be seen that the 
overall envelope does appear to fit both the globular and elongated forms of 
pectocin M1 (Figure 3-10).  This data further supports the idea that pectocin M1 
behaves in the same was as pectocin M2 in solution and can be found in multiple 
conformations.   
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Figure 3-10 Dummy atom model (DAMMIF) of pectocin M1 in solution overlaid with pectocin 
M1 in two predicted conformations.  Dimensions to show the Dmax of both the globular (blue) and 
elongated (pink) conformations of pectocin M1.  The DAMMIF model is overlaid with both the 
predicted globular and elongate conformations of pectocin M1 based on the high-resolution crystal 
structures of pectocin M2 [123] suggesting that pectocin M1 may also be found in two 
conformations.  
 Pectocin M1 crystallisation trials  
The X-ray crystal structure of pectocin M2 was able to yield information as to its 
conformations in solution.  Therefore, to assess the accuracy of the model and 
to examine its similarity to pectocin M2, crystallisation trials for pectocin M1 
were conducted. Initial crystallisation screenings were set up for pectocin M1.  
Optimisation screens using PACT, Mopheus, Mem Gold and JCSG screening trays 
from Molecular dimensions, were set up and monitored for 10 months but did not 
yield any crystals.   
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 Uptake and mechanism of action of pectocin P  
3.2.7.1 Uptake of pectocin P  
The N-terminal ferredoxin domain of pectocin M1 is known to interact with the 
FusA receptor (Chapter 4) and FusA is essential for pectocin M1 uptake (Figure 
3-2).  With respect to this, it is predicted that pectocin P, like pectocin M1, 
possesses the ferredoxin N-terminal domain to allow it to also parasitise the FusA 
receptor in Pectobacterium species, although this has not been previously 
demonstrated.   
Initial spot tests showed that, at high concentrations, pectocin P is active 
against P. atrosepticum LMG2386 with a minimum inhibitory concentration of 
8.13 µM (Figure 3-11), which is significantly less potent than pectocin M1 which 
is active down to nanomolar concentrations.   
 
Figure 3-11 Pectocin P is active against of P. atrosepticum LMG2386. Pectocin P spotted LB 
agar containing 200 μM bipyridine with an overlay of P. atrosepticum LMG2386.  Pectocin P was 
spotted in two-fold dilutions from 260 µM to 1 μM, showing a minimum inhibitory concentration of 
8.13 µM.  Plates were overlain with PrestoBlue and images taken with the Chemidoc at 546 nm.   
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Pectocin P was tested against wild-type (WT), ΔfusA and ΔfusA/pfusA strains in 
order to determine if FusA is essential for uptake.  Spot tests showed that FusA is 
essential for the uptake of pectocin P due to the absence of cell lysis in the 
ΔfusA strain and the complementation of FusA restored activity (Figure 3-12).   
 
Figure 3-12 Pectocin P uptake is dependent on the presence of FusA.  Pectocin P was spotted 
on 200 μM bipyridine, D-lactose and (100 μg ml -1 ampicillin for complimented strain) LB agar at a 
concentration of 10 mg ml-1 (280 μM), a zone of inhibition can be seen clearly on the WT strain but 
there is no activity against the ΔfusA strain.  Plates were overlain with PrestoBlue and images 
taken with the Chemidoc at 546 nm.   
3.2.7.2 Predicted mechanism of action  
Unlike the M-type pectocins, pectocin P has a cytotoxic domain which is 
homologous to that of pesticin from Yersinia pestis and lysozyme.  These 
proteins break down the mature peptidoglycan of the target cell by hydrolysing 
the bond between the N-acetylmuramic acid (NAM) and N-acetyl-D-glucosamine 
(NAG).  The important active site residues of pesticin have been identified as 
E178, T201 and D207 [49], which (Figure 3-13a) corresponding to residues E119, 
T142 and D148 of pectocin P respectively.   
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Figure 3-13 Protein sequence alignment of pesticin and pectocin P as well as an illustration 
of the mechanism of action of pesticin a) Protein sequence alignment performed in CLC 
showing similarity in some regions of the cytotoxic domain with the known catalytic residues of 
pesticin highlighted with an asterisk showing conservation of these amino acids in pectocin P and 
pesticin.  b) Peptidoglycan structure shown with arrows showing the sites of hydrolysis by 
lysozyme, pesticin and predicted for pectocin P (image taken from cronodon.com).   
Lysozyme has been extensively studied and its mechanism of action is well 
understood.  It is known to hydrolyse the glyosidic bond between NAM and NAG 
in the peptidoglycan backbone (Figure 3-13b) [153].  The subdomains of 
lysozyme are known to close around the NAM ring in order for residues E11, E20 
and T26 to interact with the substrate to catalyse the hydrolysis of the NAM-NAG 
bond [153].   
It was therefore predicted that pectocin P would hydrolyse peptidoglycan in the 
same way as both lysozyme and pesticin (Figure 3-13b).  Previous work to 
determine the mechanism of action of lysozyme has used the degradation of 
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Micrococcus lysodeikticus as a measure of enzymatic activity, the hydrolysis of 
the M. lysodeikticus peptidoglycan can be seen by a reduction of absorbance at 
450 nm (Figure 3-14) [154].   
 
Figure 3-14 Graph showing fold-change of optical density (450 nm) for pectocin P. Proteins 
were incubated with M. lysodeikticus for 45 minutes and the optical density at 450 nm was 
measured at 30 second intervals.  A reduction in absorbance is indicative of the breakdown of the 
M. lysodeikticus  peptidoglycan layer.  Substrate was incubated alone (blue) and with pectocin P at 
20 mg ml-1 (green) , pectocin P at 10 mg ml-1 (red), pectocin M1 at 10 mg ml-1 (purple), 5 μg ml-1 
lysozyme (orange) and 2.5 μg ml-1 lysozyme (black) .   
Pectocin P was tested against M. lysodeikticus at several different 
concentrations with the highest two concentrations are shown here.  When 
incubated with lysozyme the absorbance at 450 nm decreases rapidly over time 
before plateauing showing the effective hydrolysis of the peptidoglycan.  In 
contrast, when incubated with pectocin P, no hydrolysis of the M. lysodeikticus 
peptidoglycan was observed (Figure 3-14).  In parallel to this spot tests were 
carried out which confirmed the activity of recombinantly produced pectocin P 
in vivo, therefore the reduction in activity is assay specific rather than due to 
the complete loss of activity.   
This lack of activity is surprising as pectocin P is similar in structure to lysozyme, 
however when pesticin was tested for activity against M. lysodeikticus it was 
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also unable to degrade the M. lysodeikticus peptidoglycan [116,155].  Therefore, 
as pectocin P is more closely related to pesticin the lack of activity may not 
necessarily mean that it does not hydrolyse peptidoglycans but rather this assay 
is an inconclusive way to measure it.  Little is known about the conditions 
needed for pectocin P activity.  It is possible therefore, that a conformational 
change is required for enzymatic activity and that this does not occur in vitro. 
Further work should be done to analyse the activity of pectocin P to conclusively 
determine its mode of action.  
 Structural characterisation of pectocin P  
3.2.8.1 Predicted structure of pectocin P in solution  
The high-resolution structure of pectocin P is yet to be solved and therefore 
homology models have been created using both Phyre2 and I-TASSER.  Phyre2 
models based on the homology of pectocin P to both the N-terminal of pectocin 
M2 and the C-terminal of pesticin combine to suggest a folded globular 
conformation (Figure 3-15b).   
As pectocin P has less than 50% sequence identity with both homologues (Figure 
3-15a), I-TASSER was used to create a model based on the primary amino acid 
sequence [156].  The I-TASSER model of pectocin P (Figure 3-15c) suggests a 
more elongated protein with less regular secondary structure, however both 
show the cytotoxic domain to be formed primarily of α-helices.  The C-terminal 
domain of pectocin P shows a non-regular structure of 24 amino acids at the C-
terminus.  This C-terminal region contains a number of flexible amino acid 
residues (>50%) as well as three tryptophan residues and does not align with the 
pesticin sequence (Figure 3-13) suggesting it may be important for flexibility or 
activity.   
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Figure 3-15 Sequence identity, Phyre2 and I-TASSER models of pectocin P. a) Cartoon 
representation of the domain structure of pectocin P showing the percentage sequence homology 
to both spinach ferredoxin and pesticin.  b) Phyre2 combined model of the ferredoxin domain and 
cytotoxic domain of pesticin c) I-TASSER model of pectocin P with the N-terminal ferredoxin 
domain in red, flexible linker in green and the cytotoxic domain in purple.  
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3.2.8.2 Pectocin P is compact in solution  
Pectocin P, like the M-type pectocins, consists of an N-terminal ferredoxin 
domain which is linked to a C-terminal cytotoxic domain by a linker region 
largely made up of flexible residues.  In order to test the predicted models of 
pectocin P as well as determining if the two domains are indeed joined by a 
flexible linker region, pectocin P was examined by SEC-SAXS.   
 
Figure 3-16 SEC-SAXS data for pectocin P a) Raw SAXS data for pectocin P shown as q vs Log 
I(q). b) Guinier region of pectocin P scattering data and residuals. 
The Guinier region obtained from the SAXS data was analysed and showed that 
the sample was free from aggregation.  The Guinier analysis yielded a radius of 
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gyration of 22.7 Å and the extrapolation to the I(0) gived a predicted molecular 
weight of 35.4 kDa with a which is almost identical to the molecular weight of 36 
kDa calculated from the amino acid sequence (Figure 3-16) [136,152]. SAXS data 
for pectocin P was collected on multiple occasions and yielded similar results 
each time independent of concentration.  
3.2.8.3 Pectocin P model is consistent with SAXS low-resolution models  
Kratky analysis was performed to examine the shape and foldedness of pectocin 
P in solution.  As mentioned previously the high number of flexible residues 
present suggests the presence of a flexible linker region joining the N- and C-
terminal domains of pectocin P.  This suggests that the C-terminal domain of 
pectocin P, like that of pectocin M1, may be able to move in relation to the N-
terminal domain.  This conformational change would allow pectocin P to become 
more elongated in order to pass through FusA into the periplasm.   
The dimensionless Kratky distribution for pectocin P is seen to form a classical 
parabola shape with a peak occurring at √3 suggesting that pectocin P is globular 
in solution.  This is consistent with both the Phyre2 and I-TASSER predicted 
structures.  This is further supported by the Kratky-Debye and Porod-Debye 
analysis which clearly shows a plateau occurring first in the Porod-Debye when 
the scattering angle q is raised to the power of 4 and no plateau occurring in the 
Kratky-Debye plot, further supporting the model that pectocin P as a globular, 
inflexible and ordered particle (Figure 3-17).     
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Figure 3-17: Flexibility analysis of pectocin P shows that it is globular in solution and 
inflexible. a) Dimensionless Kratky plot shows the peak of the data occurring around √3 
suggesting pectocin P is globular in solution b) Porod-Debye and c) Krakty-Debye plots showing 
the plateau occurring first in the Porod-Debye plot further suggesting that pectocin P is globular 
and inflexible in solution. 
The flexibility analysis confirms the Kratky analysis that pectocin P is compact 
and inflexible in solution.  This does not necessarily mean that the particle 
cannot be found in more than one conformation but suggests that it is found in 
distinct conformations rather than being intrinsically flexible.  It could also 
suggest that pectocin P is found in one conformation in solution and an 
interaction with another protein is required for a conformation change, or it 
could be that pectocin P is simply found in one conformation.   
The p(r) distribution for pectocin P gave a maximum particle dimension of 73 Å 
and the parabola shape of the p(r) distribution further suggests that the particle 
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is globular in solution (Figure 3-18).  Dummy atom modelling of pectocin P was 
performed with both DAMMIF [141] to create an overall ab initio envelope  and 
GASBOR  to create an ab initio chain model [157].   
 
Figure 3-18 P(r) distribution of pectocin P in solution suggests it is globular in solution. a) 
Pair-set p(r) disribution of pectocin P shows gives a maximum dimension of 73 Å b) DAMMIF 
model of pectocin P created from the p(r) distribution showing the two dimensional measurements 
of the envelope.  
96 
 
 
Figure 3-19 Dummy atom model (DAMMIF) of pectocin P overlaid with I-TASSER predicted 
model of pectocin P. Pectocin P dummy atom model (pink) based on SAXS data overlaid with I-
TASSER predicted model (blue) suggests that pectocin P is compact and globular in solution which 
is consistent with the I-TASSER model. Overlay was performed using SUPCOMB [158].  
It can be see that the predicted globular structure of pectocin P fits with the 
predicted envelope of the protein suggesting that the I-TASSER model is a good 
structural prediction for pectocin P (Figure 3-19).  However, this does not 
support the hypothesis that pectocin P exists in multiple conformations in 
solution as the averaged dummy atom models clearly correspond to only one 
conformation.    
3.2.8.4 Pectocin P must exist in an unfolded conformation in solution in 
order to utilise the FusA receptor 
As shown in Figure 3-12, the uptake of pectocin P is dependent on the presence 
of the FusA outer membrane receptor.  However, by examining the SAXS 
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structure of pectocin P and the predicted structure dimensions it is clear that 
these dimensions would not be able to pass through the lumen of the FusA 
barrel.  The lumen of FusA is 35 Å in diameter and therefore any protein passing 
must have a diameter smaller than this.  At the widest point of the cytotoxic 
domain pectocin P is approximately 50 Å in the conformation consistent with the 
SAXS data.  
Therefore, computational modelling of pectocin P was performed to examine 
whether a possible elongated conformation is consistent with the SAXS data.  
The only solution which would explain the passing of pectocin P through the 
lumen of the FusA barrel is a highly elongated conformation resembling that of 
the elongated forms of pectocin M1 and M2.  This would provide the right 
dimensions to enter the cell whereas all other solutions could not explain this.  
Pectocin P was separated into 3 domains and an ensemble of conformations 
modelled using EOM (as described in 3.2.5)   
Primarily an elongated model of pectocin P was created with EOM and the fit of 
the globular, elongated and combined models were compared with the 
experimental SAXS curve using CRYSOL.  It can be seen from the data that the 
best overall fit of the data (X2= 0.178) is the combination of conformations 
(Figure 3-20c).  However, this is very similar to the fit of the globular 
conformation alone (X2=0.179), suggesting that the majority of proteins within 
the sample are likely to be in a globular conformation (Figure 3-20a).  
Contrastingly, an elongated conformation of pectocin P does not fit the data 
with a (X2= 0.248) suggesting that this is the least likely conformation in solution 
(Figure 3-20b).   
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Figure 3-20 Theoretical SAXS curves created by CRYSOL comparing pectocin P in multiple 
conformations to experimental SAXS data.  Theoretical SAXS curves generated by CRYSOL 
(red) overlain with the experimental SAXS data for pectocin P (black) for a) globular (X2= 0.179), b) 
elongated (X2= 0.248) and c) EOM modelling of a mixed population (X2= 0.178)  
The population used to create the EOM fit to the SAXS data was modelled and 
the selected population further examined.  The maximum dimensions of the pool 
of models created ranged from 59-111 Å however the range of models selected 
to fit the SAXS data was less clear cut than pectocin M1.  The models can be 
grouped into two populations with the first having the highest peak at a Dmax of 
67 Å, which is consistent with the SAXS experimental data.  However, there is 
also a small population of models with a Dmax of approximately 105 Å, which 
corresponds to an elongated model of pectocin P that is predicted to be 
necessary for uptake (Figure 3-21a).  These results are further confirmed when 
the Rg is examined (Figure 3-21b) showing a peak around 21.7 Å, similar to the 
experimental Rg of 22.7 Å and a second peak at 30.2 Å, suggestive of an 
elongated conformation.   
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Figure 3-21 Ensemble optimisation modelling of pectocin P based on SAXS data shows that 
pectocin P is found in multiple conformations in solution.  EOM predictions of a) Dmax and b) 
Rg suggest that pectocin P is found in multiple conformations in solution.  The pool of models is 
shown in grey with the population frequency shown in red.   
As the EOM modelling of pectocin P suggests a small population of proteins in an 
elongated conformation the dimensions of this elongated model were assessed to 
confirm if it would be small enough to enter P. atrosepticum cells through the 
FusA barrel.  While the dimensions of the globular model (Figure 3-22) are 
greater than the lumen of the FusA barrel, in an elongated conformation the 
dimensions modelled show that the rotation of the cytotoxic domain around the 
flexible linker region gives a dimension of 28.4 Å which is smaller than the FusA 
barrel and therefore would allow uptake.   
Pectocin P, like pectocin M1, must elongate in order to have dimensions 
compatible with FusA uptake.  Through the use of SAXS and EOM it has been 
shown that an elongated conformation of pectocin P is consistent with the in 
solution data, and in turn the predicted elongated model is consistent with the 
dimensions needed to pass through the FusA lumen.  This work goes some way to 
confirming the predicted structure models of pectocin P, however the solving of 
a high-resolution crystal structure would be beneficial.  Unfortunately to date 
attempts at this have been unsuccessful.   
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Figure 3-22 Models created by EOM showing the predicted conformations of pectocin P in 
both a globular and elongated form.  Models of pectocin P were created showing it in both a 
globular and elongated conformation with the N-terminal ferredoxin domain shown in red, flexible 
linker in green and cytotoxic domain shown in purple.  The predicted position of the iron-sulphur 
cluster is shown in orange.   
 Discussion 
All three pectocins have been shown to parasitise the FusA receptor in P. 
atrosepticum to enter the target cell. The proteins are composed of an N-
terminal ferredoxin domain and a C-terminal cytotoxic domain joined by a 
flexible linker region.    Previous work has shown that the cytotoxic domain of 
pectocin M2 can rotate around the N-terminal domain due to the presence of 
this flexible linker and that this leads to multiple conformations in solution 
[123].  It was therefore predicted that all pectocins would act this way.   
This work has shown that both pectocin M1 and pectocin P are flexible 
monomeric proteins which are active against P. atrosepticum LMG2386.  Both of 
these pectocins are dependent on the FusA outer membrane receptor for uptake 
into the cell and therefore must be found in an elongated conformation in order 
to pass through the lumen of the barrel.  SAXS data confirmed that both 
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pectocins are indeed found in multiple conformations in solution.  Scattering 
data suggests that pectocin M1 is found in both an elongated and bent 
conformation in solution.  For pectocin P, only a small population of the SAXS 
data could be accounted for by an elongated conformation.  As pectocin P is 
much less readily found in an elongated conformation it may be that an 
interaction with another protein promotes this conformation or that this 
elongated conformation is disadvantageous or requires more energy to maintain.   
The flexibility of pectocin M1 is unusual when compared with other M-type 
bacteriocins, for example it has been shown before that pyocin M is rigid in 
structure and shows little flexibility [123].  This work, similarly to previous work,  
has shown that pectocins, particularly M-type pectocins are highly flexible in 
nature [123].  Unlike other M-type bacteriocins pectocins possess a flexible 
inter-domain linker region around which the domains can move [123].  This 
region is necessary for the flexibility of the pectocins and for the conformational 
changes needed for uptake.   
Ferredoxin-containing pectocins are unique amongst the bacteriocins of Gram-
negative bacteria as, to date, they are the only known bacteriocins which have 
acquired a host-protein homologue to translocate into the cell.  It has been 
shown previously that bacteriocin translocation is dependent on the presence of 
an IUTD and its subsequent interaction with the Tol or TonB system [40,159].  
Contrastingly, pectocins use the presence of the N –terminal ferredoxin domain 
to interact with the outer membrane receptor and enter the cell.  Although 
pectocins are a novel group of bacteriocins they are not unique to 
Pectobacterium species.  Alignment searches have shown that ferredoxin-
containing bacteriocins with similar M-type cytotoxic domains can also be found 
in other related species such as Brenneria goodwinii and Dickeya chrysanthemi.  
Future work to characterise these related proteins and their uptake systems may 
suggest a conserved route of entry into plant pathogenic bacteria that could be a 
potential antibiotic target.   
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Chapter 4 The role of the fus operon in the 
uptake of ferredoxin-containing pectocins and 
virulence  
 
Disclaimer: Initial pfusA mutagenesis PCRs for AAs 151-380 were performed by Dr 
Khedidja Mosbahi, C38A mutation was created by Rhys Grinter and SEC-MALS 
experiments and analysis were performed by June Southall at the University of 
Glasgow protein facility.  
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 Introduction  
The first line of defence for Gram-negative bacteria is the presence of an outer 
membrane surrounding the cell.  Membrane proteins are crucial for the uptake 
of solutes and proteins, as well as signal transduction [160].  One family of outer 
membrane transporters are the TonB-dependent outer membrane receptors 
characterised by their conserved N-terminal plug domain and C-terminal barrel 
formed of 22 antiparallel β-strands [161].  TonB-dependent receptors import a 
wide variety of nutrients, ranging from small vitamins to carbohydrates 
[76,162,163].  A number of TonB-dependent receptors are necessary for the 
uptake of siderophores, such as ferric pyoverdine produced by Pseudomonas 
aeruginosa and taken up by the TonB-dependent FpvAI [164].   
TonB-dependent receptors are required for the uptake of many bacteriocins as 
well as their natural substrates [50].  Bacteriocin translocation begins with the 
interaction of the receptor binding domain to an outer membrane receptor, such 
as BtuB [40].  A well understood mechanism of translocation is that of pyocin S2 
which is known to parasitise the Pseudomonas aeruginosa FpvAI receptor in 
order to enter the cell [63].  The receptor binding domain of pyocin S2 interacts 
with the extracellular loops of FpvAI mimicking the substrate,  and inducing a 
conformational change in the N-terminal plug domain [63].  This conformational 
change induces the extension of the TonB-box, interaction with TonB in the 
periplasm and subsequent partial unfolding of the N-terminal plug domain [63].  
The rearrangement of the plug domain allows for the intrinsically unstructured 
translocation domain (IUTD) of pyocin S2 to pass through the lumen of FpvAI to 
interact with a second copy of TonB and its subsequent translocation into the 
periplasm [63] (diagram of uptake shown in Figure 1-3) .   
A newly discovered member of this family of β-barrel receptors is FusA which is 
responsible for the uptake of plant-type ferredoxins into the periplasm of 
Pectobacterium cells (Figure 4-1a) [124].  This protein is encoded on an operon 
containing three other proteins (FusB, FusC and FusD) thought to be essential in 
the uptake of ferredoxins [124] (Figure 4-1).  This operon can be found in several 
other plant pathogenic species including Dickeya species.  As well as this, similar 
proteins can also be found in many other Gram-negative bacteria including 
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prolific mammalian pathogens such as Yersinia spp. and Escherichia coli (Figure 
4-1) [124].  
 
Figure 4-1 FusA is essential for pectocin M1 uptake and is part of the fus operon in 
Pectobacterium spp.  a) Spot test showing that FusA is essential for pectocin M1 uptake in 
Pectobacterium atrosepticum LMG2386 under iron limiting conditions. b) Schematic diagram of the 
predicted cellular locations of the proteins encoded by the fus operon.  c) Cartoon representation of 
the genetic organisation of the fus operon in Pectobacterium species and homologous genes from 
a subset of human pathogenic bacteria.  Reproduced from [124] under a creative commons 
licence.  
FusA is an essential part of the uptake system for both ferredoxins and 
ferredoxin-containing bacteriocins which have acquired the N-terminal 
ferredoxin domain in order to parasitise this receptor [124].  This parasitisation 
of an outer membrane receptor is not unusual in bacteriocin uptake, colicins 
routinely parasitise existing outer membrane proteins to enter the target cell 
[51].  The structure of FusA from Pectobacterium atrosepticum SCRI1043 has 
been solved previously (Figure 4-2) and the potential interaction sites between 
pectocin M1 and FusA examined by NMR spectroscopy [124].   
105 
 
Figure 4-2 FusA1043 crystal structure showing the dimensions of the plug domain (orange) 
and the lumen of the barrel (blue) (PDB ID 4ZGB).  a) Top view of the C-terminal barrel domain 
of FusA1043 showing both cartoon represenations of the secondary structure as well as the surface 
view.  The dimensions of the internal of the barrel are shown.  b) N-terminal plug domain of 
FusA1043 showing two-dimensional maximum measurements. c) Cartoon representation of FusA1043 
with the two-dimensional maximum measurements of the protein showing the discrepancy in length 
due to the larger extracellular loops.  d) Top view of FusA1043 showing the plug domain occluding 
the barrel.    
The first protein encoded on the fus operon is a TonB homologue, referred to as 
FusB, which is presumed to be located in the periplasm.  TonB is a periplasmic 
protein which is known to interact with the TonB-box of TonB-dependent 
receptors in the periplasm [69,165].  As Pectobacterium spp. genomes encode 
copies of TonB it is not known whether FusB will interact with FusA or whether it 
has evolved to interact with the ferredoxin or ferredoxin-containing bacteriocin 
to aid with translocation.  
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Figure 4-3 Graphical representation of the chemical peak shifts from the ferredoxin region of pectocin M1 with the addition of FusA.  Chemical shift 
perturbations were measured with the addition of FusA at a 1:1 molar ratio.  Residues highlighted in green are those selected for alanine screening. Adapted from 
Grinter et al (2016) and reproduced here under a creative commons licence. 
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It has been shown that the uptake of pectocin M1 and plant-type ferredoxins is 
dependent on the presence of FusA in the outer membrane [124].  Previous work 
performed by Grinter et al. (2016) examined the interaction of the N-terminal 
domain of pectocin M1 with FusA from P. atrosepticum SCRI1043 (FusA1043) using 
NMR spectroscopy to determine a potential site of interaction.  The HSQC 
spectra of 15N labelled pectocin M1 chemical shifts were measured and the 
chemical shift perturbation for each residue shown in Figure 4-3 [124].  It can be 
seen in the graphical representation that there are five regions which show 
chemical changes during interaction, with all showing notable chemical shifts 
over 0.02 p.p.m in all of these sites, with the exception of residues 25-34.  
HADDOCK modelling based on the NMR data suggested an interaction between 
the N-terminal domain of pectocin M1 with the extracellular loops of FusA 
(Figure 4-4) [124].   
 
Figure 4-4 HADDOCK modelling of N-terminal of pectocin M1 with FusA suggests both a 
continuous biding site and the interaction with the extracellular loops of FusA NMR data 
suggests the presence of a continuous binding site.  Residues showing a CSP of >0.02 p.p.m. 
shown in blue, 0.01-0.02 p.p.m shown in green and <0.01 p.p.m shown in black.  
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The aim of this chapter is to examine the interaction of pectocin M1 with 
proteins encoded on the fus operon in P. atrosepticum and subsequent uptake.  
This chapter primarily aims to determine how pectocin M1 and FusA interact in 
vivo and confirm the interaction sites of both proteins.  Secondly pectocin M1 is 
a large folded protein with no IUTD, therefore this chapter aims to understand 
the mechanism by which pectocin M1 translocates into the periplasm.  Finally, 
pectocins have the potential to be used as novel therapeutics within the field, 
therefore the final aim is to elucidate under what conditions they may be used 
in novel anti-infective strategies using both chimeric proteins and plant infection 
models.   
 Results 
 Interaction sites between pectocin M1 and FusA 
4.2.1.1 Pectocin M1 binding site 
NMR spectroscopy data suggests five potential groups of residues that may be 
important in receptor binding.  In order to assess this, large or charged surface 
residues from four of these groups were chosen as candidates for site-directed 
mutagenesis (SDM).  The residues chosen were: T3, Y4, K5, K7, N12, F15, E16, 
D19, C38, S52, R58, E65, Y70, and K86. Individual residues (highlighted in Figure 
4-3) were mutated by PCR on the expression plasmid and purified using both 
nickel and size exclusion chromatography.  Wild-type (WT) pectocin M1 and 
pectocin M1 mutants were tested against P. atrosepticum LMG2386 in order to 
examine their activity and minimum inhibitory concentrations.  Preliminary 
experiments suggested that Y4 and K5 may be important residues for receptor 
interaction and therefore a double mutant was also created to see whether 
changing both of these would have a more drastic effect on activity loss.  The 
lysine residue in this mutation was changed to a glutamic acid in order to 
reverse the charge in the residue position to increase the potential disruption of 
the binding site.  
The mutation at position C38 is used in this instance as a negative control.  The 
alteration of this residue to an alanine disrupts the binding of the iron-sulphur 
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cluster and prevents correct folding of the protein.  This mutant is therefore 
unable to interact with and be taken up by FusA (Appendix 3).  
Several different concentrations of the mutants were tested, and a 
representative image is shown in (Figure 4-5) in which the mutants were spotted 
on in 3-fold dilutions with a starting concentration of 1 μM.  There is a reduction 
in activity on the mutation of T3, K5, K7, F15, and K86 to alanine, with 
mutations at K86 and F15 showing the greatest decreases in activity when 
mutated to alanine.    
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Figure 4-5 Spot tests comparing the potency of pectocin M1 mutants against P. 
atrosepticum LMG2386 under iron limiting conditions.  Pectocin M1 and mutants were spotted 
onto an overlay of P. atrosepticum LMG2386 in 3-fold dilutions from a starting concentration of 1 
µM (from left to right) to compare the minimum inhibitory concentration as compared with the wild-
type of each mutant under iron limiting conditions.  Residues showing a reduction in activity are 
highlighted.   
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A small reduction in minimum inhibitory concentration was seen for all mutants, 
with the exception of D19A and Y4A which were both active to the same 
concentration as the wild-type (representative image shown in Figure 4-5).  
Although the reduction in activity was small for each mutation it does suggest 
that these residues may be important for the interaction of pectocin M1 with 
FusA. Each of the mutated residues are either charged or large which further 
suggests that they may be important for binding as well as giving support to the 
NMR spectroscopy data which also suggested the presence of a continuous 
charged binding site (Figure 4-6) [124].  
As, ideally all surface residues would be interesting to test, low fidelity PCR 
mutagenesis was performed to create random mutations within the ferredoxin 
region of pectocin M1, however this was unsuccessful.  Future work could focus 
on creating multiple combinations of mutations to compare the potency of 
double amino acid substitutions to examine the effect this would have on 
binding affinity and potency.   
 
Figure 4-6 Surface representation of the predicted N-terminal domain of pectocin M1 
showing the predicted binding sites.  a) Surface of the N-terminal domain of pectocin M1 
showing the residues predicted to be important for FusA interaction due to the CSP shifts 
determined using NMR and reproduced from Grinter et al 2016 under a creative commons licence.  
Residues showing a CSP change of >0.02 p.p.m. are shown in blue, 0.01-0.02 p.p.m. are shown in 
green and those with a CSP <0.01 p.p.m. are shown in black.  b) Surface of the N-terminal domain 
highlighting residues chosen for SDM with those showing a decrease in potency shown in red and 
those residues thought to unimportant for the FusA-pectocin M1 interaction shown in yellow.  A full 
view of this is shown in appendix 2.   
112 
When examined on the model of pectocin M1 the amino acids suggest a binding 
surface on the opposite face of the N-terminal domain to the iron-sulphur 
cluster (Figure 4-6).  The SDM conducted in this study has shown that, with the 
exception of the phenylalanine in position 15, the residues that are involved in 
receptor binding are charged (lysine) and polar (threonine) in agreement with 
the NMR data suggesting a continuous binding surface consisting of these charged 
and polar residues.  However, the SDM also suggests potential interaction sites 
outwith this predicted continuous binding site, such as the threonine in position 
3.  When these residues are examined, in relation to the interaction model, an 
interaction between pectocin M1 and the long extracellular arm of FusA and a 
potential interaction with the N-terminal plug domain is predicted (Figure 4-2).   
4.2.1.2 CD spectra analysis of mutants  
Pectocin M1 mutants were analysed by far and near UV circular dichroism (CD) in 
order to compare the secondary and tertiary structures respectively to 
determine whether it was likely that the reduction in activity was due to the 
individual mutations or incorrect folding of the protein.  Those mutants which 
showed a reduction in activity and two that show little to no change in activity 
were measured.   
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Figure 4-7: Far and near UV spectra of pectocin M1 and single amino acid mutants. Pectocin 
M1 (blue) has the same spectra in both the far and near UV spectra as T3A (red), K5A (green), 
K7A (purple), F15A (orange), S52A (black) Y70A (dark blue) and K86A (brown) shown at near (a) 
and far (b) UV.  The CD spectra of pectocin M1 (blue) was compared with that of C38A (red) 
showing the discrepancy in both near (c) and far (d) spectra suggesting incorrect folding of the 
protein due to the lack of the iron-sulphur cluster.   
The CD spectra of each mutant tested had a similar spectrum to that of the WT 
and therefore it is likely that reduction in activity is due to the individual 
mutation rather than protein misfolding (Figure 4-7).  It can be seen that the 
spectra for C38A (Figure 4-7c and d) suggests protein misfolding compared with 
the WT.  This amino acid is essential for the co-ordination of the iron-sulphur 
cluster and therefore the iron-sulphur cluster is not present in this mutant 
(appendix 3).   
4.2.1.3 Binding site mutagenesis FusA 
As docking modelling of pectocin M1 and FusA suggested an interaction between 
pectocin M1 and the extracellular loops of the FusA receptor, and potentially the 
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N-terminal plug domain these sites were selected as candidates for SDM 
screening.  Mutations were created using SDM on the inducible pfusA2386 plasmid 
and confirmed by sequencing.  The subsequent pfusA2386 plasmids were 
expressed in the ΔfusA cells under a lactose inducible promoter and the 
susceptibility of complimented strains to pectocin M1 was tested using spot test 
assays.   
The residues chosen for SDM were based on their relative location within the 
FusA1043 crystal structure and, like pectocin M1, based on their size and charge.  
Nine initial residues were chosen to be mutated: N151, Y155, P157, F376, S378, 
F380, N401, G489 and N491.  All residues were mutated to an alanine residue, 
with the exception of P157 which was mutated to a glycine residue in order to 
minimise the effect on the secondary structure.  The positioning of each of these 
residues can be seen in Figure 4-8, residues F376-F380, N401A, G489A and N491A 
are positioned on the larger of the two extracellular domains of FusA whereas 
N151-P157 are positioned on the plug domain of FusA.   
 
Figure 4-8 Predicted structure of FusA2386 highlighting the residues chosen for mutagenesis.  
Residues chosen for mutagenesis are coloured, with those in red showing an increase in the MIC 
of pectocin M1 (red) and those showing little or no increase shown in blue.  
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Figure 4-9 Pectocin M1 potency was tested against the FusA mutants expressed in P. atrosepticum LMG2386 ΔfusA.  Pectocin M1 at 340 μM 3-fold decreasing 
concentrations was spotted onto LB agar supplemented with 2% w/v D-lactose, 200 μM bipyridine, (100 μg ml-1 ampicillin for complimented strains).  Pectocin M1 was 
tested against a) WT P. atrosepticum LMG2386, b) ΔfusA c) ΔfusA/pfusA d) ΔfusA/pfusAN151A e) ΔfusA/pfusAY155A f) ΔfusA/pfusAP157G g) ΔfusA/pfusAF376A h) 
ΔfusA/pfusAS378A i) ΔfusA/pfusAF380A j) ΔfusA/pfusAN401A k) ΔfusA/pfusAG489A l) ΔfusA/pfusAN491A 
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The complementation of fusA using an inducible plasmid restores the uptake of 
pectocin M1 (Figure 4-8c), however this complemented strain is not as 
susceptible to pectocin M1 as the WT.  It can also be seen that each of the 
mutants is susceptible to pectocin M1, however there is a reduction in the 
potency of pectocin M1 for mutations both in the long extracellular domains and 
a residue positioned on the N-terminal plug domain (P157G, Figure 4-9f).  The 
reduction in binding can be seen with mutations F376A and F380A in particular 
(Figure 4-9g and I respectively), with a small reduction in potency seen for 
N401A and N491A (Figure 4-9j and l respectively).  The reduction of activity is 
indicative that these loops are important for substrate interaction.  This 
supports the current model of substrate interaction and uptake, however as the 
expression levels may vary between each of the strains this may also cause 
variation.  Therefore, although it is indicative more work is needed to quantify 
the expression levels to determine if this reduction in activity is indeed due to 
the mutation.   
To further examine the interaction between pectocin M1 and FusA in vitro 
analytical size exclusion chromatography (SEC) was used.  Pectocin M1 was 
incubated with an equal concentration of either FusA1043 or the FusA1043 plug 
domain alone in order to examine if a complex could form in vitro.  Analytical 
SEC showed the presence of a high molecular weight species when pectocin M1 
and FusA were mixed together (Figure 4-10a).  This confirms the interaction 
between FusA and pectocin M1 in vitro, giving support to the in vivo data.   
The plug domain of FusA1043 and pectocin M1 were mixed together in order to 
determine if there was an interaction in vitro as predicted by the SDM results.  
The plug domain has molecular weight of 20 kDa, as calculated by the amino 
acid sequence, which is smaller than that of pectocin M1 at 30 kDa.  However, it 
can be seen in Figure 4-10b that the plug domain alone has a higher molecular 
weight than pectocin M1, suggesting self-association.  This self-association has 
been seen in SAXS, making it difficult to examine the plug domain in solution.  
Analytical SEC therefore does not suggest an interaction between pectocin M1 
and the plug domain due to the presence of two peaks overlaying with the 
individual species.  This data does not support the idea that the plug domain 
interacts with pectocin M1, however it is possible that the self-association of the 
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plug domain disrupts any potential interaction.  In order for this to be 
successfully assessed the plug domain would need to be monomeric in solution.   
m
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Figure 4-10 Analytical size exclusion chromatography showing an interaction between 
pectocin M1 and the FusA.  a) Analytical SEC of pectocin M1 (green), FusA (red) and a 1:1 molar 
ratio of pectocin M1 and FusA in complex (purple) using a Superdex S200 10/30L column.  b) 
Analytical SEC of pectocin M1 (green), the N-terminal plug domain of FusA alone (orange) and a 
1:1 molar ratio of pectocin M1 and the plug domain (blue) using a Superdex S75 10/30L column.  
Both experiments were performed at RT in 50 mM Tris-HCl, 200 mM NaCl, 5% glycerol and 0.01% 
LDAO, protein concentrations varied from 40-200 μM depending on absorbance at 280 nm.   
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 Uptake of pectocin M1 into the periplasm  
4.2.2.1 FusA plug domain exits the barrel and remains folded  
The mechanism by which the N-terminal plug domain is removed from the barrel 
of the TonB-dependent receptors is still poorly understood.  Some work has been 
done to support both the hypothesis that the plug exits the barrel whilst 
remaining folded and other work supports the theory that the plug domain 
unfolds or partially unfolds to exit the barrel [63,76,77].   
The dimensions of FusA and pectocin M1 suggest that the plug domain of FusA 
would have to be completely removed from the barrel in order for the substrate 
to pass into the periplasm.  At the widest point pectocin M1 is 29 Å (Figure 3-4) 
in diameter which is slightly smaller than the lumen of FusA at 35 Å (Figure 4-2).  
Therefore, there are two possible conformational changes: the plug domain of 
FusA completely unfolds to allow for substrate uptake, or the plug remains 
globular and exits the barrel in a folded conformation.   
Small-angle neutron scattering (SANS) was used to determine the behaviour of 
FusA in solution.  SANS data for FusA was collected in a quartz cuvette for 10 
minutes at a detector distance of 5.6 m (Figure 4-11a).  The Guinier region of 
FusA was examined and the sample did not show any signs of aggregation.  The 
p(r) distribution for FusA was determined giving a Dmax of 185 Å which is much 
larger than the predicted dimensions of FusA with the plug domain inside the 
barrel (Figure 4-11b).   
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Figure 4-11 SANS data for FusA1043 a) Scattering data for FusA1043 showing log I(q) vs q b) p(r) 
distribution for FusA1043 showing a maximum dimension of 185 Å.  Experimental data was collected 
at 6oC in a quartz cuvette at a concentration of 8 mg ml-1 in 5.5% D2O in a buffer of 0.1% LDAO, 50 
mM Tris-HCl, 100 mM NaCl pH 7.5 for 10 minutes.   
As with SAXS data a dummy atom (DAMMIF) model of FusA in solution was 
created.  The DAMMIF model, although larger in dimension than the crystal 
structure, suggests that the plug domain exits the barrel in a globular form 
(Figure 4-12).  This construct of FusA was sent for N-terminal sequencing showing 
the first five N-terminal amino acids were STPTS (appendix 1c).  These confirm 
that the FusA1043 protein was lacking both signal sequence and predicted TonB-
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box, suggesting that the small globular region is likely to be due to the plug 
domains exit from the barrel (Appendix 1).   
 
Figure 4-12 DAMMIF model suggest that FusA1043 plug domain exits the barrel and remains 
globular.  DAMMIF model (purple) overlaid with the N-terminal plug domain (orange) and the 
barrel (blue).  Overlay performed using SUPCOMB [166].  
In order to confirm this, constructs of both the N-terminal plug domain alone (AA 
27-208) and the barrel alone (AA 209-863) were generated, expressed and 
purified.  The plug domain could be successfully purified in the absence of the 
barrel which gives support to the plug exiting and remaining folded [77].  Both 
constructs were analysed by SANS, however neither yielded usable data.   
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As the plug domain of FusA is soluble and able to be purified on its own it was 
analysed using SAXS under several different conditions, however these revealed 
that the plug domain self-associates potentially due to the hydrophobicity of 
some residues which associate with the C-terminal barrel.  This self-association 
has previously been seen in SEC (Figure 4-10) as the plug domain is larger in 
solution than the monomeric pectocin M1.   
4.2.2.2 Characterisation of FusB 
FusB is predicted to be a member of the TonB protein family and to interact with 
the predicted TonB-box of FusA (Appendix 1).  TonB proteins are characterised by 
a flexible N-terminal domain and a folded C-terminal domain which interacts 
with the TonB-box of TonB-dependent receptors.  As TonB has a largely 
disordered and flexible N-terminal a high-resolution structure of the entire 
protein is yet to be solved.   
The N-terminal domain is flexible in order to span the periplasm to interact with 
the TonB-box of the outer membrane receptor.  The disorder of this region makes 
biophysical characterisation of TonB difficult due to its flexibility.  Models of 
FusB created by I-TASSER support the idea that it is a largely disordered and 
unstructured protein with a C-terminal globular domain (Figure 4-13).   
122 
 
Figure 4-13 Models of FusB showing a folded C-terminal domain and a flexible N-terminal 
domain a) Phyre2 model of the C-terminal domain of FusB b) I-TASSER model of FusB with the 
folded C-terminal domain shown in green and the flexible N-terminal domain in blue.  
This model is consistent with the predicted and solved structures of TonB within 
related organisms such as E. coli as it has the irregularly structured N-terminal 
region and a structured C-terminal domain with β- sheet that is in the predicted 
interaction interface based on the known interacting sites of TonB [167]. Due to 
the high levels of predicted flexibility and the lack of homologous structures 
corresponding to the N-terminal domain, these models are unreliable predictions 
of structure.  
In order to test the flexibility and potential structure of FusB in solution it was 
examined by SAXS.  Unfortunately, despite testing several conditions and 
multiple attempts, the absence of a Guinier region in each of the scattering 
curves prevented further analysis.  Although this generally suggests aggregation 
in samples it is important to note that for largely disordered or elongated 
particles it is often the case that Guinier analysis can be problematic [129].  
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Therefore, it is unclear whether this inability to analyse the Guinier is due to 
aggregation or disorder.   
As biophysical characterisation by SAXS proved difficult, FusB was examined 
using AUC in order to assess whether, like TonB, it can be found as a dimer in 
solution [168,169].  Sedimentation velocity (SV) was used to examine if FusB is 
found in one or more oligomeric states in solution.  The predicted sedimentation 
coefficient of the predicted I-TASSER structure was calculated using US-SOMO 
[149], however as the I-TASSER model is likely to be unreliable due to the 
flexibility of FusB, these were only used as a guide.   
 
Figure 4-14 Sedimentation velocity data suggest that FusB can be found as both a monomer 
and a dimer in solution.  Continuous c(s) distribution of FusB in 200 mM NaCl, 50 mM Tris-HCl, 
5% glycerol pH 7.5 at 49000 rpm, 4oC at a concentration of a) 4 mg ml-1 and a)1 mg ml-1 suggests 
the presence of multiple populations in solution.  Peaks are labelled with the corresponding 
sedimentation coefficient.  
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The sedimentation coefficient for each distinct peak was calculated by area 
under the distribution for a single peak to give the sedimentation coefficient for 
each discrete population and oligomeric state [170].  The distribution of FusB 
suggests that it can exist as both a monomer with a sedimentation coefficient of 
3.22 and a dimer with a sedimentation coefficient of 6.9 (Figure 4-14).  The tail 
of the distribution may suggest the presence of an aggregate which has been 
seen by SAXS despite thorough centrifugation.  The c(s) distribution at a higher 
concentration of FusB suggests three populations with a sedimentation 
coefficient of 2.02, 3.39 and 6 respectively.  The distribution of these peaks 
could suggest two or more conformations of FusB in solution (Figure 4-14).  As 
FusB is predicted to be largely flexible and disordered it is possible than some of 
the conformations are elongated which would decrease the sedimentation 
coefficient in comparison with the globular and compact particles of the same 
mass.   
The interacting state has been further examined by SEC-MALS which showed a 
proportion of the sample was aggregated.  The results suggest that FusB self-
associates with peaks giving a molecular weight of 56 kDa and 25.6 kDa which 
are similar to the calculated molecular weight 29 kDa calculated from the amino 
acid sequence (Figure 4-15).  This suggests that as the concentration of FusB 
increases so does the self-association.  It is well documented that in vitro TonB 
can form a dimer but when interacting with a substrate it becomes monomeric, 
this in vitro interaction seen above suggests that FusB may act in a similar way 
to TonB in vitro [87,168].   
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Figure 4-15 SEC-MALS data suggests FusB can be found as both a monomer and a dimer in 
solution SEC-MALS data was collected using a Waters Xbridge BEH200 SEC 3.5μ 7.8x300 
column in 200 mM NaCl, 50 mM Tris-HCl, 5% glycerol pH 7.5 with 10 mg ml-1 of FusB loaded.    
4.2.2.3 Interaction between FusB and pectocin M1 
The absence of an IUTD within ferredoxin-containing bacteriocins suggests a 
novel mechanism of uptake.  It is known that pectocin M1 interacts with FusA in 
order to enter the cell, however the exact mechanism of translocation is still 
unknown.  It was predicted therefore that pectocin M1 may interact with FusB in 
the periplasm in order to harness the PMF of the inner membrane.   
Sedimentation velocity (SV) was used to examine the interaction between FusB 
and pectocin M1.  As pectocin M1 and FusB have similar molecular weights but 
are predicted to have very different conformations within solution, SV allowed 
for the separation of these distinct species.  Pectocin M1 and FusB were 
incubated together for 2 hours prior to sedimentation at a variety of ratios, 
however only a 1:1 molar ratio is shown here (Figure 4-16).   
Each of the peaks here integrated to calculate the sedimentation coefficient for 
each population.  The continuous c(s) distribution for pectocin M1 alone (Figure 
4-16a) showed a broad single peak with an sedimentation coefficient of 2.02.  
Whereas FusB alone, as shown previously, shows two peaks suggesting that it can 
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be found as a monomer and a dimer in solution (Figure 4-16b).  Surprisingly, 
when mixed together at a 1:1 molar ratio a sedimentation coefficient of 1.522 
was calculated, showing a single peak (Figure 4-16c).  
 
Figure 4-16 Sedimentation velocity continuous c(s) distribution of pectocin M1 and FusB 
individually and in complex suggests an interaction. c(s) distributions of a) Pectocin M1 (33 
µM) b) FusB (99 µM) c) Pectocin M1 and FusB in a 1:1 molar ratio (33 µM of each) and d) an 
overlay showing the s shift.  The sedimentation coefficients of each peak are shown on a-c.  
The shift in the c(s) distribution cannot be explained by a simple shift to all 
monomeric proteins as the pectocin M1 and FusB peaks do not overlap due to 
their difference in shape, despite the same molecular weight (Figure 4-16d).   
Moreover, as FusB has a low absorbance at 280 nm a 3-fold concentration was 
measured alone in order to visualise the sedimentation profile of the protein, 
therefore the increase in absorbance can only be explained by the interaction of 
pectocin M1 and FusB.   
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The change in sedimentation coefficient when pectocin M1 and FusB are mixed 
together strongly suggests the interaction between the two proteins in vitro. As 
pectocins do not possess an IUTD containing a TonB-box they were thought to be 
unable to interact with TonB or FusB in the periplasm.  However, this work has 
shown that despite the lack of a TonB-box pectocin M1 can interact with FusB in 
vitro.  This work goes some way to supporting the idea of a novel uptake 
mechanism of ferredoxin-containing bacteriocins, suggesting they have found a 
novel mechanism of uptake in order to enter the target cell.   However, more 
work showing the interaction in vivo is necessary to confirm the importance of 
this interaction for translocation.  
 Fus system as a potential antibiotic target 
4.2.3.1 Pectocin M1PhiLOV II chimera 
Pectocin M1 has been shown to be an effective antimicrobial against a number of 
Pectobacterium strains under iron limiting conditions [117].  As well as this 
pectocin M1 has been shown to enhance the growth of some strains in the same 
way as spinach ferredoxin, showing that resistant strains can still take up the 
bacteriocin [117].  The N-terminal domain of pectocin M1 is known to interact 
with FusA in order for the bacteriocin to be taken up, therefore it has the 
potential to be used as a delivery method for small molecules or antibiotics.  In 
order to test whether the N-terminal domain of pectocin M1 would be able to 
interact with FusA in the absence of the cytotoxic domain, a pectocin M1 –
PhiLOV II chimera (pectocin M1PhiLOV II) was created by joining the N-terminal 
domain of pectocin M1 to PhiLOV II  (Figure 4-17a) [171,172].  The predicted 
structure of the chimera showed that it was likely to be small enough to pass 
through the lumen of the FusA (Figure 4-17b) and the fluorescence of the 
chimeric protein suggested that the C-terminal PhiLOV II domain was correctly 
folded (Figure 4-17c).   
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Figure 4-17 Pectocin M1PhiLOV II chimera of the N-terminal domain of pectocin M1 and the 
PhiLOV II protein.  a) Schematic to show the construction of the chimera protein from pectocin M1 
and PhiLOV II b) I-TASSER model of pectocin M1PhiLOV II with the N-terminal pectocin M1 domain in 
red and the PhiLOV II domain shown in green.  c) Image taken under both white light and ultra-
violet light (488 nm) showing the fluorescence of the chimera in comparison to the wild-type 
pectocin M1 suggesting the protein is correctly folded.   
4.2.3.2 Uptake of Pectocin M1PhiLOV II into the cell 
The receptor interaction and uptake of pectocin M1PhiLOV II was primarily tested 
using competition assays on LB agar supplemented with 200 μM bipyridine.  The 
chimera and WT pectocins were spotted next to each other at equal molarities 
and volumes on a lawn of P. atrosepticum LMG2386 in order to determine if they 
compete for the same uptake receptor (Figure 4-18).   
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Figure 4-18 Competition assay showing pectocin M1, pectocin P and pectocin M1PhiLOV II 
compete for the same receptor (FusA) in P. atrosepticum LMG2386.  Spots of 5 μl at 5 mg ml-1 
were spotted onto a lawn of P. atrosepticum LMG2386 on LB agar with 200 μM bipyridine.  Plates 
were overlain with PrestoBlue and images taken at 546 nm using a Chemidoc system.   
When spots of pectocin M1PhiLOV II were placed next to either pectocin M1 or 
pectocin P it can be seen that a semi-circular zone of inhibition occurs.  This 
suggests that the two proteins are competing for the same uptake receptor, in 
this case FusA.  This data suggests that the presence of the N-terminal domain of 
pectocin M1 is sufficient for receptor binding.  The limiting factor for this novel 
approach would be the size of the barrel of FusA, however this suggests that 
small antimicrobials which are otherwise unable to enter the cell could enter 
with the addition of the N-terminal pectocin M1 domain.  In order to confirm 
this, experiments using a cytotoxic C-terminal domain would confirm the ability 
of the chimera to enter the cell.  This would also confirm the potential of the N-
terminal domain as a delivery system in Pectobacterium spp., for example small 
some antibiotic, such as vancomycin, are unable to cross the bacterial outer 
membrane to reach their target, in this case the peptidoglycan layer, therefore a 
delivery mechanism could enable them to be effective against a wider range of 
pathogens as well as specifically targeted to a specific genus.   
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4.2.3.3 Pectocin M1PhiLOV II structural characterisation by SAXS 
It was shown in chapter 3 that both pectocin M1 and P are flexible and that this 
flexibility is likely to be necessary for uptake.  In order to examine the structure 
and flexibility of Pectocin M1PhiLOV II scattering data was collected using SEC-SAXS 
(Figure 4-19a).  Analysis of the Guinier region (Figure 4-19b) showed that the 
sample was free from aggregation and gave an Rg of 22.3 Å.  Extrapolation of the 
Guinier region gives an estimated molecular weight of 26 kDa (calculated using 
SASMoW2 [136]) which is similar to the calculated weight from the amino acid 
sequence of 24.7 kDa (calculated using ProtParam [152]).   
 
Figure 4-19 SAXS scattering data for pectocin M1PhiLOV II and Guinier analysis a) q vs Log I(q) 
scattering data at 5.2 mg ml-1 b) Gunier region of the scattering curve showing no aggregation and 
giving a predicted Rg of 22.4 Å and I(0) of 0.0179 
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Kratky analysis of pectocin M1PhiLOV II in solution shows the peak of the 
distribution occurs around √3 (Figure 4-20a) suggesting that the protein is 
globular in solution.  This is similar in to the model of the chimera, shown in 
Figure 4-17b, which is shown to be compact and not elongated.   
By analysing the data with both the Kratky-Debye and Porod-Debye the particle 
can be classed as either compact or flexible in solution when the low q range is 
examined. When the low q range was examined it can be seen that the plateau 
occurs first in the Porod-Debye plot, suggesting that the particle is compact and 
inflexible in solution (Figure 4-20b and c).  
 
 
Figure 4-20 Flexibility analysis of Pectocin M1PhiLOV II suggests it is both globular and 
compact in solution.  a) Kratky plot shows the peak occurring around √3 (shown by the 
crosshairs) suggesting that the particle is globular in solution.  The Kratky-Debye (b) and Porod-
Debye (c) plots suggest that the particle is compact in solution as the plateau occurs first in the 
Porod-Debye plot (q = 0.1491).   
The structural analysis of pectocin M1PhiLOV II chimera suggests it is structurally 
globular and inflexible, however in conjunction with the biochemical data this 
suggests that as the chimera has dimensions small enough to pass through the 
barrel.  Dummy atom modelling (Figure 4-21) suggests that the protein may be 
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able to elongate as the p(r) distribution gave a maximum dimension of 78 Å 
which is larger than that of the model.  
Together, this data suggests that the pectocin M1PhiLOV II is compact in solution 
and inflexible.  This suggests that flexibility found in pectocins is not necessary 
for the initial receptor interaction, however it may be required for 
translocation.  
 
Figure 4-21 DAMMIF model of pectocin M1PhiLOV II suggests possible elongation.  a) p(r) 
distribution of Pectocin M1PhiLOV II giving a Dmax of 78 Å b) Pectocin M1PhiLOV II DAMMIF model (blue) 
based on SAXS data overlaid with the I-TASSER predicted model of the chimera with the N-
terminal of pectocin M1 shown in red and the C-terminal PhiLOV II domain shown in green. 
Overlay was performed using SUPCOMB [158]. 
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 The role of the fus system in virulence 
The uptake of iron is essential for the growth of Pectobacterium spp. and is 
often scarce during infection [173].  It is proposed that the fus operon has 
evolved in order to take up ferredoxins from the host species during infection.  
It was considered that FusA may be important for virulence and the absence of 
this protein would impact the ability of P. atrosepticum LMG2386 to successfully 
infect both plant and tuber tissue.   
During a bacterial infection salicylic acid levels within plant tissue will increase 
at both the infection site as well as throughout the plant to activate the hosts 
defences [174].  NahG is a salicylate hydroxylase which breaks down salicylic 
acid and therefore increases the susceptibility of the plants to non-host 
pathogens [174].  The use of N. benthamania with the presence of the nahG 
gene was used as a model organism for P. atrosepticum black-leg infection as it 
was more susceptible and showed more classical signs of infection than wild-
type N. benthamania.   
In order to examine the potential for P. atrosepticum LMG2386 to infect plant 
tissue Nicotiana benthamiana nahG leaves were pressure infiltrated with ~0.5 or 
1 x106 P. atrosepticum LMG2386 grown in LB with 200 μM bipyridine and 2 % w/v 
D-lactose overnight (with the addition of 100 μM ampicillin for ΔfusA/pfusA).  
Initial trials of wild-type N. benthamania infection showed no infection by P. 
atrosepticum LMG2386 and therefore strain of N. benthamania lacking the nahG 
gene was used as an infection model for subsequent experiments due to its 
increased susceptibility.   
Infection of plant tissue showed that P. atrosepticum LMG2386 can successfully 
degrade N. benthamania nahG tissue through enzymatic maceration (Figure 
4-22).  These results show that the outcome of infection is the same for leaves 
infected with P. atrosepticum strains in both the presence and absence of the 
fusA gene, therefore showing that FusA does not impact virulence.  Lighter 
patches on the leaves are indicative of cell lysis as the light passes through the 
degraded tissue, a representative image is shown in Figure 4-22.   
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Figure 4-22 Representative images of infected N. benthamania nahG with P. atrosepticum LMG2386 and incubated at 28 oC for 72 hours.  Leaves were 
pressure infiltrated with 500 μl P. atrosepticum LMG2386 WT, ΔfusA and ΔfusA/pfusA resuspended in MgCl2 at two inoculums (1 x106 and 5 x105 CFU).  Leaves were 
imaged with a Chemidoc system with degraded tissue shown as a lighter grey and intact leaf tissue as a darker grey.  Tissue damage is indicated with no tissue 
maceration (-) and complete tissue maceration (+) shown.  No intermediate levels of infection were observed, experiment was performed in triplicate with a 
representative image shown. 
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To further test the role of FusA in infection the virulence of each strain was 
tested against S. tuberosum tissue as this is a natural host species of P. 
atrosepticum LMG2386.  Tuber slices were infected with P. atrosepticum 
LMG2386 and incubated at 28oC for 72 hours and examined.  After infection 
tuber tissue exhibits the classical symptoms of soft rot infection with degraded 
tissue seen to be darker in colour.  The tuber tissue was also observed to have 
lost all structural integrity due to maceration by cell-wall degrading enzymes.  
The outcome of infection was same for P. atrosepticum LMG2386 WT, ΔfusA and 
ΔfusA/pfusA (Figure 4-23).  This further suggested that the presence of FusA is 
not essential for virulence as the absence does not create a fitness cost during 
tuber or leaf infections.   
Previous work has shown that P. atrosepticum LMG2386, unlike other 
Pectobacterium species, does not show enhanced growth in the presence of 
plant-type ferredoxins under iron limiting condition [117].  This, in conjunction 
with these results, suggests that P. atrosepticum LMG2386 may be employing 
other iron sequestering mechanisms and therefore the removal of one is unlikely 
to completely disrupt virulence.  It would be interesting to determine if the fus 
system is essential for virulence in other Pectobacterium species which more 
readily use the host ferredoxins as an iron source.   
136 
 
Figure 4-23 Representative image of S. tuberosum slices of 1 cm in thickness were 
inoculated with 500 μl of P. atrosepticum LMG2386 in 10 mM MgSO4 at 1 x106 and incubated 
for 72 hours at 28 oC.  No sign of infection (-) and greater than 80% maceration (+) are indicated. 
Experiment was performed in triplicate with a representative image shown, no intermediate stages 
of infection were observed in any replicate.   
 Pectocin M1 as a potential pesticide 
P. atrosepticum LMG2386 is a major pathogen of potatoes (S. tuberosum) 
however innate resistance against this pathogen varies between individual 
varieties of potato.  It has been shown in this study that the Jura variety of 
potatoes is susceptible to P. atrosepticum LMG2386 infection.  P. atrosepticum is 
known to cause necrosis in both tuber and leaf tissue in planta and therefore it 
was predicted that pre-treatment with pectocin M1 could prevent infection with 
P. atrosepticum LMG2386 [2,175].  As pectocin M1 has been shown to reduce cell 
growth and cause cell lysis down to nanomolar concentrations it was predicted 
to be effective at low concentrations in vivo.   
Infections of ~1 x106 CFUs of bacteria were characterised previously for both 
tuber and leaf infections with P. atrosepticum LMG2386 WT, ΔfusA and 
ΔfusA/pfusA (4.2.4).  This model was used to determine whether pre-treatment 
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with recombinant pectocin M1 could potentially be used as a preventative 
treatment for P. atrosepticum infection in vivo.  Potato tubers were sliced at a 
thickness of 1cm and were treated with 500 µl of pectocin M1 in 10 mM MgCl2 30 
minutes prior to infection and incubated for 48 hours at 28oC.  
Table 12: Levels of infection in both tuber and leaf infections after treatment with pectocin 
M1.  Leaves and tubers were pre-treated 30 minutes prior to infection with pectocin M1 (0.1-2.5 
mg) and challenged with P. atrosepticum LMG2386 WT, ΔfusA, ΔfusA/pfusA or MgCl2 as a mock 
infection.  Results shown indicate no infection (-), maceration of <50% of the tissue (+), 
maceration of 50-80% of the tissue (++) and maceration of >80% of the tissue for the total tuber 
mass.  Experiments were performed in duplicate. (representative images shown in Figure 4-24 
and Figure 4-25) 
 Tubers Leaves 
 no treatment  2.5 mg 0.5 mg 0.1 mg  no treatment  2.5 mg 
MgCl2 - - - - - - 
WT ++ ++ + + +++ +++ 
ΔfusA +++ +++ +++ +++ +++ +++ 
ΔfusA/pfusA ++ +++ + ++ +++ +++ 
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Figure 4-24  Pectocin M1 treatment of S. tuberosum with different concentrations of pectocin M1 comparing P. atroseptcium LMG2386 WT, ΔfusA and 
ΔfusA/pfusA strains.  Tuber slices were pre-treated with pectocin M1 at 2.5, 0.5, 0.1 and 0 mg total protein 30 minutes prior to infection.  Tubers were then inoculated 
with 10 mM MgCl2 or 1 x106 CFUs of P. atrosepticum wild-type (WT), ΔfusA and ΔfusA/pfusA.  Tubers were incubated at 28oC for 48 hours.  Experiment was performed 
in duplicate with a representative image shown.   
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Pre-treatment of potato tubers (Figure 4-24) showed that although the lesions 
caused by P. atrosepticum infection appear to be slightly reduced with the 
addition of pectocin M1 these results are inconclusive. The difference in 
treatment response between the WT and ΔFusA strains does suggest a reduction 
in bacterial load with the addition of pectocin M1.  However, as lesions are also 
smaller in the absence of treatment this may not be indicative of successful 
treatment.  
CFU counts were initially taken before and after infection in order to quantify 
the number of bacteria within an infected tuber slice to determine if there was 
a reduction in bacterial load.  However due to the lack of resistance and no 
effective selective media for P. atrosepticum, the P. atrosepticum colonies could 
not be easily distinguished from contaminants.  An effective way to tackle this 
would be to introduce an antimicrobial marker however this could potentially 
have a fitness cost and may reduce the level of infection.  Additionally, it would 
be beneficial to examine the longevity of pectocin M1 in plant tissue over 
several days to determine if it is broken down by proteases or remains active 
over a long period of time.  
4.2.5.1 Pectocin M1 as a potential treatment for P. atrosepticum infection 
using N. benthamania as a model organism.  
Preliminary trials showed that pressure infiltration with pectocin M1 in 10 mM 
MgCl2 was the most effective method of pre-treatment before infection.  Pre-
treatment with the addition of a surfactant was also tested, however with this 
method it was difficult to determine the concentration of pectocin M1 
administered.   
Leaves were pre-treated with pectocin M1 30 minutes before inoculation.  N. 
benthamania nahG leaves were subsequently infected with P. atrosepticum 
LMG2386 WT, ΔfusA and ΔfusA/pfusA strains after pre-treatment and incubated 
for 48 hours and imaged using the white-light filter on the Chemidoc.   
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Figure 4-25 N. benthamania infection with P. atrosepticum LMG2386 after 30 minutes of pre-
treatment with 1 mg pectocin M1.  Leaves were incubated for 24 hours at 28oC after infection 
with MgCl2, P. atrosepticum WT, ΔfusA and ΔfusA/pfusA respectively.  
Uninfected leaves (MgCl2) showed no signs of cell lysis and leaves were intact, 
however some tissue damage was observed at the points of infiltration.  It can 
be seen in Figure 4-25 that pre-treatment with pectocin M1 was ineffective in 
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clearing the infection.  In the leaves infected with WT P. atrosepticum LMG2386 
there was a small reduction in the amount of leaf tissue damage however the 
lack of complete eradication of the infection or the lack of a substantial 
difference in damage made it difficult to reach any conclusions (Figure 4-25).   
As with the tuber infections, colony counts were performed from leaf sections 
however it was difficult to draw conclusions from the data collected.  Primarily 
due to the lysis of the plant cells it was difficult to collect consistent samples 
from macerated tissue.  Moreover, the bacteria counted were presumed to be P. 
atrosepticum however it was clear from the colony morphologies that there 
were other bacterial species present which were also seen in small numbers on 
the control leaves despite the lack of infection.  
Furthermore, it is unclear whether pectocin M1 is broken down by host proteases 
and the host immune response.  Western blotting was used to try and determine 
this however the level of protein in the leaf tissue after infection was too low to 
be detected in this manner.  The most efficient way to use pectocin M1 as a 
treatment method against infection would be to express the protein in planta 
under a constitutive promoter so that the presence of pectocin M1 in the leaf 
tissue prevents an infection from being established.   
 Conclusions 
Prior to this work it was known that pectocin M1 is taken up into the periplasm 
of Pectobacterium cells through the ferredoxin uptake receptor, FusA as the 
absence of this receptor eliminates the ability of pectocin M1 to enter the cell 
and cause cell lysis.  It was further proposed that pectocin M2 could only 
interact with FusA in the folded conformation based on docking models of the 
ferredoxin domain of pectocin M1 and previous NMR work [124].   
This work has furthered the understanding of the uptake and interaction of 
pectocin M1 with the FusA receptor.  It has been shown that the long 
extracellular domain of FusA, as well as the N-terminal plug domain, interacts 
with pectocin M1 in vivo.  Through the use of SDM the location of residues 
important for uptake were identified on both FusA and pectocin M1 suggesting a 
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binding interface between the two proteins and mutagenesis studies have given 
support for the current model of pectocin M1-FusA interaction.   
Furthermore, this work has allowed the model of pectocin M1 uptake to advance 
as it has been shown that the substrate interacts with the periplasmic FusB in 
vitro.  Future work will focus on successfully deleting the fusB gene in order to 
test if this protein is essential for uptake and examine the interacting sites 
through the use of NMR spectroscopy and subsequent SDM.  The current model of 
pectocin M1 uptake therefore now consists of the binding of pectocin M1 to the 
long extracellular domain of FusA and the removal of the FusA N-terminal plug 
domain to allow for pectocin M1 to enter the cell and interact with FusB.  It is 
unknown if pectocin M1 interacts with any other periplasmic proteins or 
immediately goes onto interact and cleave its substrate, lipid II (illustrated in 
Figure 4-26).   
The use of pectocin M1 as a novel antibiotic has been shown to be ineffective in 
the current in vivo studies; however, this is likely due to the concentrations of 
proteins used.  Future work should focus on developing and refining pectocin M1 
as a novel antibiotic and examining if there are reductions in bacterial load 
when pectocin M1 is used.  The current studies are limited in that the CFU 
counts at the end of an infection are difficult to determine due to the lack of 
selection media for P. atrosepticum.  For future wok, it would be beneficial to 
select for P. atrosetpicum to accurately measure the bacterial load, this could 
be done through the introduction of an antibiotic resistance marker.   
Finally, the production of a pectocin M1 chimera protein that can successfully 
interact with FusA shows that the N-terminal domain of pectocin M1 has the 
potential to be used to deliver small proteins into Pectobacterium spp. and has 
the potential to be developed as a new delivery tool for antimicrobials. 
Altogether this work has advanced our understanding of ferredoxin and 
ferredoxin bacteria uptake.  
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Figure 4-26 Schematic diagram showing the current predicted model of pectocin M1 uptake into P. atrosepticum cells.  Model shows pectocin M1 (red) 
interacting with the FusA outer membrane receptor (blue) in the bent conformation.  A conformational change occurs to allow pectocin M1 to pass through the lumen of 
the FusA barrel with the plug removed from the barrel, predicted to be in a folded conformation (orange).  Pectocin M1 is then predicted to interact with FusB (green) in 
the periplasm in order to go on and cleave lipid II anchored in the inner membrane, potentially in the bent conformation as suggested in [176].  
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Chapter 5 Biochemical and Biophysical 
Characterisation of Agalacticin A   
 
Disclosure:  Agalacticin A was discovered by Sakramanee Krajangwong; initial 
testing of strains and all Galleria mellonella model work was performed by her.  
All other work presented here was performed by the author.   
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 Introduction  
GBS is a Gram-positive bacterium which is a causative agent of infections in a 
broad range of host species.  GBS causes a wide-range of diseases from mastitis 
in cattle to neonatal infections in humans and streptococcosis in fish 
[26,29,177].  These diseases can have devastating consequences to human 
health, food security and production worldwide.  GBS is resistant to several 
antibiotics and the overuse of antibiotics in farming means that antimicrobial 
resistance is increasing [10].  Therefore, the discovery of novel antibiotics to 
target GBS is essential.   
Bacteriocins of Gram-positive bacteria are commonly peptide antibiotics [178].  
The most well characterised of these peptide antibiotics is nisin, a commonly 
used food preservative produced by Lactococcus lactis and part of the 
lantibiotics family of bacteriocins [47]. The active form of nisin A is a 34 amino 
acid polypeptide which contains several post-translationally modified amino 
acids [179].  Nisin prevents successful cell wall synthesis and consequently cell 
lysis [180].  This lantibiotic has a relatively broad spectrum of killing and can 
target a large number of Gram-positive bacteria, including Listeria and 
Clostridia species [47].  Despite their broad-spectrum, lantibiotics are largely 
ineffective against Gram-negative pathogens due to their highly impermeable 
outer membrane [47].   
Although the majority of Gram-positive bacteriocins discovered are peptide 
antibiotics, there is a class of narrow spectrum protein antibiotics, termed 
bacteriolysins, which are more similar to those found in Gram-negative bacteria 
[178].  Lysostaphin is a peptidase that is released by Staphyloccoccus simulans 
and targeted towards other Staphylococcal species, specifically S. aureus 
[96,181].   
Lysostaphin belongs to the M23 metalloprotease family which are characterised 
by their ability to hydrolyse peptide linkages within the peptidoglycan layer 
during cell division and their requirement for a zinc ion in the active site [182].   
A well characterised M23 metalloproteases is LytM, an autolysin from S. aureus 
which is very similar in structure and function to the catalytic domain of 
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lysostaphin [94].  Unlike lysostaphin, LytM is an autolysin which is responsible for 
peptidoglycan hydrolysis during cell division [94].  Lysostaphin and LytM are very 
similar in structure, with homologous active sites, both containing HXXXD and 
HXH motifs and a zinc ion at the active site [94,181].   
ZooA (ZooA) is a bacteriocin produced by and targeted towards Streptococcus 
epi ssp. zooepidemicus and is similar in both structure and function to 
lysostaphin [104,183,184].  ZooA has an N-terminal cytotoxic domain which is 
structurally similar to both lysostaphin and LytM acts by hydrolysing 
peptidoglycan [94,99,183].  Similarly to lysostaphin, ZooA has a unique C-
terminal target recognition domain (TRD) which is specific for the target 
organism, in this case Streptococcus species [94,97].  
The TRD of ZooA is presumed to be necessary in order for it to specifically target 
the Streptococcus peptidoglycan layer.  Recent work has suggested that this 
domain interacts with the tetrapeptide and alanine cross-bridges of the 
peptidoglycan layer positioning the bacteriocin on the cell surface [103].  
Structural and sequence comparisons show that ZooA, LytM and lysostaphin share 
a show a conserved HXXXD, HXH active site (Figure 5-1).  It can be seen in the 
sequence alignment that, unlike both LytM and lysostaphin, the cytotoxic domain 
of ZooA is at the N-terminus rather than the C-terminus of the protein.  However 
previous work has shown that ZooA targets D-alanyl-D-alanine peptide bonds 
[104] and the D-alanyl-L-alanine bonds [100] within the peptidoglycan layer, this 
is in contrast to the activity of lysostaphin which is known to cleave the glycine-
glycine cross-bridges of Staphylococcal peptidoglycan [97,104].  The preference 
for D-alanyl-D-alanine bonds and the ability to cleave nitrocefin suggests that 
ZooA is more similar in activity to a penicillin binding protein or β-lactamase 
[104].  
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Figure 5-1 Amino acid alignment of conserved active sites of ZooA, lysostaphin and LytM.  
The conserved active site motifs are underlined with conserved residues in all three proteins in red, 
residues conserved in two proteins in pink and non-conserved residues in blue.  Alignment of ZooA 
AA 37-162, lysostaphin AA 265-389 and LytM AA 199-315.   
Recently a bacteriocin produced by GBS was discovered which is thought to be 
similar in structure and function to ZooA.  This novel bacteriocin, named 
agalactitcin A, was shown to be targeted towards S. agalactiae strains when 
plated in direct contact with the producing strain (MRI Z2:09).  This bacteriocin 
is predicited to be similar to zoocin A from S. zooepidemicus and therefore a 
potential novel therapeutic.  The aim of this chapter is to characterise this 
bacteriocin, named agalacticin A, both biochemically and biophysically to 
examine its structure and mode of action.
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 Results 
 Agalacticin A 
Agalacticin A and ZooA have a 58% sequence identity and show a high degree of 
sequence similarity in both the cytotoxic domain and TRD (Figure 5-2a).  A 
molecular weight of 30.385 kDa was calculated for agalactin A from the amino 
acid sequence.  This calculated weight is almost identical to the calculated 
weight of ZooA at 30.617 kDa (using protparam [152]).  This, along with a high 
sequence similarity suggests a homology between ZooA and agalacticin A.  
Both domains of ZooA have been structurally determined by NMR independently 
[99,183,184] and the overlapping region suggests a flexible linker joining the two 
domains.  The recently solved NMR structure of ZooA (PDB ID 5KVP and 2LSO) 
suggests some regular secondary structure in the TRD, however the predicted 
model of agalacticin A suggests little regular secondary structure when modelled 
using I-TASSER [156].  This may be due to the lack of known homologues rather 
than the true lack of regular secondary structure suggesting that the model of 
this domain may be unreliable.  However, the cytotoxic domain is similar in 
structure to that of both lysostaphin and LytM, consisting largely of β-sheet.   
When modelled the N-terminal cytotoxic domains of agalacticin A appears to be 
highly similar to the NMR structure of ZooA.  This similarity is supported by the 
amino acid sequence alignment (Figure 5-2a).  However, the TRD of each protein 
appears to be structurally dissimilar despite 50% sequence similarity (Figure 
5-2b). The difference between the C-terminal domains may be due to their 
specificity to Streptococcal species, their lack of regular secondary structure or 
poor modelling of the Agalacticin A TRD due to the lack of known homologues.   
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Figure 5-2 Sequence and structural alignments of agalacticin A from S. agalactiae and ZooA 
from S. zooepidemicus.  a) Amino acid sequence alignment performed in CLC workbench with 
conserved residues shown in red.  b) Structural sequence alignment of the I-TASSER model of 
agalacticin A (green) compared to the NMR structures of ZooA (pink).  The N-terminal cytotoxic 
domain (PDB ID 5KVP) and the C-terminal target recognition domain (PDB ID 2LS0) performed in 
PyMOL.  The alignment shows agalacticin A AA 1-146 align with the cytotoxic domain of ZooA and 
AA 164-272 align with the target recognition domain.  
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 Agalacticin A is active against S. agalactiae strains 
GBS are prevalent worldwide pathogens that cause disease in a wide range of 
hosts.  Within recent years the prevalence of GBS isolates with either single or 
multidrug resistance is increasing [33].  Due to the wide host range it is 
important that novel antimicrobials can be used against a variety of isolates.  
The novel bacteriocin agalacticin A was recombinantly produced and was found 
to be effective against human, bovine and fish isolates.   
Three strains were chosen for this work due to the diversity of their host species 
and sequence type (ST); STIR CD01 (fish, ST7), MRI Z1-354 (bovine, ST7) and MRI 
Z2-197 (bovine, ST67) hereafter known as CD01, 354 and 197 respectively.  
Preliminary work had shown that each of the strains chosen were susceptible to 
agalacticin A at nanomolar concentrations (Figure 5-3) with agalacticin A 
inhibiting growth at 250 nM in MRI Z1:354 and growth of both MRI Z2:197 and 
STIR CD01 inhibited at a concentration as low as 125 nM.   
 
Figure 5-3 Spot test overlay of three GBS isolates with agalacticin A spotted at 2-fold 
dilutions from 66 μM to 125 nM.  Overlay of GBS in 0.8% agar onto BHI agar incubated with 2 μl 
spots of agalacticin A overnight at 37oC.   
The potency of agalacticin A in liquid culture was tested at a final concentration 
of 3 μM.  Cells were grown to mid-log phase prior to the addition of agalacticin A 
and growth was monitored for a total of 8 hours.  It can be seen in all strains 
(Figure 5-4) that growth was inhibited after the addition of agalacticin A.   
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Figure 5-4 Liquid growth of GBS strains with (red) and without (blue) the addition of 
agalacticin A. Agalacticin A was added to cells in BHI after 3 hours (*) of growth at a final 
concentration of 3 μM.  Growth of GBS MRI Z1:354 (a), MRI Z2:197 (b) and STIR CDO1 (c) was 
measured by optical density (at 600 nm) every 60 minutes.  Growth curves were performed in 
triplicate with three technical replicates in each replicate.  
As in solid media, the susceptibility to agalacticin A varies between isolates, 
however it can be seen within the liquid media that the fish isolate STIRCD01 is 
the most susceptible to agalacticin A (Figure 5-4) at a 3 μM concentration.  It can 
also be seen that agalacticin A is able to reduce the growth of two isolates, CD01 
and 197, at nanomolar concentrations showing a reduction in growth with 120 
nm of agalacticin A (Figure 5-5).   
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Figure 5-5 Liquid growth curves of GBS strains with different concentrations of agalacticin 
A. Agalacticin A was added to cells in BHI after 3 hours (*) of growth at a final concentration of 3 
μM.  a) MRI Z1:354 b) MRI Z2:197 and c) STIR CDO1 with agalacticin A added at mid-log phase (*) 
at final concentrations of 3 μM (green), 0.6 μM (purple), 120 nM (orange), 24 nM (black), no 
agalacticin (red).  Growth curves were performed in triplicate with three technical replicates in each 
replicate. 
 Recombinant agalacticin A has enzymatic activity 
5.2.3.1 In vitro β-lactamase activity assay  
Agalacticin A is predicted to be similar in structure to lysostaphin and ZooA (see 
5.2.5).  Both proteins are known to act by cleaving the peptide bonds of 
peptidoglycan causing cell lysis.  β-lactamases are enzymes which cleave β-
lactam antibiotics, such as ampicillin or nitrocefin, by hydrolysing the β-lactam 
ring.  β-lactam antibiotics mimic the structure of D-alanyl-D-alanine in order to 
interact with penicillin binding proteins to disrupt peptidoglycan synthesis.  The 
hydrolysis of beta-lactam antibiotics can therefore be equated to the hydrolysis 
of the D-alanyl-D-alanine bond in the peptidoglycan layer, as suggested by Heath 
et al. (2004).  Nitrocefin is a yellow coloured peptide antibiotic with a β-lactam 
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ring which, when hydrolysed, changes colour to red, this change can be 
measured at a wavelength of 492 nM giving a quantitative measure of hydrolysis 
[185].   
 
Figure 5-6: Schematic diagram to show the hydrolysis of nitrocefin and the points of 
hydrolysis on the peptidoglycan.  a) Chemical reaction of nitrocefin from yellow to red with the 
addition of β-lactamases (reproduced from [185] with permission from the Nature publishing group).  
b) Schematic diagram of peptidoglycan highlighting the peptidoglycan cleavage sites of ZooA (D-
ala-L-alanine) and lysostaphin (glycine-glycine) (adapted from [96] under a creative commons 
licence).  
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Previous work by Heath et al (2004) showed that ZooA could cleave nitrocefin in 
a dose-dependent manner, supporting the hypothesis that ZooA acts like a 
penicillin binding protein and can cleave D-alanyl-D-alanine peptide bonds within 
peptidoglycan [104].  Recombinant agalacticin A was incubated with nitrocefin 
for 30 minutes and the absorbance at 490 nM was measured.   
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Figure 5-7 Nitrocefin cleavage by agalacticin A shows a concentration dependent hydrolysis 
of the β-lactam ring.  a) Nitrocefin hydrolysis by agalacticin A at 3.33 μM (red), 1.67 μM (green), 
833 nM (purple), 416 nM (orange) and in the absence of agalacticin A (blue).  b) Absorbance at 490 
nM of nitrocefin after 30 minutes of incubation with agalacticin A showing a significant difference (p 
<0.0001) when all conditions were compared (ANOVA).  Multiple comparisons (Bonferroni 
correction) show a significant difference (p <0.001) between every condition. Absorbance was 
measured at 490 nm rather than the optimal 492 nm due to limitations in the plate reader filters.  
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It can be seen in Figure 5-7 that when incubated with agalacticin A the β-lactam 
ring of nitrocefin is hydrolysed, as indicated by the increase in absorbance at 
490 nm.  After incubation with agalacticin A for 30 minutes the absorbance at 
490 nm was seen to be significantly different between each of the 
concentrations of agalacticin A, showing that agalacticin A hydrolyses nitrocefin 
in a dose-dependent manner (Figure 5-7b).  These results suggest a similarity in 
the mechanism of action between ZooA and agalacticin A [104].  These data 
show that recombinant agalacticin A is enzymatically active in vitro and acts in a 
similar way to ZooA by hydrolysing peptide bonds.  It has previously been 
suggested by Xing et al. (2017) that the catalytic domain of ZooA can hydrolyse 
the D-alanyl-L-alanine peptide bonds within the Streptococcal peptidoglycan.  
Due to the similarity of the nitrocefin structure to peptide bonds it can be 
predicted that agalacticin A is likely to act by hydrolysing peptide bonds within 
the Streptococcal peptidoglycan.  
 Predicted structural model of agalacticin A 
After the discovery of the producing strain S. agalactiae MRI Z2-093, agalacticin 
A was initially examined bioinformatically using sequence and structural 
alignments.  It was discovered that agalacticin A was a homologue of ZooA with 
an N-terminal cytotoxic domain and a C-terminal target-recognition domain 
(Figure 5-8).  The model, created using I-TASSER, suggested that the N-terminal 
cytotoxic domain is similar in structure to other M23 metalloproteases, such as 
lysostaphin; however, the TRD shows little regular secondary structure and no 
close homologues (Figure 5-8).   
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Figure 5-8 Sequence alignment shows similarities to both M23 peptidases and the target 
recognition domain of ZooA.  a) Schematic diagram showing homologous proteins for both the 
N- and C-terminal domains.  b) I-TASSER model highlighting the amino acids homologous to an 
M23 peptidase in the N-terminal (blue) and the target recognition domain of ZooA (green).  
Agalacticin A from GBS has the characteristic cytotoxic domain, with the same 
HXXXD, HXH active site motif in the N-terminal cytotoxic domain.  As with ZooA, 
LytM and lysostaphin the cytotoxic domain of agalactin A is predicted to be 
structurally and functionally similar to an M23 metalloprotease and zinc 
dependent.  Classical amino acid sequence alignments show a small amount of 
similarity between agalacticin A and lysostaphin with only around 25% sequence 
identity.   However, when a structural sequence alignment is performed with the 
I-TASSER model of agalacticin A and lysostaphin it is clear that despite the 
sequence disparity they are predicted to be structurally similar (Figure 5-9).  
This was also seen with an alignment of the NMR structure of ZooA and 
lysostaphin (not shown).   This structural similarity further supports the idea that 
agalacticin A may be homologous in activity to both ZooA and lysostaphin.  
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Figure 5-9 Structural alignment of lysostaphin in pink (PDB ID 4LXC) and I-TASSER model of 
agalacticin A (green) showing structural similarity in the cytotoxic domains and dissimilarity 
in the TRD. a) Amino acid sequence alignment performed by CLC workbench with conserved 
residues highlighted in red and the active site motifs underlined. b) PyMOL was used to structurally 
align the I-TASSER model of agalacticin A and lysostaphin (PDB ID 4LXC) based on the secondary 
and tertiary structures. The cytotoxic domain shows an alignment of the C-terminal domain of 
lysostaphin is aligned with the N-terminal domain of agalactin A, the TRD shows the alignment of 
the C-terminal of agalacticin A and the N-terminal of lysostaphin.   
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 Structural characterisation of agalacticin A  
5.2.5.1 Analytical ultracentrifugation  
NMR spectroscopy has previously been used to solve the structures of the TRD 
and cytotoxic domains of ZooA individually, however no work to date has 
examined the interaction between these domains or the overall protein 
structure [99,183].  Recent work examining lysostaphin has shown that the 
flexible inter-domain linker region allows the two domains to move 
independently, giving elongated and compact conformations [97].  The current 
model of agalacticin A is similar to that of both ZooA and lysostaphin, which 
suggests that it might be flexible and potentially elongated in solution.   
In order to confirm that agalacticin A is monomeric in solution, as predicted, 
sedimentation velocity AUC was used to examine the oligomeric state of the 
protein.  Agalacticin A was tested at a range of concentrations from 0.3 to 1.5 
mg ml-1 at 49000 rpm and the sedimentation coefficient for each was 
determined.  Data acquired at three representative concentrations are shown in 
Figure 5-10.   
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Figure 5-10 AUC analysis of agalacticin A shows the particle is monodisperse in solution a) 
Continuous c(s) distributions for agalacticin A at concentrations of 1.2 mg ml-1 (red), 0.6 mg ml-
1(green) and 0.3 mg ml-1 (black) at 4oC. b) Extrapolation of sedimentation coefficients corrected to 
standard conditions (s20,w) give an s020,w of 1.205.   
The sedimentation coefficient for each concentration was calculated in order to 
extrapolate to the absolute sedimentation coefficient (S020,w), which was 
determined to be 1.21.   
To assess how well the experimental data correspond to the I-TASSER model of 
agalacticin A, hydrodynamic bead modelling was used to examine the 
hypothetical sedimentation coefficient and radius of gyration (Rg) of the model.  
Hydrodynamic calculations were performed using US-SOMO [149] in which each 
atom within a structure is replaced by a bead, i.e. a bead to represent the main 
chain and a separate bead for the side-chain of the amino acid residues.  The 
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volume of the bead is calculated based both on the residue and the amount of 
hydration predicted for that residue [149].   
The hydrodynamic bead model of agalactin A gave a predicted sedimentation 
coefficient of 2.82 s and a predicted Rg of 23.7 Å.  This predicted sedimentation 
coefficient is greater than the experimental S020,w of 1.21 s.  This lower 
experimental value suggests that agalacticin A may be more flexible in solution 
than the model predicts.  Moreover, agalacticin A could be found in multiple 
conformations, some of which may be elongated.  The continuous s distribution 
confirms that agalactin A is monomeric and therefore is a good candidate for 
small angle X-ray scattering (SAXS).   
5.2.5.2 SAXS analysis of agalacticin A 
Results from the AUC experiments suggested that there was the potential for 
agalacticin A to be flexible or in multiple conformations.  Small angle X-ray 
scattering (SAXS) was used to determine both the overall structural envelope of 
agalacticin A as well as the inter-domain flexibility.   
Scattering data were obtained at concentrations of 10, 5, 2.5 and 1.25 mg ml-1 
using a bioSAXS robot and 45 μl of each sample was analysed.  The quality of the 
data was analysed by examining the excess kurtosis of each frame.  The excess 
kurtosis is a way of examining the data set corresponds to a normal, expected 
distribution.  If the excess kurtosis suddenly increases this suggests that the 
sample is radiation damaged and the frames after this increase are omitted.  
Agalacticin A at 2.5 mg ml-1 was analysed as this sample generated the best 
quality scattering data and the largest number of frames without radiation 
damage (Figure 5-11).  Scattering data for Agalaciticin A was also collected using 
SEC-SAXS to confirm the bioSAXS data.  As the scattering data was identical to 
the data presented here it is not shown.   
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Figure 5-11 Measure of the excess kurtosis for each scattering frame for agalacticin A at 
four concentrations. Excess kurtosis for each frame was measured for agalacticin A at 10 mg ml-1 
(purple), 5 mg ml-1 (green), 2.5 mg ml-1 (red) and 1.25 mg ml-1 (blue). 
 
Figure 5-12 Scattering data obtained for agalacticin A (2.5 mg ml-1) show a non-aggregated 
sample a) q vs log I(q) b) Guinier analysis of the low q range suggests a Rg of 31.9 Å. 
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Guinier analysis of agalacticin A (Figure 5-12b) gives a predicted molecular 
weight of 29.9 kDa which is similar to the molecular weight calculated from the 
sequence, of 30.4 kDa, suggesting that agalacticin A is monomeric in solution.  
However, the Guinier analysis also suggests a Rg of 31.9 Å which is larger than 
the predicted Rg of 23.7 Å from the hydrodynamic bead model [149].  This 
discrepancy between the theoretical and experimental Rg suggests that 
agalacticin A may be more elongated in solution than the model predicted.  This 
could be due to the presence of the flexible linker region between the two 
domains (Figure 5-8).  
5.2.5.3 In solution data suggest that agalacticin A is elongated and flexible  
Kratky analysis examines the scattering data within the high q range in order to 
predict whether the protein is compact or intrinsically flexible in solution.  If a 
particle is spherical the data will form a Gaussian distribution with the peak 
occurring around √3.  The Kratky analysis of agalacticin A shows a Gaussian 
distribution, with the peak occurring at an Rg greater than √3 (Figure 5-13a).  
This suggests that the particle is structured but elongated in solution, which is 
consistent with the I-TASSER model of agalacticin A (Figure 5-8).   
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Figure 5-13 Flexibility analysis suggests agalacticin A is elongated and flexible in solution. 
a) Dimensionless Kratky analysis with √3 shown by crosshairs, as the peak of the data occurs at a 
greater value than √3 this suggests that the particle is elongated in solution b) Krakty-Debye plot 
and c) Porod-Debye plot at q= 0.1858 showing the plateau occurring first in the Porod-Debye plot 
suggesting the particle is flexible.    
SAXS data can yield information about the flexibility and shape of a particle in 
solution.  By raising q to the powers of 2 and 4 and examining the data at the 
low q range the particle can be seen to be either flexible or compact in solution.  
The flexibility of agalacticin A can be determined by examining the Porod-Debye 
plot (Figure 5-13c) and the Kratky-Debye plot (Figure 5-13b) in conjunction.  By 
lowering the q value, the plot which plateaus at the highest q value can be used 
to classify the protein as flexible or compact.  It can be seen in Figure 5-13 that 
the plateau first occurs in the Porod-Debye plot (Figure 5-13c) suggesting that 
agalacticin A is flexible.   
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5.2.5.4 Low resolution structure of agalacticin A  
A dummy atom model of agalacticin A was created based on the pair-set p(r) 
distribution of the particle using DAMMIF (Figure 5-14).  This distribution is 
created through an indirect Fourier transformation of the scattering data by 
which the maximum dimensions (Dmax) of the particle can be found.   
 
Figure 5-14 DAMMIF model of Agalacticin A a) p(r) distribution for agalacticin A scattering data 
showing a Dmax value of 108 Å b) and c) DAMMIF model of agalacticin A (green) overlaid with the I-
TASSER model of agalacticin A (pink) using SUPCOMB showing the similarity in structure with the 
C-terminal TRD on the left hand side and the compact N-terminal cytotoxic domain on the right 
hand side with the two dimensional measurements shown. 
165 
The p(r) distribution of the particle gave a Dmax of 108 Å which is longer than the 
predicted model at approximately 74 Å in length.  Due to the difference 
between the experimental Dmax and the dimension of the I-TASSER model, this 
further suggests that agalacticin A may be elongated in solution or in multiple 
conformations.  The undulations in the p(r) distribution are consistent with the 
domain separation shown in the model but may also suggest that the particle is 
found in multiple conformations within solution.   
The N-terminal domain of agalacticin A is thought to be structured and compact, 
like the cytotoxic domains of other M23 metalloproteases such as lysostaphin.  
The flexible linker region between the two domains is unstructured and 
therefore it is likely to be flexible and the potential for elongation around this 
region.  This is consistent with the SAXS data which shows agalacticin A is 
flexible in solution.   
5.2.5.5 SAXS data suggest a flexible linker region  
SAXS analysis of agalacticin A suggests that agalacticin A is both flexible and 
elongated in solution.  Previous work has suggested that the linker region may be 
flexible due to the abundance of proline and threonine residues [184].  Ensemble 
optimisation modelling (EOM) was used to examine the inter-domain flexibility 
(see Chapter 3) around the flexible linker region to determine if this allows for 
the movement of each of the domains independently.   
166 
 
Figure 5-15 CRYSOL fit to experimental SAXS data from models of agalacticin A in multiple 
conformations. Predicted SAXS curves (red) for each predicted model and a combination of 
models were compared with the experimental SAXS curves (black).  a) Compact model of 
agalacticin A, X2= 51.925 b) Elongated model of agalacticin A X2=23.807 c) I-TASSER model of 
agalacticin A, X2= 52.557 d) Combined models of agalacticin A calculated by EOM, X2= 3.407.  
CRYSOL was used to examine the fit of the current predicted agalacticin A model 
to the SAXS data, as well as modelling two other predicted conformations and a 
population in multiple conformations to determine the best fit.  The results 
shown in Figure 5-15 show that the best fit to the experimental data comes from 
a population in multiple conformations.  The best fit to the experimental data 
for agalacticin A was calculated using EOM, modelling multiple conformations of 
agalacticin A giving a fit with a X2 value of 3.407 (Figure 5-15d).  
The pool of EOM models has Dmax values that range from 63 Å to 105 Å, however 
it is clear from the frequency distribution that agalacticin A can be found in two 
distinct populations in solution (Figure 5-16).  The compact population shows a 
peak Dmax of 78.5 Å whilst the other peak suggests an elongated population with 
the peak occurring around 101 Å (Figure 5-16).  Furthermore, the Rg for these 
two populations clearly support both the predicted I-TASSER model of agalacticin 
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A with a peak Rg of 25 Å, similar to the hydrodynamic model prediction of 23.4 Å 
as well as the experimental data showing a Rg of 33 Å which is similar to the 
experimental Rg of 31.4 Å.   
 
Figure 5-16 EOM modelling of agalacticin A suggests that it is flexible and elongated in 
solution.  a) Rg and b) Dmax population of the EOM models which best fit the experimental data 
(red) shown in comparison to the pool of generated models (grey) showing two distinct populations 
c) Cartoon representations of the elongated and compact models representing the two EOM 
populations with the cytotoxic C-terminal domain in green, flexible linker in purple and the TRD in 
blue.   
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These data, shown in Figure 5-16, further suggest the elongation and flexibility 
of agalacticin A are found within the flexible linker region.  The representative 
models of the two EOM populations show a compact structure, similar to the I-
TASSER model of agalacticin A (Figure 5-16c) and an elongated structure with the 
flexible linker region predicted to be extended.   
Elastic network modelling (ENM) was used to compute the normal modes of 
agalacticin A [186].  ENM uses computational modelling to determine potential 
conformational changes of a molecule.  Using this method, the flexibility of 
agalacticin A was found to be centred around the flexible inter-domain linker 
region, further supporting the model that agalacticin A may become compact 
and elongated around this central region (Figure 5-17).    
 
Figure 5-17 Illustration of the elastic network modelling conformational changes suggesting 
the movement of domains around the flexible linker region.  ENM was conducted using 
ELNemo [186] to determine the potential conformational changes of agalacticin A.  Two 
representative models are shown here with the N-terminus of each of the extreme conformational 
changes aligned to show the movement of the C-terminal domain around the flexible linker region.   
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5.2.5.6 Crystallisation trials  
A high-resolution structure of agalacticin A has yet to be solved and therefore 
crystal trays were set up for agalacticin A at both 10 mg ml-1 and 5 mg ml-1.  
Optimisation trays PACT, JSCG, Morpheus and Memphsis were set up and 
incubated at 16oC and checked weekly for 2 months.  After 2 months crystals 
started to appear however none of these grew large enough to collect a data 
set.   
 The active site of agalacticin A 
5.2.6.1 Similar structural predictions  
The active site of M23 metalloproteases has been characterised by the presence 
of a zinc ion co-ordinated by three histidines and an aspartic acid [95] found in 
two motifs (Figure 5-9).  The NMR structure of the cytotoxic domain of ZooA 
(PDB ID 2LS0) was solved by Timkovich et al. (2017) showing the presence of a 
zinc ion in the predicted active site of ZooA.  This conserved active site can be 
seen in the high-resolution crystal structure of LytM (PDB ID 4ZYB), NMR 
structure of ZooA and the I-TASSER model of agalacticin A.  Therefore, it is 
predicted that the active site of agalacticin A will consist of the same residues as 
those found in other M23 metalloproteases (Figure 5-18).   
A high-resolution structure of the M23 peptidase LytM, a homologue of the 
lysostaphin from S. aureus was published by Grabowska et al. (2015) showing the 
active site of LytM and the positions of each amino acid involved in both activity 
and zinc ion binding [94].  This active site has been shown to involve three 
histidine residues (H210, H291 and H293) and an aspartic acid (D214) which 
corresponds to the active site motifs shown in Figure 5-1 [94].  Using structural 
and sequence alignments the active site residues of agalacticin A were predicted 
to be H23, D27, H109 and H111 (Figure 5-18).   
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Figure 5-18 Cartoon representation of LytM and agalacticin A predicted active sites. a) High 
resolution structure of the active site of LytM with residues used in the active site shown as sticks, 
image adapted from Grabowska et al (2015) and reproduced under a creative commons license 
[94]. b) I-TASSER model of agalacticin with the predicted active site residues highlighted as sticks 
and labelled to compare with the LytM structure.  The zinc ion is represented by a purple sphere.  
Two active site residues, H23 and H109, were successfully mutated to alanine by 
site-directed mutagenesis as well as the non-active site residue C63.  It was 
shown that these mutations had no effect on the overall protein structure (see 
5.2.8).  Previous work with ZooA had also mutated C74 (corresponding to C63 in 
agalacticin A) to create an active site more similar to that of lysostaphin, 
however this mutation had no effect on enzymatic activity.  Initial tests of 
activity were performed against three GBS strains.   
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Figure 5-19 Soft agar overlays of three GBS species comparing the activity of mutant 
agalacticin A proteins. Overlays of GBS on BHI agar plates were spotted with 2μl of agalacticin A 
at 2-fold decreasing concentrations from left to right from 67μM -1 μM.   
Initial tests showed no difference in potency for C63A compared to the wild-type 
(WT) agalacticin A, whereas there was a reduction in activity for both H23A and 
H109A against all three strains.  The mutation at H109 completely eradicated 
activity (Figure 5-19) suggesting that it may be essential for activity.  This 
supports the hypothesis that these residues are part of the active site of 
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agalacticin A.  H23 and H109 correspond to H279 and H360 respectively in the 
LytM active site, further supporting the hypothesis that these are important for 
activity.   
 
Figure 5-20  Growth curves showing the optical density of the three species of GBS in 
response to administration of WT and mutant agalacticin.  MRI Z1:354 (a), MRI Z2:197 (b) and 
STIR CD01 (c) were grown in BHI with measurements taken at 630 nm for 8 hours total growth. 
Agalacticin A was administered at 3 μM total concentrations after 3 hours of initial growth (*). 
Growth was monitored without any agalacticin (blue) and in the presence of WT agalacticin (red), 
H23A (green), C63A (purple) and H109A (orange).  Each growth curve was performed in triplicate 
with three technical replicates per replicate.  
To test the activity of agalacticin A in liquid culture both the wild-type 
agalacticin A (WT) and mutants were added at mid-log phase of growth to each 
of the three strains.  It can be seen that H109A and H23A do not inhibit the 
growth of any of the strains compared with the WT thus confirming that there is 
no difference in activity between liquid and solid media (Figure 5-20).   
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Interestingly C63A is active against both CD01 and 197 in liquid culture 
confirming the results of the solid agar test, but in liquid culture it is inactive 
against 354 which is contrary to the results shown in the spot-tests.  This could 
potentially be due to small changes in the active site caused by the mutation.  It 
is likely that there is some small difference in the protein which prevents it from 
effectively lysing the cells.  Furthermore, this strain is the least susceptible to 
agalacticin A in both liquid and solid culture and therefore any disruption in 
activity could result in uninhibited growth.  
 In vitro assessment of enzymatic activity of agalacticin 
mutants 
As previously shown in Figure 5-7, agalacticin A can hydrolyse nitrocefin, 
therefore the activity of agalacticin A mutants were tested in the same way.  
Agalacticin A and its mutants were incubated with nitrocefin for 30 minutes and 
the optical density at 490 nm was measured (Figure 5-21).   
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Figure 5-21 Nitrocefin degradation assay comparing WT agalacticin A with that of the 
mutants. a) Time course of nitrocefin degradation over 30 minutes at 37oC with 3.33 μM of 
agalacticin A(blue), H23A (red), C63A (green) and H109A (purple) with the absorbance measured 
at 490 nm. b) Absorbance values at 490 nm after incubation with agalacticin A(blue), H23A (red), 
C63A (green) and H109A (purple) at 4 concentrations of agalacticin A after 30 minutes.  A 
significant difference (p<0.0001) was observed between each of the concentrations, multiple 
comparisons also showed a significant difference (p<0.001) between each of the mutants at each 
concentration, with the exception of 0 µM.  
As with the WT, there is a dose dependent enzymatic rate at which each of the 
agalacticin A mutants hydrolyses nitrocefin (Figure 5-21).  Interestingly, although 
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the nitrocefin assay confirmed a reduction in enzymatic activity of the mutants 
it did not fully confirm the results of both the spot tests and the liquid growth 
curves as each mutant had residual activity, including H109A.   
H109A was inactive against all three strains of GBS in both solid and liquid media 
and it is apparent from the nitrocefin assay that it does retain some enzymatic 
activity, even at low concentrations, this activity is significantly lower than that 
of the WT. This suggests that although enzymatic activity with the single 
substitution is possible in vitro, the disruption in activity is too great to prevent 
lysis of bacterial cells.  
Cytotoxicity assays show that agalacticin A with the C63A mutation was as potent 
against each strain of GBS as the WT, however it has been shown to have 
reduced enzymatic activity against nitrocefin in vitro.  The amino acid 
substitution C63A was based on the work by Xing et al. (2017) who substituted 
the C74 residue of ZooA with an alanine to create an active site more 
structurally similar to that seen in lysostaphin.  It was found by Xing et al. (2017) 
that this substitution had little effect on enzymatic activity based on the 
hydrolysis of purified peptidoglycans rather than β-lactamase activity [100].  
Lysostaphin is an endopeptidase which cleaves the amide bonds between the 
pentaglycine cross-bridges within a peptidoglycan, however it does not show any 
β-lactamase activity due to its affinity for glycyl-glycine bonds [96,187,188].  It 
is clear from the nitrocefin assay that agalacticin A has β-lactamase activity.  
This is consistent with the prediction that agalacticin A, like ZooA, hydrolyses 
the peptide cross-bridges within Streptococcal species as these are composed of 
alanine residues rather than the glycine residues found in Staphyloccocus 
peptidoglycan layers [189,190].   
The alteration of C63 to an alanine residue shows no effect on activity in vivo, 
though within the nitrocefin assay there is a reduction in activity compared with 
both the WT and the other two mutations.  The NMR structure of ZooA C74A 
[183] showed that this amino acid substitution increased the dimensions of the 
substrate binding groove.  This disruption of the binding groove may explain the 
discrepancy between the in vivo and in vitro results due to slight differences in 
the bonds it may be targeting, however, there is no clear explanation for this 
176 
difference in activity.  More work is needed to decipher this difference both 
biochemically and structurally as this still remains unclear.   
 Circular dichroism of mutants  
Circular dichroism (CD) was used to compare the secondary (far UV) and tertiary 
(near UV) structure of WT agalacticin A with the mutant proteins to determine if 
the amino acid substitution had any effect on the structure (Figure 5-22).   
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Figure 5-22: Circular dichroism spectra for agalacticin A and mutants in both far (a) and 
near (b) UV. Spectra for agalacticin A WT and mutants comparing the secondary and tertiary 
structures of the proteins of the WT (blue) against H23A (red), C63A (green) and H109A (purple) 
plotted against the molar ellipticity.  
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There are small differences in the secondary and tertiary structures of 
agalacticin A and the mutants, the difference seen in H23A may be explained by 
the positioning of the residue in the centre of a β-strand, therefore the 
replacement of a histidine with an alanine in this position may cause some 
misfolding.  The discrepancy in the secondary structure can be seen between the 
C63A, H23A and the WT protein, but there is no difference between the H109A 
and the WT protein.  The lack of activity by the substitution of H109 with an 
alanine residue is therefore due to the single amino acid change rather than a 
difference in structure.  The difference in far UV spectra between H23A and WT 
agalacticin is harder to explain without further biophysical characterisation.   
 In vivo Galleria model of agalacticin activity  
Agalacticin A has proven to be a potent novel antibiotic against GBS infection in 
vitro.  In order to test the potential of agalacticin A in vivo against GBS, Galleria 
mellonella were used as a model organism for infection.  The use of G. 
mellonella as a model for Streptococcal infection is well established and 
therefore a good candidate for testing the effectiveness of agalacticin A in vivo 
[191].  The H109A mutant was used as an inactive control in vivo as it shows the 
most structural similarity to the WT within the CD spectrum but has been shown 
to be enzymatically inactive.  Agalacticin A and H109A were tested against 
clinically relevant S. agalactiae strains which had been well established in this 
model MRI Z2:366 and STIR CD25.   
G. mellonella were injected with GBS MRI Z2:366 (2 x106 CFU) and STIR CD25 
(4.33 x106 CFU) and incubated for 2 hours before being administered with 20 μg 
(67 nM) of WT agalacticin A, H109A agalacticin or PBS.  G. mellonella were 
incubated at 37oC and monitored at 12 and 24 hours.   
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Figure 5-23: Survival curves of G. mellonella after GBS infection.  Larvae were treated two 
hours post infection with agalacticin A at 67 nM concentration.  Survival curves for larvae infected 
with MRI Z2-366 (a) and STIR CD25 (b) show that survival rates are higher when larvae are 
treated with WT agalacticin (red) as compared to mock treatment with PBS (blue) and treatment 
with the inactive H109A agalacticin A mutant (green).  Mantel-Cox comparisons show a significant 
difference (p <0.001) between treatments in both strains.  
The administration of WT agalacticin A increased survival rates of G. mellonella 
after 24 hours in comparison with both no treatment and treatment with the 
inactive H109A (Figure 5-23).  After infection with GBS MRI Z2:366, treatment 
with WT agalacticin A resulted in 100% survival compared with larvae treated 
with PBS or H109A groups which succumbed 24 hours after infection.  In the case 
of STIR CD25 infection there was a small increase in survival at 12 hours post-
infection with H109A in comparison with no treatment.  This is consistent with 
the in vitro nitrocefin data showing the presence of some enzymatic activity.  
After 24 hours there was still no survival with either no treatment or treatment 
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with H109A compared to 70% survival when treated with the WT agalacticin A.   
This is further support for the hypothesis that H109A is part of the active site of 
agalacticin A and required for activity.    
In order to examine the longevity of treatment G. mellonella were infected with 
GBS MRI Z2:366, treated after two hours and survival was observed over 72 
hours.   
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Figure 5-24 Survival curves of G. mellonella after GBS infection.  G. mellonella infected with S. 
agalactiae MRI Z2:366 and treated after 2 hours with WT agalacticin (red), agalacticin A H109A 
(green) and no treatment (blue), with mock infection shown in purple. Mantel-Cox comparisons 
show a significant difference of p<0.001 between treatments.  
It can be seen in Figure 5-24 that treatment with WT agalacticin A increases the 
survival of G. mellonella larvae infected with GBS, rescuing 50% of infected 
larvae after 72 hours.  This is a significant increase in survival compared with 
both the mock treatment group and treatment with the inactive H109A mutant.  
Survival of G. mellonella with treatment by agalacticin A shows that agalacticin 
A is a good candidate for further in vivo study to tackle GBS infection. 
 Conclusions  
Agalacticin A is a novel bacteriocin which is active against Streptococcus and 
some Enterococcus species.  Agalactin A is thought to be similar in structure and 
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function to ZooA and lysostaphin.  Prior to this work it was known that ZooA was 
a M23 metallopeptidase capable of cleaving D-alanyl-D-alanine and D-alanyl-L-
alanine bonds within Streptococcus peptidoglycan in order to cause cell lysis 
[100,104,184]. The TRD and cytotoxic domains of ZooA have been solved using 
NMR spectroscopy showing that both domains individually are globular and 
joined by a linker region [99,100].    
This work has shown the inter-domain flexibility and overall structure of 
agalacticin A, confirming its similarity to lysostaphin and ZooA.  SAXS data have 
shown that agalacticin A is flexible and elongated in solution with the flexible 
linker region allowing for independent movement of the two domains.  Recent 
work by Tossavainen et al. (2018) has examined the overall structure and 
flexibility of lysostaphin in solution using SAXS.  This work determined that 
lysostaphin is flexible in solution and that the flexibility is found within the 
inter-domain linker region [97].  The work presented in this chapter suggests 
that agalacticin A is similar to lysostaphin in solution with the flexibility of the 
protein found in the inter-domain linker region.  An X-ray crystal or NMR solution 
structure of the entire protein would be beneficial in order to assess the overall 
structure of agalacticin A and to examine the elongated and compact forms in 
more detail.   
Previous work has reported that ZooA is active against the D-alanyl-D-alanine 
bonds within the peptidoglycan [104], however it has also been reported that 
ZooA can hydrolyse the D-alanyl-L-alanine bonds [100].  Work presented here 
supports the idea that agalacticin A, like ZooA, is able to hydrolyse the the D-
alanyl-D-alanine bonds of both nitrocefin and Streptococcal peptidoglycan.  The 
active site of agalacticin A has been found through the use of site-directed 
mutagenesis; however more mutations are needed to confirm all the residues 
necessary for activity.  It would also be beneficial to examine the exact position 
within the peptidoglycan that agalacticin A cleaves.  Understanding the 
interaction and cleavage sites of agalacticin A would help further characterise 
agalacticin A and understand potential mechanisms of resistance. 
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Agalacticin A has been shown to be an effective treatment of GBS infection in G. 
mellonella models suggesting that it has the potential to be developed as a 
novel therapeutic to combat Streptococcus infection in other organisms.   
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Chapter 6 Concluding remarks 
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 Key findings 
 Pectocins and the Fus system 
The initial aims of this study were to better understand the interaction and 
uptake of pectocins M1 and P by the Fus uptake system in P. atrosepticum.  It 
has been shown previously that FusA is essential for pectocin M1 uptake, 
however this work has shown that it is also essential for the uptake of pectocin 
P.  The parasitisation of the ferredoxin uptake system within Pectobacterium 
spp. appears to be a universal trait of ferredoxin-containing pectocins.  This 
work also suggests that the presence of the ferredoxin domain is necessary for 
the uptake of these pectocins due to its interaction with the FusA receptor.   
The N-terminal domain of pectocins is necessary for the interaction with FusA, 
with a chimeric protein suggesting that the presence of the N-terminal domain is 
sufficient for receptor binding and potentially for uptake.  Through the use of 
docking modelling it was predicted that the N-terminal domain of pectocin M1 is 
likely to interact with the long extracellular loops of FusA.  This model has been 
supported through the use of mutagenesis studies showing that the extracellular 
loops of FusA and the N-terminal of pectocin M1 interact.  This work further 
confirmed the predicted binding site of pectocin M1, showing that it is likely to 
consist of both large and polar residues [124].   
Previous work has shown that pectocin M2 is is flexible in solution which is 
unusual for M-type bacteriocins [123].  Moreover, the structures of pectocin M2 
in both a bent and elongated conformation in conjunction with docking 
modelling suggested that these conformations were necessary for receptor 
binding and translocation respectively [123,124].  The flexibility observed for 
pectocin M2 can be found in all three of the known pectocins, suggesting that 
this flexibility is a universal feature.  Using SAXS it was shown that both pectocin 
M1 and P are likely to be found in multiple conformations in solution.  This data 
is supported by their uptake through the lumen of FusA which would only be 
possible if both were able to elongate.  This flexibility is unusual amongst most 
Gram-negative bacteriocins, with the uptake of some reliant on unfolding rather 
than domain flexibility [63,192].   
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The elongation of the pectocins is necessary for uptake due to the dimensions of 
the lumen of FusA.  However, the uptake of these pectocins can only occur if the 
N-terminal plug domain of FusA is entirely removed from the barrel.  SANS data 
suggests that the plug domain of FusA can exit the barrel and remain folded in 
solution.  Although these data are not conclusive they suggest that the plug 
domain remains intact when exiting the barrel rather than partially unfolding.  It 
is thought that the majority of TonB-dependent outer membrane receptors 
undergo a partial unfolding of the plug domain to allow for substrate uptake 
[63,78].  However, for a large folded substrate the unfolding or entire removal of 
the plug domain seems necessary.  Therefore, it is thought that, in the case of 
FusA, the most likely solution is the exit of the plug domain from the barrel 
whilst remaining folded.   
The distinct structure of ferredoxin-containing bacteriocins suggests a novel 
mechanism of uptake for Gram-negative bacteriocins in the absence of an IUTD.  
Without the presence of this TonB-box containing peptide it was not known 
whether pectocin M1 would be able to interact with the PMF of the inner 
membrane.  Work here suggests that pectocin M1 is able to interact with FusB, 
an inner membrane homologue of TonB, suggesting a novel uptake mechanism.  
This interaction has been shown in vitro, however work to examine this in vivo is 
necessary to determine the importance of this interaction for uptake.  In order 
to further investigate this interaction, it would be beneficial to examine the C-
terminal folded domain of FusB and its interaction with pectocin M1.  This would 
allow for the interaction site to be determined using NMR spectroscopy as well 
as reducing the flexibility and likelihood of self-association due to the removal 
of the highly flexible N-terminal.   
It is known that pectocin M1 is active against P. atrosepticum LMG2386 at low 
concentrations.  Contrastingly, pectocin P is only active against P. atrosepticum 
LMG2386 down to a concentration of 8 µM.  Therefore, it is not known whether 
the reduced potency of pectocin P is due to the enzymatic activity or a reduced 
efficiency in uptake.  The N-terminal domains of pectocin P and pectocin M1, 
although similar, are not identical.  Therefore, it would be interesting to see if 
the N-terminal of pectocin M1 would increase the level of uptake of pectocin P 
and enhance its potency against Pectobacterium strains.  This approach would 
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also allow for the N-terminal of pectocin M1 to be examined as a delivery system 
as the uptake of the bacteriocin could be observed.   
 Agalactin A is a homologue of lysostaphin and ZooA.  
This work has gone some way to confirming the active site of agalacticin A.  As 
the structure of M23 metalloproteases is highly conserved it was predicted that 
the active site residues of agalacticin A would be homologous to those found in 
lysostaphin, LytM and ZooA [94].  This work has shown that both the substitution 
of H23 and H109 with alanine reduces enzymatic activity compared to the WT.  
This reduction in activity is consistent with the active sites found in homologues 
from other M23 metalloproteases and therefore further suggests that agalacticin 
A is similar to both ZooA and lysostaphin [94].  
Agalacticin A, like its homologues, targets species closely related to the 
producing strain.  This targeting is predicted to be due to the presence of the 
TRD at the C-terminus of the protein, similarly to lysostaphin which requires the 
TRD to interact with the target cell [97].  The enzymatic activity of both ZooA 
and agalacticin A suggest that it may enzymatically active against any cells that 
possess alanine peptide cross-bridges, such as enterococcus spp. [104,183].  This 
TRD may be necessary for activity but it may also be possible to create chimeric 
proteins allowing agalacticin A to target a wider number of Gram-positive 
species or to target another specific pathogen by altering the TRD.   
It has been shown in this work that agalacticin A, like lysostaphin, is flexible in 
solution.  The ability of agalacticin A and lysostaphin to elongate and contract 
may be important for both target recognition and enzymatic activity [97].  The 
removal or partial removal of the flexible linker domain of agalacticin A may 
allow for the importance of this flexibility to be examined.  Although the 
flexibility and overall structure of agalacticin A can be shown using SAXS, the 
high-resolution structure of agalactin A would be highly beneficial in 
understanding its detailed mechanism of killing.   
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  Future work  
 The role of the fus operon in the uptake of pectocins 
Although this work has gone some way to examining the interaction of pectocin 
M1 with the proteins encoded on the fus operon, the uptake of these proteins is 
far from understood.  Future work should focus on elucidating the roles of both 
FusB and FusC in the uptake and processing of pectocins in order to determine if 
these are essential.  It would also be beneficial to examine the role of this 
operon in virulence; work within this thesis has shown that FusA is not essential 
for virulence of P. atrosepticum LMG2386 in both N. benthamania nahG or tuber 
infections.  However, this may not be the case for all Pectobacterium strains 
carrying the fus operon.  It is likely that the inability of P. atrosepticum to 
acquire iron from a host source is compensated for by the production of 
siderophores.  
 It has been shown in other closely related species that siderophore production is 
upregulated under the iron limiting conditions of infection [193,194].  It would 
be interesting to determine if the deletion of the fus system increased the 
production of siderophores or led to an upregulation of other iron scavenging 
pathways to retain iron uptake.  Moreover, under iron-limiting conditions, this 
strain of P. atrosepticum does not appear to use ferredoxins as an iron source to 
enhance growth [117], however this is not the case for all Pectobacterium spp.  
Therefore, it would be interesting to examine if the virulence of strains which do 
exhibit this enhanced growth is affected by the deletion of the fusA gene.   
The conformational change needed for pectocin M1 to both bind and be taken up 
by the FusA is predicted from the NMR spectroscopy data, however the 
mechanism by which this occurs remains unclear.  It is known that pectocin M1, 
like pectocin M2, can be found in multiple conformations within solution in the 
absence of FusA [123].  This suggests that the conformational change may not be 
dependent on the interaction with the outer membrane receptor.  However if, as 
predicted, the pectocin M1 can only interact with FusA in a bent conformation a 
conformational change would be required upon receptor binding for uptake 
[124].  Future work should focus on the conformational change of pectocin M1 in 
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the absence and presence of FusA in order to determine this mechanism.  This 
flexibility should also be examined for pectocin P, it may be that this 
conformational change is more reliant on receptor interaction as the SAXS data 
suggest that only a small percentage of the population may be elongated in 
solution.   
Moreover, more data is needed to determine the mechanism by which the plug 
domain from FusA is removed in solution.  As the removal of the plug domain is 
normally reliant on the presence of the TonB complex it is unusual that the SANS 
data suggest that it can exit the barrel in the absence of the TonB interaction.  
Moreover, future work should focus on whether the predicted TonB-box of FusA 
interacts with TonB in the periplasm, or in fact interacts with FusB.  In order to 
fully examine this, the use of atomic force microscopy would allow for the 
removal of the plug to be examined.  AFM has been successfully used to examine 
the plug domain rearrangement of BtuB upon its interaction with TonB [76], 
therefore the same approach could be used to determine if the plug domain of 
FusA is removed or unfolded upon its interaction with TonB or FusB.   
 Development and discovery of novel antimicrobials 
This work has shown the potential of both Gram-negative and Gram-positive 
bacteriocins as antimicrobials.  Both pectocin M1 and agalacticin A are potent 
antimicrobials against Pectobacterium and GBS respectively when tested in 
vitro.  It has been shown that agalacticin A is successful in reducing infection in 
G. mellonella and increasing survival rates suggesting that it may be a candidate 
for further testing.   
Pectocins have the potential to be used as potent antibiotics, however work here 
has shown that further optimisation and development is needed in order to 
examine the optimum conditions for both delivery and disease prevention. It has 
been shown previously that bacteriocins against plant pathogens such as 
Pseudomonas syringe are effective in the prevention of infection, specifically 
olive knot [195].   Previous work has shown that the production of T4 lysozyme 
by potato plants significantly reduces the susceptibility of the plant to infection 
by P. atrosepticum without a detectable effect on the rhizosphere microbiota 
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[196–198].  Therefore, the potential for bacteriocins to be used to prevent 
infection by phytopathogens has been shown.  It is also possible that the N-
terminal domain of pectocin M1 could be used to import antimicrobial 
compounds, such as vancomycin, which are normally ineffective against Gram-
negative bacteria due to the presence of the outer membrane.  Furthermore, 
the ability to deliver a cocktail of chimeric bacteriocins could potentially reduce 
the emergence of resistance within Pectobacterium spp.  The presence of 
ferredoxin-containing bacteriocins encoded by other phytopathogens suggests 
that a universal mechanism of bacteriocin uptake may have the potential to be 
exploited.   
The use of bacteriocins within the food industry has the potential to reduce the 
amount of food lost to bacterial pathogens every year.  Within recent years 
protein bacteriocins have been used to prevent the spread of Salmonella 
infection through treatment of meat as well as the use of endolysins to prevent 
the spoilage of dairy products [199].  This work has explored the structural and 
functional characteristics of bacteriocins from both Gram-positive and Gram-
negative bacteria.  This work has gone some way to showing the efficacy of 
these bacteriocins against their target organisms and that agalacticin A has the 
potential to be developed as a therapeutic against GBS infection.  Pectocins, 
although potent in vitro against Pectobacterium spp. have not been shown to 
effectively clear infection in leaf or tuber tissue in this study, however 
optimisation of these infection models may yet show that they can be effective 
in vivo.   
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Appendix 1 Sequence alignments of FusA to 
known proteins highlighting the conserved TonB-
box  
 
Appendix 1a Sequence alignments of FusA with TonB-dependent receptors from E. coli.  
Amino acid sequence alignment of FusA from P. atrosepticum LMG2386, SCRI1043 with BtuB and 
FepA from E. coli with the TonB-box conserved motif underlined.  Conserved residues are shown in 
Red and unconserved residues shown in blue, with residues shared by three or two proteins 
highlighted in pink and white respectively.   
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Appendix 1b Conserved TonB-box motifs based on sequence homology with other known 
TonB-dependent receptors.  a) TonB-box sequences from FusA2386 and known TonB-boxes from 
TonB-dependent receptors and colcins (sequences taken from [85] and aligned using Clustal 
Omega) with colours representing conserved properties.  b) Graphical representation of the 
sequences shown in a using MEME [200]  
 
Appendix 1c Amino acid sequence of FusA1043.  Amino acids corresponding to the N-terminal 
plug domain are shown in blue, the C-terminal barrel shown in purple.  The red underlined residues 
(STPTS) are the first five amino acids of the protein used for SANS experiments.  The eight 
residues underlined in green correspond to those of the predicted TonB-box.  
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Appendix 2 N-terminal domain of pectocin M1  
 
Appendix 2 N-terminal domain of pectocin M1 showing the surface, with colours indicating 
chemical shift perturbations as measured by NMR spectroscopy and described in Chapter 4.  
Residues showing a CSP of >0.02 p.p.m. shown in blue, 0.01-0.02 p.p.m shown in green and 
<0.01 p.p.m shown in black with those residues bound to the iron-sulphur cluster shown in orange.  
Panels show the four face of pectocin M1 for example panel b is a 90o to the left rotation of panel a, 
with residues R58 and C38 shown as a reference.   
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Appendix 3 Absence of the iron-sulphur cluster 
disrupts both receptor binding and protein uptake.    
 
Appendix 3a Competition assay between pectocin M1 and pectocin M1C38A (at a concentration of 3 
mg ml-1)showing that C38A does not cause cell lysis or compete with pectocin M1 for the FusA 
outer membrane receptor likely due to its improper folding (shown in Figure 4-7). 
 
 
Appendix 3b Mutation of residue C38 to an alanine prevents the binding of an iron-sulphur 
cluster.  a) Light image of WT pectocin M1 and pectocin M1C38A showing the lack of the distinctive 
red colour indicating the absence of the iron-sulphur cluster.  b) Absorbance spectra of pectocin M1 
(blue) and pectocin M1C38A showing the lack of distinctive peaks associated with the presence of 
the iron-sulphur cluster.   
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